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 Abstract 
An investigation into the use of selective serotonin reuptake inhibitors for improving low lung function and 
pulmonary exacerbations 
Hilary F. Armstrong 
Chronic obstructive pulmonary disease (COPD) is characterized by periodic episodes of worsening 
symptom (e.g., shortness of breath, irregular breathing, and worse coughing with increased phlegm 
production), also called pulmonary exacerbations. Inflammation is an important cause of reduced lung 
function as inflammation contributes to airflow obstruction in the small airways and lung parenchyma [1]. 
Even in individuals with mild COPD [2], inflammation reduces lung function, accelerates decline in lung 
function overtime, and increases the risk for respiratory exacerbations [3-7]. Agents that reduce systemic 
inflammation are hypothesized to decrease the inflammation in the lungs, resulting in improvements in lung 
function and a decrease in exacerbation frequency. We hypothesize that antidepressants have a beneficial 
effect on lung function. In addition to having anti-inflammatory properties, antidepressants act upon 
serotonin, which is integral in central breathing control. The combination of the anti-inflammatory and 
serotonergic effects may provide users of selective serotonin reuptake inhibitors with a lung function benefit 
while avoiding the side effects of steroids. This dissertation assesses whether selective serotonin reuptake 
inhibitors increase concurrent lung function and reduce the risk for respiratory exacerbations. It consists of 
three parts: a systematic literature review and two analytic papers using large prospective databases. The 
systematic review of the literature identified limitations concerning the effect of selective serotonin reuptake 
inhibitors on lung function. Overall, the analytic papers found no support for a beneficial association 
between selective serotonin reuptake inhibitors and spirometry, dyspnea or pulmonary exacerbations; 
indeed the association was in the opposite direction as hypothesized. In addition, there was no support for 
meaningful mediation by inflammatory markers. Further research is needed to determine if selective 
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COPD refers to a group of diseases that cause airflow obstruction, respiratory muscle weakness, 
and breathing-related problems (such as increased breathlessness, frequent coughing, and tightness in the 
chest) that result in reduced lung function [8]. Symptoms include shortness of breath (or dyspnea), 
persistent (chronic) cough, wheezing and labored breathing during physical activity. Recent estimates 
suggest there are approximately 12-16 million men and women with COPD in the U.S. and 52 million 
worldwide [9]. However, the actual prevalence of low lung function is likely under-estimated since potentially 
treatable mild cases of obstructive lung disease often go undetected [10]. Respiratory exacerbations, a 
sudden worsening of respiratory symptoms and airway function, are also a concern for COPD patients and 
their practitioners. Currently, there is no cure for COPD; therefore, practitioners focus on reducing the risk 
of respiratory exacerbations and mortality and improving symptoms as the primary treatment goals [11]. 
Inflammation plays a large role in COPD, as evidenced by the Global Initiative for Chronic 
Obstructive Lung Disease classifying COPD as an inflammatory disease [8]. As the pathogenesis of COPD 
becomes better understood, systemic inflammation is hypothesized to be responsible for many symptoms 
leading to a reduction in quality of life [12, 13]. Current treatments for COPD are therefore targeted at 
reducing inflammation [14, 15]; however, no medication indicated for COPD treatment has satisfactorily 
done so [14, 15] and most result in significant adverse outcomes.  
Adverse events and a lack of efficacy leads researchers to consider other drugs. Some 
antidepressants, namely selective serotonin reuptake inhibitors, may have off-label uses in treating COPD 
symptoms. Selective serotonin reuptake inhibitors are anti-inflammatory and act upon serotonin, which is 
integral to central breathing control [16, 17]; this combination may provide an additional benefit over current 
COPD treatment regimes.  
While there is evidence for the underlying biological mechanism, very few studies have actually 
tested the effect of antidepressants on lung function. This dissertation aims to test whether participants on 
selective serotonin reuptake inhibitors have better concurrent lung function and a lower risk for respiratory 
exacerbations then those not on selective serotonin reuptake inhibitors.  
CHAPTER 1. INTRODUCTION 
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The dissertation consists of three parts: a systematic literature review and two analytic research 
papers investigating the effect of selective serotonin reuptake inhibitors on lung function and respiratory 
exacerbations. First, the systematic literature review critically evaluates the existing literature and identifies 
what further evidence would be required to warrant the use of selective serotonin reuptake inhibitors for 
lung function improvement. Two analytic chapters follow the systematic review. These are written to 
determine whether selective serotonin reuptake inhibitors increase concurrent lung function and lower the 
risk for exacerbations. Using a large population-based dataset, the Multi Ethnic Study of Atherosclerosis, 
Chapter 3 assesses whether those on selective serotonin reuptake inhibitors have better lung function than 
those not on selective serotonin reuptake inhibitors and if those who switch their medication status have a 
greater change in lung function than those who remained consistently on or off selective serotonin reuptake 
inhibitors. In Chapter 4, we use the Subpopulations and Intermediate Outcome Measures in COPD Study 
to investigate whether those on selective serotonin reuptake inhibitors have a lower risk for respiratory 
exacerbations than those not on an antidepressant or on other antidepressants, and whether the 
association between selective serotonin reuptake inhibitors and lung function is partly mediated by 
inflammatory markers. Lastly, an integration and discussion of the findings is provided in Chapter 5. This 
dissertation aims to provide information on whether selective serotonin reuptake inhibitors can be used to 






Background: Chronic lower respiratory diseases, which include chronic obstructive pulmonary disease, 
asthma, emphysema and chronic bronchitis, are now the third leading cause of death in the US and the 
fourth leading worldwide. Current treatments for chronic obstructive pulmonary disease aim at reducing 
inflammation; however, there is room for improvement as no medications influence central breathing control 
in COPD. Some antidepressants are anti-inflammatory and act upon the neurotransmitter serotonin, which 
is integral to central breathing control; this combination may provide an additional benefit over current 
chronic obstructive pulmonary disease treatment regimes. Objectives: This paper aims to systematically 
review the empirical research on the relationship between antidepressants and lung function. Furthermore, 
this paper assesses whether the variation in observed associations can be explained by antidepressant 
type. Data sources: MEDLINE, PsychINFO, EMBASE and COCHRANE were searched from inception of 
the search engine until June 1, 2016. The search strategy used medical subject headings (MeSH) and text 
word terms relating to lung function and antidepressants. Study selection: Peer reviewed research reports 
on humans, written in English, including a clinically relevant lung function measurement as an outcome, 
and assessing the effect of at least one antidepressant were evaluated for eligibility. Data collection and 
analysis: In addition to lung function outcomes, data extraction included first author, year of publication, 
study design, information regarding participant characteristics, type and dose of antidepressant, attrition, 
and duration of intervention. For studies that had more than one measure of lung function, we recorded 
results for each measure. Main results: Twenty-three publications were included in the review, reporting 24 
separate studies. The 24 studies covered four types of antidepressants: selective serotonin reuptake 
inhibitors, tricyclic antidepressants, and other antidepressants (type not always given). Many of the studies 
reported both dyspnea and spirometry and used multiple measures of assessment. Overall, there were 21 
studies with spirometry as an outcome. For selective serotonin reuptake inhibitors, 40% of the studies had 
a significant association and 42% of tricyclic antidepressant studies had a significant association with 
improvement in spirometry. Eleven studies assessed dyspnea as an outcome. For selective serotonin 
CHAPTER 2. THE ASSOCIATION OF ANTIDEPRESSANTS AND LUNG 




reuptake inhibitors, 33% of the studies had a significant association; for tricyclic antidepressants, 25% of 
the studies had a significant association with improvement in dyspnea. Conclusions: Results tended to vary 
by inclusion of participants with comorbid depression, severity of lung function impairment, and type of 
antidepressant. The information provided in these studies suggest the potential for certain antidepressants 




Chronic lower respiratory diseases, primarily chronic obstructive pulmonary disease (COPD), is 
now the third leading cause of death in the United States [18] and the fourth leading worldwide [19]. Recent 
estimates suggest there are approximately 12-16 million men and women with COPD in the U.S. and 52 
million worldwide [9]. However, the actual prevalence of low lung function is likely under-estimated since 
potentially treatable mild cases of obstructive lung disease often go undetected [10]. A study from the 
National Health and Nutrition Examination Survey demonstrated that many US adults have low lung 
function but no reported lung disease diagnosis [10]. Even in those who are asymptomatic, low lung function 
can have debilitating effects. For example, the leading cause of death from COPD is respiratory failure, 
however the majority of those with mild-to-moderate COPD die from cardiovascular disease which likely 
occurs from chronic low-grade inflammation, a common cause of both COPD and cardiovascular disease 
[20].  
The need for more effective medication 
As the pathogenesis of COPD becomes better understood, inflammation is hypothesized to be 
responsible for many symptoms leading to a reduction in quality of life [12, 13]. Current treatments for 
COPD are therefore targeted at reducing inflammation [14, 15]. For example, inhaler-based steroids for 
long-term treatment of COPD are used for symptom control and prevention of pulmonary exacerbations 
[12]. Due to their anti-inflammatory effects, inhaled corticosteroids can improve short-term pulmonary 
function and dyspnea, shorten hospitalizations, and decrease the frequency of exacerbations [21, 22]. 
Most studies however have found that regular treatment with inhaled corticosteroids alone does not 
change the long-term decline of FEV1 nor mortality in participants with COPD [23, 24]. Inhaled 
corticosteroid use is also associated with a higher prevalence of oral candidiasis, hoarse voice, skin 
bruising, and pneumonia [24].  Results from observational studies also suggest that inhaled 
corticosteroids are associated with increased risk of diabetes [25], cataracts [26], and mycobacterial 




example, observational studies have shown statins, approved as lipid-lowering agents, are useful in 
COPD due to their anti-inflammatory effects [14, 28-30].  
Like statins, some antidepressants, particularly selective serotonin reuptake inhibitors, may have 
off-label uses in treating COPD symptoms. Selective serotonin reuptake inhibitors are anti-inflammatory 
and act upon serotonin, which is integral to central breathing control [16, 17]; this combination may 
provide them with an additional benefit over current COPD treatment regimes.  
Antidepressants 
Major types of antidepressants include tricyclic antidepressants, selective serotonin reuptake 
inhibitors and serotonin-norepinephrine reuptake inhibitors. Generally, the choice of an antidepressant 
depends on finding a medication that works with an individual’s needs and tolerance of side effects. 
Selective serotonin reuptake inhibitors have the lowest side effect profile compared with older 
antidepressants and are the most widely prescribed [31]. Possible side effects of selective serotonin 
reuptake inhibitors are generally mild but include drowsiness, nausea, dry mouth, some sexual side 
effects, insomnia and dizziness [31]. In general, these side effects are milder, or similar, to the side 
effects of current COPD drugs. 
Effect of selective serotonin reuptake inhibitors on inflammation 
Seen in both animal [32-34], and human [16] models, selective serotonin reuptake inhibitors reduce 
the microglial production of the pro-inflammatory-cytokine tumor necrosis-α and the free radical nitric oxide, 
both key players in inflammation in the brain [35]. In an animal model of the lungs, fluoxetine, a selective 
serotonin reuptake inhibitor, inhibits airway inflammation through affecting the capacity of monocytes and 
lung epithelial cells to produce inflammatory cytokines [36]. These effects are potentially due to selective 
serotonin reuptake inhibitors’ influence on serotonin, as serotonin has a role in anti-inflammatory processes 
[33, 37].  
Although tricyclic antidepressants, serotonin norepinephrine reuptake inhibitors and selective 
serotonin reuptake inhibitors are all thought to have serotoninergic effects, in two similar studies by Bianchi, 
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only selective serotonin reuptake inhibitors increase the level of serotonin, resulting in anti-inflammatory 
effects [33, 37]. Additional trials show that serotonin-norepinephrine reuptake inhibitors [16] and tricyclic 
antidepressants [38] do not have anti-inflammatory effects.  
The narrowly targeted action of selective serotonin reuptake inhibitors on serotonin may explain 
the discrepancy between the effects of selective serotonin reuptake inhibitors and other classes of 
antidepressants on inflammation. Selective serotonin reuptake inhibitors do not increase norepinephrine, 
but both tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors do [39]. Consistent with 
the known pro-inflammatory effects of norepinephrine on innate immune cells [40], serotonin-
norepinephrine reuptake inhibitors are associated with an increase in inflammatory markers [41], 
suggesting that norepinephrine may cancel out the anti-inflammatory effects of serotonin.  
Serotonin, breathing control, and dyspnea 
In addition to anti-inflammatory pathways, serotonin is involved in the central control of breathing 
[17]. The serotonin transporter, a protein that transports serotonin and regulates plasma serotonin levels 
[42], is highly expressed in the lungs, predominately in pulmonary-artery smooth muscle cells. The 
serotonin transporter is important in maintaining patent upper airways [43] and affects phrenic nerve activity 
[44]. Since the serotonergic system is linked to respiratory function, serotonergic drugs may increase the 
coordination and force-generating capacity of the weakened respiratory muscles seen in COPD [45], 
resulting in decreased upper-airway resistance. Additionally, serotonin modulates the central control of 
breathing in part by decreasing sensitivity to carbon dioxide [46]. In participants with COPD, greater degrees 
of carbon dioxide sensitivity are associated with more severe dyspnea  [47]. In light of this link with carbon 
dioxide, researchers have suggested that drugs that increase serotonin levels may also have anti-dyspneic 
effects [48].  
Due to the evidence presented above, we hypothesize that selective serotonin reuptake inhibitors 




Previous studies provide evidence for an association between lung function and antidepressants; 
however, to our knowledge a systematic review of the literature has not been performed. The purpose of 
this paper is to systematically review the empirical research on the relationship between antidepressants 
and lung function in humans. Furthermore, this paper assesses whether variation in observed associations 
can be explained by antidepressant type. 
The study goal is as follows: 
1. To critically evaluate the existing literature and identify what further evidence would be required to 
warrant the use of antidepressants for lung function improvement. 
Information sources and search criteria 
This systematic review follows the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [49]. We searched MEDLINE, PsychINFO, EMBASE, and COCHRANE 
from inception of the search engine until June 1, 2016. The search strategy uses medical subject headings 
(MeSH) and text word terms. For lung function, the terms include “respiratory function tests”, “spirometry”, 
“pulmonary ventilation”, “forced expiratory volume”, “dyspnea”, “breath shortness”, “shortness of breath”, 
“breathlessness”, “breathing discomfort”, and “respiratory symptoms”. The antidepressant terms include 
“antidepressive agents”, “serotonin uptake inhibitors”, “monoamine oxidase inhibitors”, “tricyclic 
antidepressive agents”, as well as individual antidepressants (e.g. citalopram, sertraline, and amitriptyline). 
We searched using the combination of lung function and antidepressant terms (requiring at least one of 
each). Additional studies were found through the reference lists of the articles selected for review. 
Eligibility criteria 
The inclusion criteria are: 1- peer-reviewed research report (case studies were excluded); 2- written 
in English; 3- includes spirometry or dyspnea as an outcome (see measures section below); 4- assesses 





Two outcome measures of lung function were assessed: spirometry and dyspnea.  
 
Spirometry: Spirometry assesses how well the lungs work by measuring how much air is inhaled, how much 
is exhaled, and how quickly you exhale. Spirometry is often used in diagnosing pulmonary disease since it 
is standardized and the current gold standard for objectively defining airflow obstruction [50]. A decreased 
forced expiratory volume in one second (FEV1), the maximal volume of air expired in the first second after 
a full inspiration [50], is the measure primarily used to show reduced lung function in COPD [51]. Predicted 
reference values have been calculated and compared with samples of healthy subjects drawn from the 
general population to yield percent predicted (%) standards.   
Dyspnea: Dyspnea is the main symptom perceived in participants affected by chronic respiratory diseases 
[52]. Even modest improvements in dyspnea are likely to determine clinically relevant changes in patient 
quality of life. There are numerous modes for classifying and characterizing the tools used to assess 
dyspnea, which are all self-reported. Types of scales include “discriminative” (that differentiate study 
populations based on the level of perceived dyspnea), “evaluative” (that identify variations with respect to 
a baseline condition), and “categorical” (which quantify the symptom according to categories). While these 
scales are associated with parameters of physiological impairments, they are not well interrelated [53, 54].  
Study selection 
We examined the titles and abstracts to remove reports not meeting eligibility criteria. If it was not 
clear from the title or abstract that the study should be excluded, the full text was assessed. The same 
approach was used for additional publications identified through the reference lists of relevant papers.  
Data extraction 
In addition to lung function outcomes, data extraction included first author, year of publication, study 
design, information regarding participant characteristics, type and dose of antidepressant, attrition, and 
duration of intervention (if applicable). For studies that had more than one outcome (spirometry and 
dyspnea), we recorded results for each. Study design was inferred from the study description used by the 
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authors. If the study design was not stated, it was marked as unknown; however, we were usually able to 
infer what it was and noted the potential design. The same procedures apply to the sample recruitment. 
Results are reported as mean±SD, except where noted. 
Study quality 
We assessed all studies for methodological quality for the following conditions: study participation, 
study attrition, outcome measurement and reporting, and study confounding. Criteria for each domain are 
listed in Appendix Figure 1. Directed Acyclic Graph for hypothesized confounders with lung function 











Appendix Figure 2. Directed Acyclic Graph for hypothesized confounders with exacerbations in the 
SPIROMICS study 










Appendix Table 1Error! Reference source not found. and were modified from a previous study 
[55]. A judgement and support for each entry are given in the ‘Risk of bias’ table; the judgement for each 
entry assesses the risk of bias as ‘low risk’ or ‘high risk’; if there was not enough information given in the 
study to determine adequacy, it was marked as ‘unclear’.  
Investigation of heterogeneity 
 We explore possible clinical or methodological reasons for variation by subgrouping studies based on 
characteristics that are potentially responsible for differences in outcomes. We considered if the following 
are likely to explain differences between and within studies: study design, population, intervention and 
setting, or the type of outcome measure(s) used. We categorized the effects into three categories: effects 
that were statistically significant (p<0.05) and in the hypothesized direction (i.e. supported the hypothesis), 
non-significant effects regardless of direction, and significant effects in the opposite direction (i.e. evidence 
against the hypothesis). 
This review begins with a synthesis of the findings of the included studies. We then stratify the 
results by antidepressant type and outcome assessed (spirometry or dyspnea) to identify patterns across 
the included studies, followed by an assessment of the study quality, and conclude with a discussion of the 
potential effect moderators.  
Article selection 
Figure 2.1 provides the process of article selection for inclusion in the present systematic review. 
Electronic database searches yielded 3,485 unique results. We then examined the titles and abstracts of 
publications identified for eligibility. After this screening, we reviewed the remaining reports to determine 
agreement with inclusion criteria and examined references from the selected papers to look for other 
references not yet included; this resulted in a set of 67 articles. Of these manuscripts, 44 were considered 
ineligible including 10 that did not include a lung function measurement as an outcome, 24 that were case 




were published in languages other than English, 2 that were animal studies, and 2 that were duplicates of 
the exact same trials. This yielded 23 articles for review. 
Study characteristics 
While 23 publications are included in the review, one paper [56] reported two studies within the 
same publication; therefore, 24 separate studies are considered and reported below. A summary of the 
study characteristics stratified by antidepressant type is provided in Table 2.1. 
The 24 studies covered four types of antidepressants; 8 of the studies assessed selective serotonin 
reuptake inhibitors (Column A) [45, 56-61], 12 evaluated tricyclic antidepressants (Column B) [62-73], and 
the other four studies used tianeptine [74], mianserin [75], or multiple antidepressants (type not always 
given) [76, 77]- grouped together as ‘other antidepressants’ (Column C). Tianeptine increases serotonin 
uptake in the brain (in contrast with most antidepressant agents) while mianserin is a tetracyclic 
antidepressant, closely related to tricyclic antidepressants.  
The largest proportion of studies used a crossover design (33%), closely followed by cohort (29%), 
and then randomized controlled trials (RCTs) (21%). There was one case control study by Adams et al. 
who performed a long-term follow up of a previous randomized, double-blind, placebo-controlled trial [70]. 
The only large cohort study was by van Milligen et al. who analyzed cross sectional data to assess the 
association between depression and physical function [77]. The sample size ranged from six to 2,258 with 
the approximately half (46%) of the studies having between one and 20 participants. Almost 80% of the 
studies recruited participants from the outpatient population. The study duration ranged from one day [71] 
to long-term follow-ups lasting one to three years [70]. While the majority of studies assessed participants 
with COPD (58%), others included asthma, cystic fibrosis, and those without any respiratory disorders. This 
variation in disease states lead to a wide range in study-specific baseline FEV1 (0.62 to 3.58 liters and 22.3 
to 107.1 percent predicted). A quarter of the studies did not present any information on the baseline FEV1 
of the participants. Of those that did, 12 presented it in liters only and nine in percent predicted only; three 
reported both liters and percent predicted [56, 63, 76]. Half of the studies included between 26-50% of 
females, with a range from zero to 80.5%. All but one study [74] enrolled adult participants, with an average 
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age of 49.87.2 years. However, even excluding the study of children, the mean age still varied widely (28.4 
to 70.5 years). Both participants with and without comorbid depression were eligible for inclusion in this 
review. Approximately half of the studies included participants with comorbid depression (54%).  
Study results 
Many of the 24 studies report both dyspnea and spirometry and used multiple measures for 
assessing each measure; 21 studies measured spirometry and 11 measured dyspnea. While spirometry is 
standardized in how it is measured, 12 studies presented FEV1 in liters and nine in percent predicted, 
making the results non-comparable. The dyspnea measurements ranged widely with nine distinct scales 
being used across 11 studies (Appendix Table 2). Of the 11 studies that included dyspnea measurements, 
only one used a diary to keep track of patient’s dyspnea outside of the hospital. Because of the various 
disease states, study designs, and statistical techniques used, we noted substantial clinical, 
methodological, and statistical heterogeneity across included studies and therefore were unable to report 
pooled results from a meta-analysis and instead use a narrative approach to data synthesis. 
To assess the general results when the authors use different metrics, we categorized studies into 
‘significant’, when they were in the hypothesized direction and statistically significant, ‘non-significant’ when 
they were non-significant regardless of the direction of effect; and ‘unexpected’ if they were in the opposite 
direction as hypothesized. We found that 38% were significant, 58% non-significant and 4% unexpected. 
Results across antidepressant types 
We stratified the results by antidepressant type since we hypothesized that there is a difference in 
the magnitude of association between antidepressant types. We will first present the spirometry results by 
antidepressant type, then the dyspnea results. Detailed results for individual studies are presented in 




Selective serotonin reuptake inhibitors (Table 2.2, Column A) 
Five of the studies using selective serotonin reuptake inhibitors assessed spirometry as an outcome 
[45, 58, 59, 78]. Two (40%) of these showed a significant association between selective serotonin reuptake 
inhibitors and increased lung function. Momtaz et al. studied two groups of age and sex matched severe 
COPD participants (n=50), one of which received fluoxetine [59]. After 3 months on the antidepressant, the 
treatment group increased their FEV1 from 1.10±0.49 to 1.20±0.44 liters (p=0.01); the group that did not 
receive antidepressant had no change in FEV1. In the study by Perna et al., six participants were treated 
with citalopram, after 1-month their FEV1 significantly increased (p<0.05) from 0.91±0.17 to 1.12±0.15 liters 
[45].  
In contrast, the study by Papp et al. (statistics not reported) [58] and two studies by Eiser et al. 
(change in FEV1 for the treatment group: 1.14±0.65 (baseline) to 1.18±0.70 liters (post 3 months) (open-
label cohort study), p=0.22 and 1.13±0.64 (baseline) to 1.12±0.69 liters (post 6 weeks), p=0.43 (double-
blind cohort study)) found no significant association between selective serotonin reuptake inhibitors and 
spirometry [78].  
In summary, there were two studies using selective serotonin reuptake inhibitors with significant 
associations that assessed spirometry (one cohort, one pre/post comparison, average sample size=28) 
and three non-significant studies (two cohort and one crossover, average sample size=25). Overall, 
regardless of significance, the four studies that reported quantitative spirometric outcomes had an average 
difference in FEV1 (in liters) of 0.09 (range: -0.01 to 0.21) between those on and off selective serotonin 
reuptake inhibitors. There were no selective serotonin reuptake inhibitor studies that reported FEV1 as 
percent predicted.  
Tricyclic antidepressants (Table 2.2, Column B) 
All twelve studies involving tricyclic antidepressants included spirometry as an outcome [62-70, 72, 
73, 79], five (42%) of these showed a significant association between tricyclic antidepressants and 
spirometric measures [69, 70, 72, 73, 79]. 
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In the pre/post comparison study by Sugihara et al., 60 hospitalized patients and outpatients with 
bronchial asthma were given amitriptyline [69]. There were only descriptive results reported in this study, 
labeling the responses to therapy as ‘excellent’, ‘good’, or ‘poor’. While the authors explained the definitions 
for each category, (i.e. a grade of ‘excellent’ meant subjective and objective symptoms had disappeared 
completely) no quantitative results were reported and they did not discriminate between spirometry and 
dyspnea. Meares et al. performed a study with an intramuscular injection of amitriptyline in 12 asthmatics, 
they reported significant improvements in 11 out of 12 participants (mean FEV1 improved from 2.02 to 2.37 
liters) [79]. Riethmuller et al.’s study consisted of 36 cystic fibrosis participants enrolled in a randomized, 
double-blind, placebo-controlled crossover study of amitriptyline [73]. After 14 days of treatment, FEV1 
improved significantly in the 25 mg amitriptyline group relative to placebo (absolute change in FEV1 percent 
predicted of +3.04 and a relative change of +4.07.0, p=0.048). Of note, the researchers did not observe 
a significant change in lung function when participants took 50 mg or 75 mg of amitriptyline, showing there 
was not a dose response. In the same group that published the study by Riethmuller, Nahrlich et al.’s study 
assessed both the per-protocol (PP) and intent-to-treat (ITT) groups in a similar study of cystic fibrosis 
patients and found both to have significant increases in FEV1 (PP: treatment group +2.2±5.2 change in 
FEV1 percent predicted from baseline, placebo -2.7±5.0 change in FEV1 percent predicted from baseline, 
p=0.013; ITT: treatment group +0.6±5.7 change in FEV1 percent predicted from baseline, placebo -3.8±6.9 
change in FEV1 percent predicted from baseline, p=0.034) [72]. After the studies by Riethmuller et al. and 
Nahrlich et al. were completed, some of the cystic fibrosis participants continued to take amitriptyline; 
Adams et al. followed twenty participants on amitriptyline for one, two, and three years compared with 14 
control participants [70]. The lung function of cystic fibrosis participants, measured as FEV1 percent 
predicted, improved significantly in the treatment group each year (average of ~5%). In contrast, the control 
group’s FEV1 percent predicted consistently decreased by 1 to 2.6%.  
Two studies, both published by Series et al., reported no significant change in FEV1 (baseline: 
40.8±3.9%, week 10: 46.0±3.9% [66]; baseline: 1.04±0.12 liters, week 10: 1.21±0.10 liters [67]). Gordon et 
al reported that FEV1 tended to be higher after treatment with desipramine (770262 mL) compared with 
placebo (657225 mL), but this did not reach statistical significance [64]. In the study by Carroll et al., the 
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authors reported no differences between groups for spirometry, however no numbers are reported for FEV1 
even though it was stated as being measured [63]. In the study by Light et al., there were no substantial 
differences between the treatment (0.80±0.21 liters) and placebo (0.82±0.25 liters) groups [65]. Similarly, 
in the study by Strom et al., there were no differences between the treatment (0.7±0.3 liters) and control 
(0.7±0.3 liters) groups [68]. The study by Borson et al. reported that there were no differences between the 
treatment and control groups, although pulmonary numbers were not reported [62].  
In summary, there were five studies using tricyclic antidepressants with significant associations that 
assessed spirometry (two pre/post comparison studies, one crossover, one RCT and one case control / 
long-term follow-up of a previous study; average sample size=34) and seven non-significant studies (two 
cohort, four crossover, one RCT; average sample size=16).  Regardless of significance, for the five studies 
that reported quantitative spirometric outcomes, the average difference of FEV1 (in liters) was 0.11 (range: 
-0.005 to 0.35) between those on and off tricyclic antidepressants. Four studies used FEV1 percent 
predicted and the average difference reported was 4.4% (range: 2.2 to 7.2%).  
Other antidepressants (Table 2.2, Column C) 
There were four studies using antidepressants that were not selective serotonin reuptake inhibitors 
or tricyclic antidepressants; therefore, we combined them into a category of ‘other antidepressants’. Two 
(50%) of these studies had significant associations with improved FEV1. Nascimento enrolled panic 
disorder participants and had them washout from their regular drug regime and re-tested after 1 week [76]. 
The majority (64%) were on imipramine + clonazepam, the rest were on clonazepam alone, paroxetine + 
clonazepam, paroxetine alone, or imipramine alone; FEV1 was significantly higher when on anti-panic 
drugs (3.580.71 liters, 107.0913.74%) than after the washout period (3.420.67 liters, 101.8114.40%). 
Lechin et al. assessed tianeptine in children with asthma for 52 weeks; they reported that tianeptine, but 
not placebo, provoked a dramatic increase in FEV1 [74]. The RCT study by Grove et al. reported no effect 
of mianserin (baseline: 0.92 liters, placebo: 0.90 liters, miaserin: 0.82 liters) [75]. 
Only one study found a significant association in the unexpected direction. Van Milligen et al. 
performed a large cohort analysis in persons with current depressive and/or anxiety disorders (n=1629) 
and healthy controls without a lifetime diagnosis of these disorders (n=629) [77]. The authors reported that 
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women using antidepressants have significantly poorer lung function compared with those with pure anxiety 
disorder (adjusted for age, education, BMI, lung medication, chronic diseases, smoking and physical 
activity), although this was not true in men; they further speculated this could be due to severity of 
depression as depression was associated with worse lung function.  
In summary, there were two studies using other antidepressants with significant associations that 
assessed spirometry (one pre/post comparison, one crossover; average sample size=47); one non-
significant study (RCT; sample size=12), and one study in the unexpected direction (cohort; sample size 
2258). Regardless of significance, for the two studies that reported quantitative spirometric outcomes, the 
average effect of other antidepressants on FEV1 (in liters) was 0.04 (range: -0.08 to 0.16). One study used 
FEV1 as a percent of predicted and the average difference reported was 5.3%.  
Overall, there were 21 studies with spirometry as an outcome, nine (43%) of these showed a 
significant association with antidepressants and improved spirometry. For selective serotonin reuptake 
inhibitors, 40% of the studies had a significant effect, with an average difference in FEV1 of 0.16 (range: 
0.1 to 0.21) between those on and off selective serotonin reuptake inhibitors. For tricyclic antidepressants, 
42% of the studies had a significant effect, with an average difference in FEV1 of 0.35. While firm 
conclusions cannot be drawn, so far there is no strong, consistent evidence that selective serotonin 
reuptake inhibitors positively improve spirometric outcomes. 
Dyspnea 
Selective serotonin reuptake inhibitors (Table 2.3, Column A) 
Six of the selective serotonin reuptake inhibitor studies included dyspnea as an outcome; the same 
two (33%) studies that found an association with spirometry also found one with dyspnea [45, 59]. In the 
study by Perna et al., six participants treated with citalopram had a decrease in their dyspnea scale from 
7.7±1.4 to 3.5±1.4 (p<0.05) [45]. In the study by Momtaz et al., the treatment group had a decrease in their 
dyspnea scale from 4.36±0.99 to 3.68±1.09 (p=0.001); the group that did not receive treatment had an 
increase their dyspnea scale (4.50±1.01 to 5.17±0.99, p=0.001 [59]).  
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In the study by Lacasse et al., the authors reported that unadjusted changes in the Chronic 
Respiratory Questionnaire at follow-up showed results favoring the hypothesized effect of selective 
serotonin reuptake inhibitors on reducing dyspnea, however this did not reach statistical significance; 
tabular results are not reported, but numeric results were displayed graphically [57]. In the study by Brown 
et al., there were no significant differences between the treatment and placebo groups for the change in 
ratings on the asthma control questionnaire (-7.17.6 vs. -8.510.1, p=0.47) [61]. The later study by Brown 
et al. also reported no improvements in the asthma control questionnaire scores [60].  
In summary, there were two studies using selective serotonin reuptake inhibitors with significant 
associations that assessed dyspnea (one cohort and one pre/post comparison; average sample size=31); 
four non-significant studies (one cohort and three RCTs; average sample size=41). An average effect for 
antidepressants on dyspnea could not be assessed since each study used a different method to assess 
dyspnea and these scales are not comparable (i.e. some range from 0-100 and some from 0-10) resulting 
in a wide range of effect estimates. Additionally, pooled effect estimates with methods such as Cohen’s d 
were not feasible given the small sample sizes.  
Tricyclic antidepressants (Table 2.3., Column B) 
In total, there were four studies that assessed dyspnea involving tricyclic antidepressants [62, 63, 
68, 69], only one (25%) of them showed a significant effect [69]. 
As mentioned earlier, Sugihara et al. did not report specific results or discriminate between 
spirometry and dyspnea outcomes, they only reported that 62% of participants had an excellent or good 
therapeutic effect [69]. Borson et al. also noted that antidepressant treatment was associated with a small 
improvement in dyspnea in their RCT, however this was only during activities requiring little energy 
(differential treatment effect: 0.37±0.28, p=0.04) [62], but overall there was no change. The other two 
studies reported no impact of antidepressants on the dyspnea score. Carroll et al. noted that there was no 
statistical difference in the visual analog scale completed by participants; however, a small increase was 
noted during the placebo arm when the same scale was completed independently by the participants’ 
spouse [63]. The median visual analog scale registered by the spouse was 47 (range 34-82) at entry, 54 
(range 35-77) on placebo, and 46 (range12-68) on protriptyline (p<0.01). 
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In summary, there was one study using tricyclic antidepressants that noted significant associations 
with spirometry (pre/post comparison; average sample size=60) and three non-significant studies (two 
crossover and one RCT; average sample size=27). 
Other antidepressants (Table 2.3., Column C) 
Only one study assessed dyspnea using other antidepressants, the study by Grove et al. In their 
RCT of 12 individuals with COPD, the authors reported that the Borg score for perceived exertion on a 6-
minute walk test was unchanged (Borg scale at baseline: 12; placebo: 12.5, treatment: 12.5) [75]. 
In summary, there were 11 studies that assessed dyspnea as an outcome, three (27%) of these 
found a significant association between antidepressants and decreased dyspnea. For selective serotonin 
reuptake inhibitors, 33% of the studies had a significant effect; for tricyclic antidepressants, 25% of the 
studies had a significant effect. As with spirometric outcomes, firm conclusions cannot be drawn but there 
is no strong, consistent evidence that selective serotonin reuptake inhibitors positively improve dyspneic 
outcomes. 
We will now assess the study quality for methodological limitations.  
Although 12 (50%) of the studies were randomized controlled trials or randomized crossovers, 
there were important methodological limitations across the studies (Table 2.5). Fifty-four percent of the 
studies had unclear, incomplete follow-up of participants or unbalanced attrition between the treatment 
and control groups (detailed results on attrition for all studies are presented in Appendix Table 4). A 
quarter of studies measured and analyzed an outcome of interest, but did not completely report the 
results. Lastly, approximately a third of studies failed to control for important confounders or had 
inadequate measurement and testing of confounders. Detailed assessment for each study on the risk of 





Appendix Table 5. 
Spirometry  
Selective serotonin reuptake inhibitors 
There are some possible methodological explanations for the discrepancies between significant 
and non-significant selective serotonin reuptake inhibitor studies. The sampling for the non-significant 
studies all came from outpatient populations compared with inpatient or unknown populations for the 
significant studies. If the outpatient population was healthier (with a resulting higher lung function) than the 
inpatient population, this would produce an effect towards the null. Unfortunately, we are unable to compare 
the baseline FEV1 of the significant and non-significant studies since it was not reported for all; but among 
those that did report it, the non-significant studies had slightly higher lung function. All non-significant 
studies included participants with depression, while significant studies included both participants with and 
without comorbid depression. Including participants with comorbid depression would shift the effect towards 
the null if the inflammation seen in depression were hampering the effect of the antidepressants on lung 
function. Since the participants with depression have increased inflammation, they may need a higher dose 
to see an effect. There was a large amount of attrition in two of the studies that were non-significant [78]. 
Paroxetine was originally used in both Eiser et al.’s studies, in the cohort study and in the crossover study 
[78]. In the crossover study, four participants developed significant side effects on paroxetine and finished 
the study on lofepramine 140 mg in a single-blind fashion; in the cohort study, two participants switched to 
dothiepin 150 mg daily. Lofepramine and dothiepin are tricyclic antidepressants; if our hypothesis is true 
and selective serotonin reuptake inhibitors are more effective than other antidepressants, switching 
antidepressants during the trial would shift the effect towards the null and towards the intent to treat 
estimate.  
In terms of the selective serotonin reuptake inhibitor used, the significant studies used citalopram 
and fluoxetine while the non-significant studies used sertraline or paroxetine. We have not seen any 
POTENTIAL EFFECT MODERATORS 
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literature that compares these specific drugs concerning lung function, but this in something to note and a 
possibility for future research.  
Tricyclic antidepressants 
As with selective serotonin reuptake inhibitors, there are some potential methodological reasons 
for the discrepancies between significant and non-significant tricyclic studies. One of these is inconsistent 
dosing during the study. Series et al. reduced the dose of protriptyline to 10 mg a day after 2 weeks of 
therapy in two participants because of severe dryness of the mouth [66]; the other Series et al. study 
reported using a range of dosing (10-20 mg [67]). In Gordon et al., the investigators used the maximum 
tolerated dose or 100 mg [64]; Light et al. also used various doses of doxepin (150 mg max, if side effects 
occurred dosing was decreased) [65]. In contrast, the large majority of the significant tricyclic antidepressant 
studies reported using consistent dosing. The exception to this was Sugihara et al. who used 20-40 mg of 
amitriptyline; researchers discontinued the drug if symptoms were aggravated and increased it if there was 
no response [69]. Changing the dosing levels (especially lowering them) may result in a decreased 
response but is likely more representative of the effectiveness in clinical practice.  
The baseline FEV1 of significant studies was double that of non-significant studies, but still below 
normal. The average age of the participants is approximately 40 years older in the non-significant studies 
than the significant studies. This is likely linked to the disease of the participants since three of the significant 
studies enrolled cystic fibrosis participants, a disease seen in youth, and all of the non-significant studies 
enrolled COPD participants, who are typically older. The significant studies had a larger median sample 
size (34 vs 16 participants). Additionally, the significant studies did not specifically include participants with 
depression while some of the non-significant studies did. Lastly, it was interesting to note that all of the 
significant studies employed amitriptyline, while the non-significant studies used protriptyline, doxepin, 
desipramine, or nortriptyline. 
Other antidepressants 
Similar to studies of tricyclic antidepressants and selective serotonin reuptake inhibitors, the 
average sample size of the significant studies assessing other antidepressants was higher than the non-
significant study and included both participants with and without depression. Furthermore, the baseline 
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FEV1 reported in the non-significant study by Grove et al. was 29% [75], which is categorized as very 
severe COPD according the GOLD criteria [8]. These participants are very sick so it is not surprising that a 
low dose of mianserin did not produce an effect. There was one cross-sectional study; interestingly this 
was the only study that found an effect in the unexpected direction [77]. Unfortunately, parameters such as 
pre-treatment FEV1 were not reported so it is unknown if this had an effect on study outcome. However, 
this study did include participants with depression and had a very large sample size (2,258 participants). 
Unfortunately, the type of antidepressant was not given and the authors did not provide information on how 
common each antidepressant type was nor any heterogeneity of the association by antidepressant type. 
Overall, across antidepressant types, there was no clear commonality among statistically significant 
studies. Notably, selective serotonin reuptake inhibitors did not stand out as more strongly associated with 
lung function improvements compared with tricyclic antidepressants or other antidepressants. 
Dyspnea 
Selective serotonin reuptake inhibitors 
Similar methodological discrepancies found in studies assessing spirometry were seen in studies 
assessing dyspnea (Table 2.3.A and B, Column A). The non-significant studies [57, 60, 61] all reported 
increasing the dose as tolerated, in contrast to the significant studies which kept participants on continuous 
doses. Both studies by Brown et al. [60, 61] increased the dosage for those who showed no response to 
the drug, and Lacasse et al. used 20 mg or the highest dose not associated with any side effect [57]. As 
with studies assessing spirometry, all of the non-significant studies included participants with depression 
while significant studies were mixed. All significant studies used the modified Borg scale to assess dyspnea. 
The non-significant studies used the asthma control questionnaire, a daily diary card of dyspnea on a 5-
point scale, or the chronic respiratory questionnaire. The Borg scale is typically used during physical 
activities, such as walking or exercising; it is feasible that in order for the participants to notice a difference 




Since there is only one study that showed a significant result (Table 2.3. A and B, Column B), 
sound conclusions could not be made on the methodological differences; however, we still compare 
differences across all studies below.  
The significant study by Sugihara et al. was a cohort study with 60 participants (both in and out 
patients) [69]. In contrast, the non-significant studies were either crossovers or randomized controlled trials, 
with an average sample size of 27 out patients. We were unable to compare the baseline FEV1 or mean 
age of the participants, as it was not reported in Sugihara et al. Interestingly, as with the tricyclic 
antidepressant studies investigating spirometric outcomes, the significant study used amitriptyline, while 
the non-significant studies used protriptyline or nortriptyline. 
Other antidepressants 
There was only one study of other antidepressants that had an outcome of dyspnea (non-
significant) [75], therefore there are no comparisons to be made (Table 2.3. A and B, Column C). The 
limitations of this study, including enrolling participants who are classified as very severe COPD, have been 
discussed earlier in the spirometry section.  
Across the dyspnea and spirometric outcomes, the majority of these studies are subject to 
methodological limitations and thus require caution in their interpretation. 
 To our knowledge, this is the first systematic review of the literature on the effect of antidepressants 
on lung function. Our extensive literature search across multiple electronic databases revealed only 24 
studies eligible for inclusion in this review.  
 We showed that the currently available published studies do not consistently support the 
hypothesized association between antidepressants and increased lung function. Specifically, 38% of 
studies had results that were significant and in the hypothesized direction, 58% non-significant, and 4% in 




severity of baseline lung function impairment, and type of antidepressant. The inconsistent association may 
be because antidepressants truly are not advantageous for lung function, but it could also be due to the 
small sample sizes (median n=23), poor and inconsistent confounder control (1/3 of studies), and lack of 
complete reporting across studies. In order to elucidate if a true association exists, further research is 
needed properly controlling for key variables [80] such as baseline FEV1 and implementing suitable 
methodology such as accounting for change/switch in antidepressant type. 
 Since all but two [70, 77] of the studies were performed in controlled environments where 
researchers closely monitored or interacted with the participants, the effectiveness of antidepressants on 
lung function is not well established in the real world. Real-world applicability includes participants being 
adherent to the treatment regime. An important consideration of this is that over half of the studies had 
significant attrition or uneven attrition between the control and treatment groups, a common reason being 
side effects of the drug. Thirty-eight percent of selective serotonin reuptake inhibitor studies had significant 
differential attrition compared with 58% of tricyclic antidepressant studies, suggesting that tricyclic 
antidepressants have worse side effects than selective serotonin reuptake inhibitors [81].  
 More research is needed using population-based data to provide information on the potential for 
certain antidepressants in improving lung function. For example, all but one study [77] had sample sizes 
with less than 91 participants, with the large proportion (46%) having less than 20 participants. Only one 
large cohort study was found, and the authors did not report the antidepressant type of the participants. 
Combined with the significant attrition in a large portion of the studies, many outcomes were based on very 
small sample sizes. In order to enhance knowledge on the potential effects of antidepressants on lung 
function, a large, well-measured dataset is needed.   
 In summary, while individual studies showed statistical and clinical improvement in lung function, 
overall there was no strong evidence for the use of antidepressants as a whole, or specifically selective 
serotonin reuptake inhibitors, to improve lung function. There was large variation in results and, while 
potential effect modifiers were noted, no single parameter stood out as being consistently different between 
significant and non-significant studies. However, this may be due to the small sample sizes used and lack 
of complete data reported. Given the small sample sizes noted, null findings aren’t unexpected. However, 
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when assessing the average effect of selective serotonin reuptake inhibitors on spirometry, the average 
difference in FEV1 between those on and off selective serotonin reuptake inhibitors was 0.09 (range -0.01 
to 0.21). This small change is unlikely to represent a clinically meaningful or symptomatic difference for the 
individual.  
 This review has several limitations. First, the study results were categorized according to the 
direction and significance of effect, potentially overemphasizing the importance of statistical significance. 
Given the restrictions in the details published, this approach was considered acceptable, despite the 
limitations. An additional limitation was that many studies did not report complete information, leading to 
high assessments for risk of bias; for example, categorizing failure to report baseline FEV1 as high risk may 
overestimate risk. Future reviews could be enhanced by obtaining additional information from the study 
authors. Lastly, this review relied on a single screening interpretation, is therefore subject to error, and can 
be refined through additional quality control measures and coauthor input in the future. 
 Overall, more research is needed, specifically in population-based models, to assess the 
effectiveness of antidepressants in improving lung function. Researchers should consider controlling for 




Figure 2.1. Flow chart of studies included in systematic literature review 
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Table 2.1. Characteristics of the twenty-four studies included, stratified by antidepressant type 
 A. SSRI B. TCA C. Other Total 
N (%) or 
MeanSD 
N (%) or 
MeanSD 
N (%) or 
MeanSD 
N (%) or 
MeanSD 
Studies (%) 8 (33%) 12 (50%) 4 (17%) 24 (100%) 
Study design (text):  Cohort 3 (37.5%) 4 (33.3%) 1 (25%) 7 (29%) 
 Crossover 1 (12.5%) 5 (42%) 2 (50%) 8 (33.3%) 
 RCT 4 (50%) 2 (16.7%)  5 (21%) 
 Other  1 (8%) 1 (25%) 2 (8%) 
Sample size:  1-20 2 (25%) 7 (58%) 2 (50%) 11 (46%) 
 21-40 4 (50%) 4 (33%)  8 (33%) 
 >40 2 (25%) 1 (8%) 2 (50%) 5 (21%) 
Sampling:   In-patient 1 (12.5%)   1 (4%) 
 Out-patient 6 (75%) 10 (83%) 4 (100%) 20 (83%) 
 Both in & out patient  1 (8%)  1 (4%) 
 Unknown 1 (12.5%) 1 (8%)  2 (8%) 
Duration: Cross sectional   1 (25%) 1 (4%) 
 <1 wk-4 wks 1 (12.5%) 3 (25%) 2 (50%) 6 (25%) 
 5-10 wks 2 (25%) 4 (33%)  6 (25%) 
 11 wks -<1 yr 5 (62.5%) 3 (25%)  8 (33%) 
  1 yr  2 (16.7%) 1 (25%) 3 (12.5%) 
Population: No respiratory problems   2 (50%) 2 (8%) 
 COPD 6 (75%) 7 (58%) 1 (25%) 14 (58%) 
 CF  3 (25%)  3 (12.5%) 
 Asthma 2 (25%) 2 (17%) 1 (25%) 5 (21%) 
Baseline FEV1:  Liters 1.10.5 1.00.3 3.60.7 1.20.4 
 % predicted 56.128.7 49.913.1 82.510.1 51.413.3 
 Unknown, n (%) 3 (37.5%) 1 (8%) 2 (50%) 6 (25%) 
% female: 0-25%  1 (8%) 1 (25%) 2 (8%) 
 26-50% 3 (37.5%) 7 (58%) 2 (50%) 12 (50%) 
 51-75% 2 (25%) 3 (25%) 1 (25%) 6 (25%) 
 76-100% 1 (12.5%)   1 (4%) 
 Unknown, n (%) 2 (25%) 1 (8%)  3 (12.5%) 
Mean age:  59.57.8 48.77.8 37.01.8 49.87.2 
 Unknown, n (%) 2 (25%) 2 (16.7%)  4 (16.7%) 
Participants with 
comorbid depression: 
Yes 7 (87.5%) 2 (16.6%) 2 (50%) 11 (45.8%) 
No 1 (12.5%) 10 (83.3%) 2 (50%) 13 (54.2%) 
SSRI: selective serotonin reuptake inhibitors; TCA: tricyclic antidepressants; RCT: randomized controlled trial; 





Table 2.2.A. Spirometry study results by antidepressant type 
 A. SSRI B. TCA C. Other 
 Sig. Non-sig. Total Sig. Non-sig. Total Sig. Non-sig. Unexpected Total 
Overall results (%) 2 (40%) 3 (60%) 5 (24%) 5 (42%) 7 (58%) 12 (57%) 2 (50%) 1 (25%) 1 (25%) 4 (19%) 
Study 
design:  
Cohort 2 (50%) 2 (50%) 4 (80%)  2 (50%) 2 (16.7%)   1 (100%) 2 (50%) 
Crossover  1 (100%) 1 (20%) 1 (20%) 4 (80%) 5 (42%) 1 (100%)   1 (25%) 
RCT    1 (50%) 1 (50%) 2 (16.7%)  1 (100%)  1 (25%) 
 Other    3 (60%)  3 (25%) 1 (100%)    
Sample 
size: 
Average 28 25 25 34 16 19 47 12 2258 47 
 1-20 1 (50%) 1 (50%) 2 (40%) 2 (28.5%) 5 (71%) 7 (58%) 1 (50%) 1 (50%)  2 (50%) 
 21-40  2 (100%) 2 (40%) 2 (50%) 2 (50%) 4 (33%)     
 >40 1 (100%)  1 (20%) 1 (100%)  1 (8%) 1 (50%)  1 (50%) 2 (50%) 
Sampling:   In-patient 1 (100%)  1 (20%)        
 Out-patient  3 (100%) 3 (60%) 4 (40%) 6 (60%) 10 (83%) 2 (67%) 1 (33%) 1 (100%) 4 (100%) 
 In & out 
patient 
   1 (100%)  1 (8%)     














Table 2.2.B. Spirometry study results by antidepressant type 
Moderators of effect 
Baseline FEV1:  Liters 1.00.4 1.10.6 1.10.5 2.0 0.9±0.4 1.00.3 3.60.7   3.60.7 
% predicted  4316 4316 62.1±18.6 31.6±4.9 49.913.1 10714 29±3.2%  82.510.1 
 Unknown  1 (100%) 1 (33%) 1 (100%)  1 (8%) 1 (50%)  1 (50%) 2 (50%) 
% female:  33.7 50 39.1 49.4 35.1 41.5 44.5 25 65.2 44.8 
 Unknown  2 (100%) 2 (40%)  1 (100%) 1 (8%)     
Mean age:  65.53.0 688 66.34.7 28.6±9.3 72.2±7.3 48.77.8 22.3 62.5±1.5 41.1 37.01.8 
 Unknown  2 (100%) 2 (40%) 1 (50%) 1 (50%) 2 (16.7%)     





        1 (100%) 1 (25%) 
 <1 wk-4 wks 1 (100%)  1 (20%) 2 (67%) 1 (33%) 3 (43%) 1 (50%) 1 (50%)  2 (50%) 
 5-10 wks  2 (100%) 2 (40%)  4 (100%) 4(33%)     
 11 wks -<1 yr 1 (50%) 1 (50%) 2 (40%) 2 (67%) 1 (33%) 3 (25%)     
  1 yr    1 (50%) 1 (50%) 2 (16.7%) 1 (50%)   1 (25%) 
Participants w/ 
depression: 
Yes 1 (25%) 3 (75%) 4 (80%)  2 (100%) 2 (16.6%) 1 (50%)  1 (50%) 2 (50%) 
No 1 (100%)  1 (20%) 5 (50%) 5 (50%) 10 (83.3%) 1 (50%) 1 (50%)  2 (50%) 
Antidepressant:
  
Citalopram 1 (100%)  1 (20%)        
Sertraline  1 (100%) 1 (20%)        
 Paroxetine  2 (100%) 2 (40%)        
 Fluoxetine 1 (100%)  1 (20%)        
 Amitriptyline    5 (100%)  5 (42%)     
 Protriptyline     4 (100%) 4 (33.3%)     
 Doxepin     1 (100%) 1 (8%)     
 Desipramine     1 (100%) 1 (8%)     
 Nortriptyline     1 (100%) 1 (8%)     
 Tianeptine       1 (100%)   1 (25%) 
 Mianserin        1 (100%)  1 (25%) 
 Various       1 (50%)  1 (50%) 2 (50%) 





Table 2.3.A. Dyspnea study results by antidepressant type 
 A. SSRI B. TCA C. Other 
 Sig. Non-sig. Total Sig. Non-sig. Total Non-sig. Total 
Overall results (%) 2 (33%) 4 (67%) 6 (55%) 1 (25%) 3 (75%) 4 (36%) 1 (100%) 1 (9%) 
Study design:  Cohort 1 (50%) 1 (50%) 2 (33%)      
 Crossover     2 (100%) 2 (50%)   
 RCT  3 (100%) 3 (50%)  1 (100%) 1 (25%) 1 (100%) 1 (100%) 
 Other 1 (50%)  1 (17%) 1 (100%)  1 (25%)   
Sample size: Average 31 41 36 60 27 35 12 12 
 1-20 1 (100%)  1 (17%)  1 (100%) 1 (25%) 1 (100%) 1 (100%) 
 21-40  3 (100%) 3 (50%)  2 (100%) 2 (50%)   
 >40 1 (50%) 1 (50%) 2 (25%) 1 (100%)  1 (25%)   
Sampling:   In-patient 1 (100%)  1 (17%)      
 Out-patient  5 (100%) 5 (83%)  2 (100%) 2 (50%) 1 (100%) 1 (100%) 
 Both in & out 
patient 
   1 (100%)  1 (25%)   











Table 2.4.B. Dyspnea study results by antidepressant type  
Moderators of effect 
Baseline FEV1:  Liters 1.00.4 1.10.6   0.69±0.41    
 % predicted  34.620.7   22.3±6.0  29±3.2% 29±3.2% 
 Unknown, n (%)  2 (100%) 2 (33%) 1 (100%)  1 (25%)   
% female:  33.7 56.7  31.6 43.7  25 25 
 Unknown, n (%)         
Mean age:  65.53.0 52.6   61.2  62.5±1.5 62.5±1.5 
 Unknown, n (%)  1 (100%) 1 (17%) 1 (100%)  1 (25%)   
Duration: Average 10 weeks 12 weeks 11 weeks 16 weeks 9 weeks 11 weeks 3 weeks 3 weeks 
 Cross sectional         
 <1 wk-4 wks 1 (100%)  1 (17%)    1 (100%) 1 (100%) 
 5-10 wks     2 (100%) 2 (50%)   
 11 wks -<1 yr 1 (20%) 4 (80%) 5 (83%) 1 (50%) 1 (50%) 2 (50%)   
  1 yr         
Participants with 
depression: 
Yes 1 (20%) 4 (80%) 5 (83%)  2 (100%) 2 (50%)   
No 1 (100%)  1 (17%) 1 (50%) 1 (50%) 2 (50%) 1 (100%) 1 (100%) 
Antidepressant: Citalopram 1 (50%) 1 (50%) 1 (17%)      
 Paroxetine  2 (100%) 2 (33%)      
 Fluoxetine 1 (50%) 1 (50%) 2 (33%)      
 Escitalopram         
 Amitriptyline    1 (100%)  1 (25%)   
 Protriptyline     2 (100%) 2 (50%)   
 Nortriptyline     1 (100%) 1 (25%)   
 Mianserin       1 (100%) 1 (100%) 





Table 2.5. Overview of study quality, stratified by antidepressant type 
  A. SSRI B. TCA C. Other Total 
  8 (33%) 12 (50%) 4 (17%) 24 (100%) 
Study participation: High 1 (13%) 3 (25%)  4 (17%) 
Low 7 (87%) 9 (75%) 4 (100%) 20 (83%) 
Unclear     
Study Attrition: High 3 (38%) 7 (58%)  10 (42%) 
Low 3 (38%) 5 (42%) 3 (75%) 11 (46%) 
Unclear 2 (25%)  1 (25%) 3 (12%) 
Outcome Measurement 
and Reporting: 
High 2 (25%) 2 (17%) 2 (50%) 6 (25%) 
Low 6 (75%) 10 (83%) 2 (50%) 18 (75%) 
Unclear     
Study Confounding: High 3 (38%) 3 (25%) 1 (25%) 7 (29%) 
Low 5 (62%) 9 (75%) 3 (75%) 17 (71%) 
Unclear     





Background: COPD refers to a group of inflammatory diseases that cause airflow obstruction, respiratory 
muscle weakness, and breathing-related problems (such as increased breathlessness, frequent coughing, 
and tightness in the chest) that result in reduced lung function. Some antidepressants, namely selective 
serotonin reuptake inhibitors, may have potential off-label uses in treating COPD symptoms. Objectives: 
This study aims to investigate whether participants taking selective serotonin reuptake inhibitors have better 
concurrent lung function than those not taking selective serotonin reuptake inhibitors. Methods: Analyses 
were conducted using exam 4 and 5 data from the Multi Ethnic Study of Atherosclerosis-Lung Study. 
Participants brought to the exam visit containers for all medications taken during the prior two weeks. 
Different antidepressants were categorized according to the Anatomical Therapeutic Chemical 
classification system. Lung function and patient symptoms were assessed through two measures: 
spirometry and dyspnea ratings. Included confounders consisted of smoking status, pack-years and 
depressive symptoms. We used two different approaches to analyzing the data, linear regression and 
difference-in-difference analyses. Main results: There were 3,542 eligible participants at exam 4 and 2,954 
participants at exam 5. At both exams, findings indicate an inverse relationship between selective serotonin 
reuptake inhibitors and FEV1%, contrary to our hypothesis. Selective serotonin reuptake inhibitors were 
also significantly associated with a higher odds of dyspnea. The difference-in-difference analysis revealed 
that those who went on selective serotonin reuptake inhibitors decreased their lung function while those 
who remained off increased their lung function for a net effect of 4.0% (p=0.03). Results do not support 
hypothesized associations between selective serotonin reuptake inhibitors and improved lung function. 
Conclusions: The overall results suggest selective serotonin reuptake inhibitors do not positively affect lung 
function or dyspnea.  
CHAPTER 3. A POPULATION BASED STUDY OF THE ASSOCIATION 
BETWEEN SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND 





COPD refers to a group of diseases that cause airflow obstruction, respiratory muscle weakness, 
and breathing-related problems (such as increased breathlessness, frequent coughing, and tightness in the 
chest) that result in reduced lung function [8]. Middle-aged and older adults are most likely to have a 
diagnosis of COPD. Worldwide, COPD affects men and women equally. Symptoms include shortness of 
breath (or dyspnea), persistent (chronic) cough, wheezing and labored breathing during physical activity. 
Respiratory exacerbations, a sudden worsening of respiratory symptoms and airway function, are also a 
concern for COPD patients and their practitioners. Currently, there is no cure for COPD; therefore, 
practitioners focus on reducing the risk of respiratory exacerbations and mortality and improving symptoms 
as the primary treatment goals [11].  
Inflammation plays a large role in COPD, as evidenced by the Global Initiative for Chronic 
Obstructive Lung Disease classifying COPD as an inflammatory disease [8]. The inflammatory markers 
found in older adults with stable COPD [5, 82] reflect disease severity and functional status. However, even 
in young adults without COPD, and independent of asthma, smoking, and body weight, an inverse 
association is seen between lung volumes and systemic inflammation [83]. This association of higher 
inflammatory markers with lower lung function in those without COPD suggests an association between 
lung function and inflammation predating the clinical development of obstructive disease. Therefore, 
reducing inflammation may be beneficial for subclinical disease, in addition to those with clinically defined 
obstructive disease. 
Since inflammation is relevant to COPD symptoms, current treatments for low function are 
designed to decrease inflammation [12-15]. For example, due to their anti-inflammatory effects, inhaled 
corticosteroids improve pulmonary function and dyspnea, shorten hospitalizations, and decrease the 
frequency of exacerbations [21, 22]. However, they also result in significant adverse outcomes, which 
lead researchers to consider other drugs. Statins, approved as lipid-lowering agents, are potentially useful 
in COPD due to their anti-inflammatory effects, as evidenced by observational studies showing that 





Like statins, some antidepressants, namely selective serotonin reuptake inhibitors, may have off-
label uses in treating COPD symptoms. Selective serotonin reuptake inhibitors are anti-inflammatory and 
act upon serotonin, which is integral to central breathing control [16, 17]; this combination may provide an 
additional benefit over current COPD treatment regimes.  
Prior research on antidepressants & lung function 
Several small studies have examined the effect of antidepressants on lung function. A recent review 
showed that the currently available published studies do not consistently support the hypothesized 
association. Only 38% of studies observed a significant positive association between antidepressants and 
lung function (Chapter 2). Of the remaining studies, 46% found a non-significant association regardless of 
the direction and 4% found a significant result in the opposite direction as hypothesized. Results tended to 
vary by inclusion of participants with comorbid depression, severity of lung function impairment, and type 
of antidepressant. However, the majority of the studies were subject to methodological limitations including 
small sample sizes, poor or inconsistent confounder control, and lack of complete reporting across studies. 
Given the plausibility of a mechanism of action and the limitations of previous studies, more research is 
needed using population-based data to provide information on the potential for certain antidepressants in 
improving lung function.  
The purpose of this study is to investigate whether participants on selective serotonin reuptake 
inhibitors have better concurrent lung function than those not selective serotonin reuptake inhibitors. It aims 
to help augment the limited evidence on the effect of selective serotonin reuptake inhibitors on lung function. 
This paper estimates the effect of selective serotonin reuptake inhibitors on lung function, after adjusting 






Sample: The Multi Ethnic Study of Atherosclerosis-Lung Study 
  Sponsored by the National Heart Lung and Blood Institute, the Multi Ethnic Study of Atherosclerosis 
(MESA) is a multi-center, population-based, longitudinal study of 6,814 men and women aged 45-64 years 
at baseline across six sites in the United States (Columbia University, New York; Johns Hopkins University, 
Baltimore; Northwestern University, Chicago; UCLA, Los Angeles; University of Minnesota, Twin Cities; 
Wake Forest University, Winston Salem) (ClinicalTrials.gov Identifier: NCT00005487) [84]. MESA 
investigates the prevalence, correlates, and progression of subclinical cardiovascular disease and risk 
factors that predict progression to clinical cardiovascular disease. Exclusion criteria consisted of clinical 
cardiovascular disease (physician diagnosis of heart attack, stroke, transient ischemic attack, heart failure, 
or angina), current atrial fibrillation, any cardiovascular procedure, pregnancy, active cancer treatment, 
weight greater than 300 pounds, a serious medical condition which preclude long term participation, nursing 
home residence, cognitive inability, inability to speak English, Spanish, Cantonese, or Mandarin, plans to 
leave the community within five years, and a chest CT within the past year. At baseline, approximately 38% 
of the recruited participants were White, 28% Black, 22% Hispanic, and 12% Asian, predominantly of 
Chinese descent. A full description of the objectives and design has previously been published [84].  
  As illustrated in Figure 3.1, the first MESA exam visit was from July 2000-August 2002 and was 
followed by four follow-up exams: September 2002-February 2004, March 2004-September 2005, 
September 2005-May 2007, and April 2010-December 2011. The MESA protocol, including information 
about the source populations from which recruitment occurred, further details on exclusion criteria, and 
other information, is available at www.mesa-nhlbi.org. A description of the cohort at exams 1-5, study 




Appendix Table 6 and Appendix Table 7. 
MESA-Lung is an ancillary study of MESA to test the endothelial hypothesis of COPD and 
emphysema (ClinicalTrials.gov Identifier: NCT00843271). The biological hypothesis that underlies the 
MESA-Lung Study is that alterations in endothelial and vascular function are associated with the 
pathogenesis and progression of subclinical COPD and emphysema, in part through the effects of systemic 
inflammation on the vascular endothelium.  
In 2004-2006, the MESA-Lung study recruited 3,965 participants sampled randomly from MESA 
exam 3 and 4 participants who had baseline flow-mediated dilatation measures (89% of MESA 
participants), attended MESA exam 3 or 4 (87% of MESA participants), and consented to genetic analyses 
(99% of MESA participants). The MESA-Lung cohort is approximately 35% White, 24% Black, 23% 
Hispanic, and 18% Asian, mostly of Chinese descent. Of the original MESA-Lung cohort, over 3,000 were 
re-examined in 2010-2012 (MESA-Lung 2). Our analyses use the MESA-Lung data 1 and 2 (which 
corresponds to MESA exam 3, 4 and 5). The institutional review boards of all collaborating institutions and 
the National Heart Lung and Blood Institute (National Institutes of Health, Bethesda, MD, USA) approved 
the protocols of MESA and all procedures described herein. All participants provided informed consent. 
The MESA publications and presentations committee approved a proposal for this analysis. 
Exposure variable 
The exposure of interest was use of antidepressants, specifically selective serotonin reuptake 
inhibitors. Participants brought to the exam visit containers for all medications taken during the prior two 
weeks. Different antidepressants were categorized according to the Anatomical Therapeutic Chemical 
classification system (selective serotonin reuptake inhibitors, tricyclic antidepressants, and serotonin 
norepinephrine reuptake inhibitors) [85]. We coded this variable as an indicator variable (yes (1)/no (0)) for 







 The outcome was lung function and patient symptoms, assessed through two measures: 
spirometry and dyspnea ratings. Spirometry assesses how well the lungs work by measuring how much air 
is inhaled, how much is exhaled, and how quickly the air is exhaled. Normal spirometry readings vary, 
depending on age, size and gender. If the airways are narrowed from obstruction, then the amount of air 
that can be exhaled is reduced. Spirometry can also help to assess if treatment opens the airways through 
an improvement in the readings. Dyspnea ratings measure the subjective experience of breathing 
discomfort. We assessed both because spirometry gives an objective assessment of lung function 
improvement while dyspnea gives a patient-centered outcome on how the patient feels. While it is important 
to know if the objective lung function improves, having patient-centric results is also important- it does not 
matter how much the lung function improves if the patient does not feel better. Spirometry is often used in 
diagnosing pulmonary disease since it is standardized and the current gold standard for objectively defining 
airflow obstruction [50]. In contrast, there are various questionnaires and scales used to measure dyspnea, 
making comparisons across studies challenging. 
Spirometry:  A decreased forced expiratory volume in one second (FEV1) is the measure primarily used to 
show reduced lung function in COPD [51]. Predicted reference values have been calculated and compared 
with samples of healthy subjects drawn from the general population to yield percent predicted (%) 
standards. While many different percent predicted standards exist, the American Thoracic Society uses an 
equation that gives referents based on height, age, gender, and race [86]. Spirometry was measured in the 
MESA-Lung study in accordance with American Thoracic Society/European Respiratory Society guidelines, 
[50, 87] on a dry-rolling-sealed spirometer (Occupational Marketing, Inc., Houston, TX) as previously 
described [88]. We used percent-predicted values (FEV1%) that are continuous in our analyses. 
Dyspnea: Trained interviewers assessed dyspnea at both exams. We defined dyspnea as a positive answer 
to one of the following questions: “When walking on level ground, do you get more breathless than people 
your own age?” or “Do you ever have to stop walking due to breathlessness?” This definition corresponds 
to the modified Medical Research Council dyspnea scale grade 2 or worse [89]. Dyspnea was coded 





To identify potential confounders and the minimal set necessary for control, we developed a 
directed acyclic graph based on previous literature (Appendix Figure 1). From the literature aided by the 
directed acyclic graph, we deemed health insurance, smoking status, and depressive symptoms to be 
potential confounders. We also considered age and gender, but since these variables are adjusted for in 
FEV1% equations we did not adjust for them in the analyses. 
Health Insurance: Different health coverage results in different prescription coverage (some plans have 
better coverage of prescription drugs than others do). Additionally, lack of health insurance has been 
associated with a decline in overall health [90]. Health insurance was categorized as indicator variables for: 
None (referent group), Medicaid, Medicare, Private, and VA/Other. 
Smoking status and pack-years: Smoking destroys the alveoli in the lungs, reducing lung function. Smoking 
is also linked to depression [91, 92]. Depression leads to antidepressant use. Smoking status was 
categorized into never (0), former (1) and current smokers (2), with never smokers as the referent group.  
Pack-years is a measure of smoking duration and amount. Quantification of pack-years is important 
because increased tobacco exposure is closely associated with lower lung function [93, 94]. Additionally, 
depression is associated with increased pack-years [95].  
Depressive symptoms: In epidemiologic studies, depression is associated with lower lung function [96]. 
One potential mechanism for this association is that those who are depressed put less effort forth on their 
spirometry tests, resulting in lower lung function scores. Additionally, depression is an indication for 
antidepressant medication. In MESA, the Centers for Epidemiologic Studies Depression (CES-D) scale 
[97], was used as a measure of depressive symptoms. The 20 items in the CES-D scale measure symptoms 
of depression: sadness, loss of interest, appetite, sleep, thinking/concentration, guilt, being tired, 





Analyses were conducted in SAS 9.4. We excluded participants if they a) did not have exposure 
(medication) information available, b) were on more than one antidepressant or c) were missing data on 
any confounder included in the model. See Error! Reference source not found., Error! Reference source no
t found. for an explanation on this choice of handling missing data.  
Confounder selection: Final selection of confounders included an observed association with the exposure 
and outcomes (p<0.20) in linear or logistic regression (depending on the dependent variable), and a change 
of 10% or more in the crude exposure-outcome (betas) [98] when the potential confounder was added to 
the crude model. To keep the models consistent between exams, confounders that were found to have a 
10% change in the crude exposure-outcome in either exam 4 or 5 were used.  
Main analyses: We used two different approaches in analyzing the data, linear regression and difference-
in-difference analyses. The linear regression approach assesses the association of selective serotonin 
reuptake inhibitors on lung function at exam 4 and exam 5, separately, which allows us to see the average 
difference between the control and treatment groups. The difference-in difference approach compares the 
effect of those who change their selective serotonin reuptake inhibitor status between exams 4 and 5 with 
those who do not. The advantage of also performing the difference-in-difference analysis is that it allows 
us to remove biases between groups that do not change overtime.  
Linear regression models 
The effects of selective serotonin reuptake inhibitors are likely to be short-lived as the half-life of 
these drugs is limited, ranging from approximately 4-7 hours to about 4-6 days. Therefore, we would expect 
concurrent effects of selective serotonin reuptake inhibitors on lung function. It may be odd to expect this 
given that the effect of antidepressants on depression is slow [99]; however, antidepressants quickly stop 
the process of serotonin transports from taking up released serotonin. In people with depression, G proteins 
build up and lose access to a molecule called cyclic AMP, which the proteins need in order to transmit the 




However, these G proteins are not involved in the pathways for lung function [100], so we would still expect 
to see immediate effects of selective serotonin reuptake inhibitors on lung function.  
We examined selective serotonin reuptake inhibitors and lung function at exam 4 and at exam 5; 
FEV1% was normally distributed and analyzed using multiple linear regression, assumptions were checked 
by inspection of the residuals. Dyspnea was analyzed using logistic regression. 
Difference-in-Difference analysis 
The difference-in-difference technique aims at restructuring observational data to approximate an 
experimental design and accounts for the time-invariant effect of any measured or unmeasured person-
level characteristic. We employed a difference-in-difference analysis comparing those who changed their 
selective serotonin reuptake inhibitor status (inconsistent status) between exam 4 and exam 5 with those 
who did not (consistent status). Because difference-in-difference models are a repeated measures design, 
the outcome values for a subject are assumed to be correlated. To account for this correlation, we used a 
repeated measures ANOVA (generalized estimating equations (GEE) for dyspnea); this allows us to 
account for the correlation within subjects and provides the mean outcome values in each exposure group 
for each exam [101].  
As illustrated in Table 3.1, we stratified by selective serotonin reuptake inhibitor use at exam- those 
who were on selective serotonin reuptake inhibitors at exam 4 (Column A) and those who were not on 
selective serotonin reuptake inhibitors at exam 4 (Column C). The control and treatment groups were 
determined by the selective serotonin reuptake inhibitor status at exam 5 (Columns B and D). Those who 
had consistent status between exam 4 and 5 were the control group and those who switched were the 
treatment group. We repeated this for dyspnea, as a percentage of patients who reported dyspnea. If our 
hypothesis is supported, we would expect the treatment group in comparison group 1 to have a decrease 
in lung function compared with the control group; in comparison group 2, we would expect the treatment 
group to have an increase in lung function compared with the control group,  
Although our interest is in selective serotonin reuptake inhibitors, we also investigated other classes 




and those that work through the biological pathways mentioned above (serotonin and inflammation). We 
hypothesized that the effects of selective serotonin reuptake inhibitors on lung function are due to their 
biological mechanisms as opposed to their effect on depression. If the other antidepressants also have a 
positive effect on lung function, then we will have less confidence that it is due to the biologic mechanisms 
rather than a reduction of depression symptoms.  
Corticosteroid analysis 
There are approximately 400 participants with COPD in the cohort. As inhaled corticosteroids and 
bronchodilators are the current medications for low lung function, we performed an additional analysis that 
included an indicator variable for common medications that affect lung function in the model (Appendix 
Table 8). The purpose of our analysis was to determine if our results remain when accounting for other 
medications that affect lung function.  
Sample characteristics 





Table 3.2, the MESA-Lung sample consisted of 3,542 eligible participants at exam 4. The mean 
age of the sample was 66 years, 51% were female, 35% White, 16% Asian, 26% Black, and 23% Hispanic. 
Approximately 9% were current smokers and 39% were former smokers, with an average of 22 pack-years. 
The mean FEV1%, was 94±18%; dyspnea was reported in 15% of the cohort. The average CES-D score 
was eight, with 14% classified as depressed from the CES-D. We excluded 11 participants from further 
analysis since they were on more than one antidepressant and we would not be able separate out the 
effects of the antidepressants if they were on more than one concurrently.  
At exam 4, 178 participants were on selective serotonin reuptake inhibitors, 42 on serotonin 
norepinephrine reuptake inhibitors, and 38 on tricyclic antidepressants. The average age was roughly 
similar across antidepressant groups, with those on tricyclic antidepressants being slightly older. The 
selective serotonin reuptake inhibitor group had the highest proportion of current smokers and the lowest 
FEV1% at baseline. This group also had the largest proportion of participants who were depressed.  
As shown in Table 3.3 there were 2,954 participants at exam 5. As expected, the mean age at 
exam 5 increased from exam 4 to 69 years. The demographic distribution was similar from exam 4 with the 
cohort being 51% female, 38% White, 14% Asian, 26% Black, and 21% Hispanic. Approximately 7% were 
current smokers and 39% were former smokers, with an average of 22 pack-years. Mean FEV1% was 95% 
with 15% of the population reporting dyspnea. The average CES-D score was eight, with 14% classified as 
depressed. We excluded 10 individuals from further analysis since they were on more than one 
antidepressant. 
At exam 5, 152 participants were on selective serotonin reuptake inhibitors, 54 on serotonin 
norepinephrine reuptake inhibitors, and 25 on tricyclic antidepressants. The average age was similar 
between all groups. At this exam, the tricyclic antidepressant group had the highest proportion of patients 
who were current smokers and the lowest FEV1%. The selective serotonin reuptake inhibitor group still had 




Confounder criteria  
Before running any models, we tested the potential confounders to confirm their association with 





Table 3.4). At exam 4, all potential confounders were significantly associated with dyspnea and 
selective serotonin reuptake inhibitors. The only variable that was not significant with FEV1% was type of 
health insurance. Similar patterns of association were seen at exam 5 (see Appendix Table 9). 
Next, we placed each confounder into the model with selective serotonin reuptake inhibitors and 
the outcomes to see if a 10% change in the crude exposure-outcome beta was seen. All confounders except 
for health insurance met this criterion and therefore were included in further analyses. We also looked at a 
model including health insurance and the estimates did not change, suggesting that the results were robust 
to the exclusion of this variable in further analyses.  
Linear regression models 
Forced expiratory volume in one second 
The unadjusted and adjusted findings from the linear regression models between selective 




Table 3.6. At both exams, findings indicate an inverse relationship between selective serotonin 
reuptake inhibitors and FEV1%, against our hypothesis. This association was moderately attenuated by the 
inclusion of confounders in the model, but still had a substantial negative association in the fully adjusted 
model (Column B) at exam 4 and exam 5. 
When other antidepressants were added to the model (Column C), the associations remained 
consistent at exam 4 and were again in the same inverse direction at exam 5. Except for tricyclic 
antidepressants at exam 4, all antidepressants were inversely associated with FEV1% at both exams; 
however, these estimates were not very precise as evidenced by their wide confidence intervals.  
We performed an analysis including a variable for medications that affect lung function in the 
models. At exam 4, 4.5% of participants were on these medications, with 9.4% on them at exam 5. When 
adding corticosteroid use to the adjusted linear regression model (Adjusted model 1 from tables 4 and 5), 
being on selective serotonin reuptake inhibitors was now associated with a -2.38 (95% CI: -4.94 to 0.17) 
lower FEV1% at exam 4 and a -1.11 (95% CI: -4.08 to 1.85) lower FEV1% at exam 5. For the logistic 
regression models, when adding the variable for lung function medications, being on selective serotonin 
reuptake inhibitors was now associated with a 1.23 (95% CI: 0.85 to 1.80) increased odds for dyspnea at 
exam 4 and a 1.25 (95% CI: 0.86 to 1.82) increased odds at exam 5. 
Dyspnea 
 The logistic regression models assessing the relationship between selective serotonin reuptake 
inhibitors and dyspnea are in Table 3.7 and Table 3.8. Selective serotonin reuptake inhibitors were 
significantly associated with an increased odds of dyspnea in the unadjusted models; but after controlling 
for confounders (Column B), this association was attenuated. 
 When other antidepressants were added to the model, (Column C) the odds ratio for dyspnea when 
on selective serotonin reuptake inhibitors remained consistent. Although not always significant, all 





Table 3.9 shows the unadjusted changes in FEV1% from exam 4 to exam 5 in the control and 
treatment groups. The average FEV1% at exam 4 was similar between the control and treatment groups 
for all comparisons. In the treatment group that went off selective serotonin reuptake inhibitors (comparison 
group 1- on/off), the average FEV1% increased from 89% to 93%. The average FEV1% similarly increased 
in the control group who stayed on selective serotonin reuptake inhibitors (on/on) from 90% to 92%. The 
net effect (difference-in-difference) of going off selective serotonin reuptake inhibitors was 2% but was not 
significant (p=0.49). Results were similar when adjusting for CES-D score, smoking status, and pack-years. 
The average FEV1% decreased from 91% to 89% in the treatment group that went on selective 
serotonin reuptake inhibitors (comparison group 2-off/on) and increased in the control group who stayed 
off selective serotonin reuptake inhibitors (off/off) from 94% to 96%. The net effect (difference-in-difference) 
of going on selective serotonin reuptake inhibitors was 4% and was significant (p=0.03). Results were 
similar when adjusting for CES-D score, smoking status, and pack-years. We also assessed the difference-




Appendix Table 10 and Appendix Table 11); none of these associations were significant.  
 Results remained consistent when adding an indicator variable for lung function medications to the 
difference-in-difference models. The control group (those that remained on selective serotonin reuptake 
inhibitors-on/on) had an FEV1% of 84% at exam 4, which increased to 86% at exam 5 resulting in an 
absolute difference of 2%. The treatment group (those that went from being on selective serotonin reuptake 
inhibitors at exam 4 to being off them at exam 5-on/off) had an FEV1% of 81% at exam 4, increasing to 
83% at exam 5, with an absolute difference of 2%. The net effect (difference-in-difference) of going off 
selective serotonin reuptake inhibitors was 0% and was not significant (p=0.86). For comparison group 2, 
when adding lung function medication use to the difference-in-difference models, the control group (those 
that remained off selective serotonin reuptake inhibitors-off/off) had a FEV1% of 83% at exam 4, which 
remained consistent at 83% at exam 5 resulting in an absolute difference of 0. The treatment group (those 
that went on selective serotonin reuptake inhibitors at exam 5-off/on) had an FEV1% of 81% at exam 4, 
decreasing to 78% at exam 5, with an absolute difference of 3%. The net effect (difference-in-difference) 
of going on selective serotonin reuptake inhibitors was 3% and was significant (p=0.049). 
The difference-in-difference in patients reporting dyspnea was then assessed (Table 3.10). In the 
treatment group that went off selective serotonin reuptake inhibitors (on/off), the proportion of patients 
reporting dyspnea decreased from 27% to 25%. The average proportion of patients reporting dyspnea 
similarly decreased in the control group who stayed on selective serotonin reuptake inhibitors (on/on) from 
25% to 23%. The net effect (difference-in-difference) of going off selective serotonin reuptake inhibitors 
was 0%. Results were similar when adjusting for CES-D score, smoking status, and pack-years. 
The proportion of patients reporting dyspnea increased from 22% to 26% in the treatment group that 
went on selective serotonin reuptake inhibitors (off/on) and increased in the control group who stayed off 
selective serotonin reuptake inhibitors (off/off) from 13% to 14%. The net effect (difference-in-difference) of 
going on selective serotonin reuptake inhibitors was 3%, but was not significant (p=0.65). 
We also assessed the difference-in-difference analyses for serotonin norepinephrine reuptake 








Appendix Table 13); none of the analyses were significant but also had small sample sizes for the 
proportion of patients on treatment.  
Similar to FEV1, results remained consistent when adding an indicator variable for lung function 
medications to the difference-in-difference models for dyspnea. In comparison group 1 the control group 
decreased from 47% reporting dyspnea at exam 4 to 41% at exam 5, with an absolute difference of 6%. 
The treatment group increased from 38% at exam 4 to 39% at exam 5, with an absolute difference of 1%. 
The net effect (difference-in-difference) of going off selective serotonin reuptake inhibitors was 7% and was 
not significant (p=0.44). In comparison group 2, the control group decreased from 29% reporting dyspnea 
at exam 4 to 24% at exam 5, with an absolute difference of 5%. The treatment group decreased from 33% 
at exam 4 to 26% at exam 5, with an absolute difference of 7%. The net effect (difference-in-difference) of 
going off selective serotonin reuptake inhibitors was 2% and was not significant (p=0.63). 
 In summary, adding lung function medications to the models decreased the effect sizes slightly, 
but the direction and results remained consistent. 
Post-hoc analysis 
Since approximately 20% of those on antidepressants still had CES-D scores indicating they were 
depressed (uncontrolled depression), we looked at the effect CES-D score (both as a continuous measure 
as dichotomized by cutoffs for depression) had on the crude association. Participants with a CES-D score 
≥16 are identified as having depression, while those with a score <16 are not [102]. 
Appendix Table 14 to 17 compare the crude and adjusted effects. FEV1% at exam 4 and 5 (Error! 
Reference source not found. and 15) showed a small difference when controlling for CES-D as a continuous 
measure, but the effect is very slight. In the case of dyspnea (Error! Reference source not found. and 17) w
here the effect decreases, it still does not support our hypothesis of depression causing selective serotonin 
reuptake inhibitors to be poorly associated with FEV1%. The adjusted models still show selective serotonin 




Results were similar when assessing CES-D dichotomized as cutoffs for depression. None of the 
analyses resulted in a change in the direction of the relationship between selective serotonin reuptake 
inhibitors and FEV1% or dyspnea.  
It is hypothesized that selective serotonin reuptake inhibitors may improve lung function through 
their anti-inflammatory and serotonergic effects. Prior research on the effects of antidepressants and lung 
function has been in small studies with minimal confounder control. To fill evidence needs, this study aimed 
to test the effect of selective serotonin reuptake inhibitors on lung function using a population based cohort 
with control for confounders. The results did not support our hypothesis; indeed, the associations were in 
the opposite direction. Using a large population-based prospective dataset, we found that selective 
serotonin reuptake inhibitors are inversely associated with FEV1%, after controlling for depression score, 
smoking status, pack-years, and other types of antidepressants. Selective serotonin reuptake inhibitors 
were associated with a 4.66% decrease in FEV1% at exam 4; after controlling for depression score, 
smoking status, and pack-years, this association remained significant and in the inverse direction. 
Furthermore, this association persisted after additionally controlling for serotonin norepinephrine reuptake 
inhibitors and tricyclic antidepressants. In the adjusted difference-in-difference models, the net effect of 
going on selective serotonin reuptake inhibitors was 3% for FEV1% (p=0.03); those that went on selective 
serotonin reuptake inhibitors decreased their lung function, while those that remained off increased it. 
Selective serotonin reuptake inhibitors were also significantly associated with an increased odds of dyspnea 
at exam 4 and 5. This association was consistently in the positive direction, after including the control 
variables and other antidepressants in the models. The difference-in-difference analysis also did not 
support our hypothesis; compared with those who remained off selective serotonin reuptake inhibitors the 
group that initiated them had a larger increase in the proportion who reported dyspnea, however the point 
estimate was above the null and had wide confidence intervals.  
Both the linear regression and difference-in-difference results were unexpected and in the opposite 





between those who remained on selective serotonin reuptake inhibitors and those who went off. If there 
were a true harmful effect of selective serotonin reuptake inhibitors and lung function, we would expect to 
see an improvement in the lung function of those who went off medication compared with the control group. 
Of note, our sample size was smaller in the on/off groups, which may have prevented us from finding an 
association.  Additionally, we have not come across any previous studies demonstrating patients who went 
on selective serotonin reuptake inhibitors having a decrease in lung function. 
Another hypothesis for this inverse association is depression. Although depression is controlled for 
through the CES-D score, we have no measure of the severity of depression prior to being on an 
antidepressant. Additionally, even in individuals who were on antidepressants, the CES-D scores were still 
elevated and a significant proportion still had CES-D scores ≥16, indicating depression. Since depression 
is linked to increased levels of inflammation [103], it is possible that the increased inflammation seen in 
depression overrides the potential anti-inflammatory effects of selective serotonin reuptake inhibitors on 
reducing inflammation. Therefore, what we are really seeing is an increase in inflammation from depression 
leading to a decrease in lung function rather than the selective serotonin reuptake inhibitors causing a 
decrease in lung function. Supporting this are results from two randomized, placebo-controlled studies by 
Brown et al involving patients with asthma and major depressive disorder. The authors found there was no 
change in the dyspnea scale after treatment with selective serotonin reuptake inhibitors [60, 61]; however, 
participants who were able to achieve a depression remission had greater reductions in dyspnea than those 
that did not. Our post-hoc analysis did not support the hypothesis that depression was responsible for the 
inverse association between selective serotonin reuptake inhibitors and lung function. However, further 
studies can assess inflammation as a mediator between antidepressant and lung function. 
There are several limitations to this study, including several sample-related limitations. We did not 
assess the specific drug (other than antidepressant type) that was prescribed or the dose. While drugs in 
an antidepressant class have a similar chemical make-up, other fillers and additives may change their 
effects on lung function. For example, in the systematic literature review (Chapter 2), it was noted that 
studies investigating citalopram and fluoxetine were consistently among the studies with positive 




the anti-inflammatory effects of antidepressants to affect lung function. Additionally, it would be ideal to 
have a measure of lung function and confounders just prior to taking the antidepressant, and then measure 
these again after placing participants on the antidepressant. This would allow us to determine the change 
in confounders (for example depression) in parallel with the change in lung function. Lastly, exam 4 and 5 
are separated by approximately 5 years, so our difference-in-difference estimate has a wide gap between 
estimates.  
There are several strengths to this study as well. This investigation was among the first to assess 
the impact of antidepressants on lung function using epidemiologic methods. Prior studies have been 
limited to small sample sizes and often did not consider potential confounding; this study included measures 
of depressive symptoms, smoking status and health insurance. To assess the impact of selective serotonin 
reuptake inhibitors, we conducted an analysis of individual level data. In order to control for the limitations 
of this approach, including incomplete confounder control, we additionally performed a difference-in-
difference method to estimate the effect of individual-level selective serotonin reuptake inhibitor exposure 
on lung function. While still potentially suffering from bias due to residual confounding, this method 
addresses confounding by unmeasured time-invariant attributes.  
In conclusion, there is no evidence to support our hypothesis of selective serotonin reuptake 
inhibitors improving concurrent lung function. Further research can improve upon this study by including 
measures of confounders prior to and after antidepressant initiation to understand the change in depression 





Figure 3.1.Timeline of the Multi Ethnic Study of Atherosclerosis and ancillary study exam visits 
 
Table 3.1. Difference-in-difference stratification 
 A. SSRI use at Exam 4 B. SSRI use at Exam 5 
 
Comparison group 1 
Control Group On On 
Treatment Group On Off 
 
 C. SSRI use at Exam 4 D. SSRI use at Exam 5 
 
Comparison group 2 
Control Group Off Off 
Treatment Group Off On 
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% N or 
mean±SD 
% N or 
mean±SD 
% N or 
mean±SD 
% N or 
mean±SD 
% 
Age, years, mean±SD 66±10  66±10  64±10  70±10  66±10  
Age group, years           
45-54 445  14 28 16 9 21 3  8 486 14 
55-64 1081  33 64  36 13 31 10  26 1172 33 
65-74 1026 31 44  25 13 31 13  34 1100 31 
75-84 649 20 35  20 7 17 8 21 701 20 
>85 72 2 7 4 0 0 4 11 83 2 
Gender           
Male 1656  51 65 37 9 21 13 34 1748 49 
Female 1617  49 113 64 33 79 25  66 1794 51 
Race/ethnicity           
White 1086 33 113 64 30 71 16  42 1254 35 
Asian 559 17 4 2 3 7 1 3 567 16 
African-American 876  27 19  11 4 10 7  18 907 26 
Hispanic 752  23 42  24 5 12 14  36 814 23 
Height, cm, mean±SD 166±10  165±9  167±9  164±7  166±10  
BMI, kg/m2, mean±SD 28±5  29±6  31±6  29±7  28±5  
Health Insurance           
None 181  6 5  3 2 5 1  3 189 5 
Medicaid 268  8 16  9 5 12 7 18 297 8 
Medicare 325  10 10  6 3 7 3  8 341 10 
HMO 2147  66 128  72 30 71 19  50 2331 66 
VA/Other 352 11 19 11 2 5 8 21 384 11 
Cigarette smoking status           
Never-smokers 1720  53 80  45 17 42 16  42 1835 52 
Former smokers 1257  39 69  39 20 49 17  45 1371 39 
Current smokers 286 9 29 16 4 10 5 13 325 9 
Smoking history pack-
years# 
22±25  27±36  18±15  34±36  22±26  
FEV1 % predicted, mean±SD 94±18  90±18  91±12  97±16  94±18  
COPD Stage           
None 2551 78 139 78 31 74 29 76 2757 78 
Mild 420 13 17 10 6 14 6 16 449 13 
Moderate 265 8 19 11 5 12 3 8 295 8 
Severe 32 1 2 1 0 0 0 0 35 1 
Very Severe 5 .15 1 .60 0 0 0 0 6 .17 
Dyspnea 465  14 42  24 14 33 14  37 541 15 
CES-D Score, mean±SD 7±7  13±11  11±11  10±8  8±8  
Depressed (CES-D≥16) 413  13 54  30 10 24 8 21 489 14 
Corticosteroid use           
Yes 135 4 17 10 2 5 5 13 159 5 
No 3138 96 161 91 40 95 33 87 3383 96 
SSRI: selective serotonin reuptake inhibitors, TCA: tricyclic antidepressants, SNRI: serotonin-norepinephrine reuptake inhibitors; 
cm: centimeters; kg: kilogram; m: meter; CES-D: Center for Epidemiological Studies-Depression #among ever-smokers. All 
numbers reported as number and percentage unless otherwise stated. Shaded variables or values were not applicable for 

























N or  
mean±SD 
% N or  
mean±SD 
% N or  
mean±SD 
% N or  
mean±SD 
% N or  
mean±SD 
% 
Age, years 69±9  67±9  68±9  70±9  69±9  
Age group, years           
45-54 48  2 4 3 1 2 0  0 53 2 
55-64 957  35 66  43 19 35 8 32 1053 36 
65-74 871  32 41  27 19  35 9  36 947 32 
75-84 693 26 33  22 14  26 5 20 745 25 
>85 144  5 8 5 1  2 3  12 156 5 
Gender           
Male 1367 50 53  35 15 27 12  48 1449 49 
Female 1346 50 99  65 41 73 13  52 1505 51 
Race/ethnicity           
White 983 36 93  61 39  72 11  44 1134 38 
Asian 414 15 7  5 3  6 0  0 424 14 
African-American 723 27 26  17 6  11 7 28 763 26 
Hispanic 593 22 26  17 6  11 7 28 633 21 
Height, cm 166±10  164±10  166±8  165±9  166±10  
BMI, kg/m2 28±5  29±6  31±6  27±5  28±6  
Health Insurance           
None 130  5 5 3 1 2 0  0 136 5 
Medicaid 218  8 8  5 4  7 2  8 233 8 
Medicare 298  11 16  11 3 6 3  12 320 11 
HMO 1777 66 100 66 42 78 17  38 1944 66 
VA/Other 287 11 23 15 4  7 3 12 318 11 
Cigarette smoking status           
Never-smokers 1490  55 68 45 25  48 6 24 1595 54 
Former smokers 1034  38 70  46 25  48 13  52 1146 39 
Current smokers 170  6 13  9 2 4 6 24 191 7 
Smoking history pack-
years# 
18±24  25±34  23±26  31±30  22±25  
FEV1 % predicted, mean 
(SD) 
96±20  93±20  91±16  86±20  95±20  
COPD Stage           
None 1997 74 109 72 44 79 13 52 2169 74 
Mild 425 16 23 15 3 5 6 24 457 16 
Moderate 242 9 17 11 9 16 5 20 275 9 
Severe 43 2 3 2 0 0 1 4 47 2 
Very Severe 3 0.11 0 0 0 0 0 0 3 .10 
Dyspnea, No. (%) 385 14 35 23 13 24 5 20 440 15 
CES-D Score  8±7  12±10  12±10  9±8  8±8  
Depressed (CES-D≥16) 353  13 47  31 14  26 5 20 421 14 
Corticosteroid use           
Yes 232 9 27 18 10 19 7 28 279 9 
No 2481 92 125 82 44 82 18 72 2675 91 
Time between exam ¾ and 
5 spirometry in days 
1890±279  1885±263  1860±273  1863±263  1889±278  
SSRI: selective serotonin reuptake inhibitors, TCA: tricyclic antidepressants, SNRI: serotonin-norepinephrine reuptake inhibitors; 
cm: centimeters; kg: kilogram; m: meter; CES-D: Center for Epidemiological Studies-Depression #among ever-smokers. All 
numbers reported as number and percentage unless otherwise stated. Shaded variables or values were not applicable for 







Table 3.4. Associations of confounders with selective serotonin reuptake inhibitors and outcome variables: 
Exam 4 
Sample characteristics 
  Crude relationship to  
A. SSRI B. FEV1% C. Dyspnea 
OR 95% CI b 95% CI OR 95% CI 
Health Insurance       
None Ref Ref Ref Ref Ref Ref 
Medicaid 2.23 0.81 to 6.16 1.07 -2.22 to 4.35 1.46 0.87 to 2.44 
Medicare 1.11 0.37 to 3.30 -0.82 -4.02 to 2.38 1.32 0.79 to 2.19 
HMO 2.24 0.91 to 5.55 0.09 -2.59 to 2.76 1.11 0.72 to 1.72 
VA/Other 2.24 0.83 to 6.00 2.54 -0.60 to 5.68 1.39 0.82 to 2.28 
Cigarette smoking status       
Never-smokers Ref Ref Ref Ref Ref Ref 
Former smokers 1.29 0.94 to 1.78 -4.04 -5.28 to -2.79 1.23 1.01 to 1.50 
Current smokers 2.20 1.42 to 3.41 -9.68 -11.78 to -7.58 1.56 1.15 to 2.11 
Smoking pack-years* 1.09 1.03 to 1.15 -1.77 -2.05 to -1.50 1.08 1.04 to 1.12 
CES-D Score 1.06 1.05 to 1.08 -0.09 -0.17 to -0.02 1.07 1.06 to 1.08 






Table 3.5. Percent of predicted forced expiratory volume in one second at exam 4: unadjusted and adjusted 
models 
 A. Unadjusted model B. Adjusted model 1 C. Adjusted model 2 
b 95% CI b 95% CI b 95% CI 
SSRI -4.66 -7.31 to -2.02 -3.18 -5.80 to -0.56 -3.30 -5.92 to -0.67 
SNRI     -4.43 -9.73 to 0.86 
TCA     2.12 -2.91 to 7.15  
Cigarette smoking status       
Never-smokers   Ref Ref Ref Ref 
Former smokers   -1.02 -2.41 to 0.37 -0.99 -2.38 to 0.40 
Current smokers   -5.33 -7.59 to -3.06 -5.31 -7.57 to -3.05 
Smoking pack-years   -0.15 -0.18 to -0.12 -0.15 -0.18 to -0.12 
CES-D Score    -0.06 -0.14 to 0.02 -0.06 -0.14 to 0.02 
Bold indicates significant (p<0.05). Shaded variables or values were not included in the model.  







Table 3.6. Percent of predicted forced expiratory volume in one second at exam 5: unadjusted and adjusted 
models 
 A. Unadjusted model B. Adjusted model 1 C. Adjusted model 2 
b 95% CI b 95% CI b 95% CI 
SSRI -3.22 -6.37 to -0.08 -2.43 -5.56 to 0.70 -2.25 -5.39 to 0.90 
SNRI     -4.26 -9.53 to 1.01 
TCA     -5.96 -12.70 to 
0.79 
Cigarette smoking status       
Never-smokers   Ref Ref Ref Ref 
Former smokers   -0.22 -1.92 to 1.49 -0.17 -1.87 to 1.54 
Current smokers   -6.25 -9.46 to -3.04 -6.17 -9.38 to -2.96 
Smoking pack-years   -0.14 -0.18 to -0.10 -0.14  -0.18 to -0.10 
CES-D Score    -0.07 -0.17 to 0.02 -0.07 -0.16 to 0.03 
Bold indicates significant (p<0.05). Shaded variables or values were not included in the model.  





Table 3.7. Dyspnea at exam 4: unadjusted and adjusted models 
 A. Unadjusted model B. Adjusted model 1 C. Adjusted model 2 
OR 95% CI OR 95% CI OR 95% CI 
SSRI 1.99 1.41 to 2.80 1.32 0.91 to 1.91 1.27 0.88 to 1.85 
SNRI     1.98 0.98 to 4.00 
TCA     3.27 1.78 to 6.01 
Cigarette smoking status       
Never-smokers   Ref Ref Ref Ref 
Former smokers   1.06 0.85 to 1.34 1.05 0.84 to 1.32 
Current smokers   1.14 0.81 to 1.61 1.13 0.80 to 1.60 
Smoking pack-years   1.01 1.00 to 1.01 1.01 1.00 to 1.01 
CES-D Score    1.07 1.06 to 1.08 1.07 1.06 to 1.08 






Table 3.8. Dyspnea at exam 5: unadjusted and adjusted models 
 A. Unadjusted model B. Adjusted model 1 C. Adjusted model 2 
OR 95% CI OR 95% CI OR 95% CI 
SSRI 1.76 1.20 to 2.57 1.35 0.90 to 2.01 1.35 0.91 to 2.02 
SNRI     1.52 0.79 to 2.92 
TCA     1.07 0.43 to 2.66 
Cigarette smoking status       
Never-smokers   Ref Ref Ref Ref 
Former smokers   1.03 0.81 to 1.32 1.03 0.80 to 1.32 
Current smokers   0.88 0.56 to 1.38 0.88 0.56 to 1.39 
Smoking pack-years   1.01 1.01 to 1.02 1.01 1.01 to 1.02 
CES-D Score    1.06 1.04 to 1.07 1.06 1.04 to 1.07 






Table 3.9. Unadjusted and adjusted difference-in-difference analysis of percent of predicted forced 
expiratory volume in one second: selective serotonin reuptake inhibitors 
Unadjusted     
Comparison group 1 
n=125 
SSRI use at 
Exam 4 
SSRI use at 
Exam 5 
Absolute difference 
between exam 4 and 5 
p-value 
Control Group (on/on) 90% 92% 2  
Treatment Group (on/off) 89% 93% 4  
Difference 1 1 2 0.49 
Comparison group 2 
n=2285 
    
Control Group (off/off) 94% 96% 2  
Treatment Group (off/on) 91% 89% 2  
Difference 3 7 4 0.03 
Adjusted†     
Comparison group 1 
n=125 
SSRI use at 
Exam 4 
SSRI use at 
Exam 5 
Absolute difference 
between exam 4 and 5 
p-value 
Control Group (on/on) 93% 94% 1  
Treatment Group (on/off) 91% 93% 2  
Difference 2 1 1 0.93 
Comparison group 2 
n=2285 
    
Control Group (off/off) 93% 94% 1  
Treatment Group (off/on) 89% 87% 2  
Difference 4 7 3 0.04 
The first comparison group had 71 patients that remained on selective serotonin reuptake inhibitors (control group) 
compared to 54 who went from being on selective serotonin reuptake inhibitors at exam 4 to being off them at 
exam 5 (treatment group). The second comparison group had 2225 patients that remained off selective serotonin 
reuptake inhibitors (control group) compared to 60 who went on them at exam 5 (treatment group).  








Table 3.10. Unadjusted and adjusted difference-in-difference analysis of proportion of participants reporting 
dyspnea: selective serotonin reuptake inhibitors 
Unadjusted     
Comparison group 1 
n=131 
SSRI use at 
Exam 4 
SSRI use at 
Exam 5 
Absolute difference 
between exam 4 and 5 
p-value 
Control Group (on/on) 25% 23% 2%  
Treatment Group (on/off) 27% 25% 2%  
Difference 2 2 0 0.88 
Comparison group 2 
n=2279 
    
Control Group (off/off) 13% 14% 1%  
Treatment Group (off/on) 22% 26% 4%  
Difference 9 12 3 0.65 
Adjusted†     
Comparison group 1 
n=131 
SSRI use at 
Exam 4 
SSRI use at 
Exam 5 
Absolute difference 
between exam 4 and 5 
p-value 
Control Group (on/on) 26% 23% 1%  
Treatment Group (on/off) 27% 24% 3%  
Difference 1 1 2 0.93 
Comparison group 2 
n=2279 
    
Control Group (off/off) 13% 14% 1%  
Treatment Group (off/on) 16% 19% 3%  
Difference 3 5 2 0.60 
The first comparison group had 71 patients that remained on selective serotonin reuptake inhibitors (control group) 
compared to 54 who went from being on selective serotonin reuptake inhibitors at exam 4 to being off them at 
exam 5 (treatment group). The second comparison group had 2225 patients that remained off selective serotonin 
reuptake inhibitors (control group) compared to 60 who went on them at exam 5 (treatment group).  







Background: Chronic Obstructive Pulmonary Disease (COPD) refers to a group of lung diseases that cause 
airflow obstruction, respiratory muscle weakness, and reduced lung function that result in breathing-related 
problems (such as increased breathlessness, frequent coughing, and tightness in the chest). COPD is 
characterized by periodic episodes of increased symptoms (e.g., shortness of breath, irregular breathing, 
and worse coughing with increased phlegm production), also called pulmonary exacerbations. Although 
pulmonary exacerbations are expected in COPD, epidemiological studies in the general population and in 
primary care practices show that pulmonary exacerbations can even occur among those who do not meet 
criteria for COPD. Due to their anti-inflammatory and serotonergic effects, selective serotonin reuptake 
inhibitors may provide a lung function and exacerbation-prevention benefit. Objectives: This study aims to 
investigate whether those on selective serotonin reuptake inhibitors have a lower pulmonary exacerbation 
rate than those not on selective serotonin reuptake inhibitors. We will also assess if inflammatory markers 
mediate the association between selective serotonin reuptake inhibitors and lung function. Methods: The 
data for this paper came from the Subpopulations and Intermediate Outcome Measures in COPD Study 
(SPIROMICS). At each annual visit, information was collected on medical history and current medications, 
including antidepressants. Pulmonary exacerbation history was gathered prospectively (every 3 months) 
with the use of a structured questionnaire. Cox proportional hazards models with time-dependent covariates 
were used to obtain hazard ratios (HRs) for time to first exacerbation since enrolling in the study. Main 
results: There were 2221 eligible participants after exclusions for missing data. Findings indicate an 
increased rate of exacerbations for those on selective serotonin reuptake inhibitors compared with those 
not on selective serotonin reuptake inhibitors, against our hypothesis. In the crude analysis, for any given 
visit, if a participant was on selective serotonin reuptake inhibitors the rate of first exacerbation was 36% 
CHAPTER 4. A LARGE COHORT STUDY ON THE ASSOCIATION BETWEEN 






higher (crude HR 1.36, 95% CI: 1.13 to 1.65) than if they were not on selective serotonin reuptake inhibitors; 
this association decreased and was no longer significant after adjustment (adjusted HR: 1.12, 95% CI: 0.86 
to 1.44). Inflammation was not a mediator in the association between selective serotonin reuptake inhibitors 
and FEV1. Conclusions: We found no evidence to support the hypothesis that selective serotonin reuptake 
inhibitors provide a benefit in reducing pulmonary exacerbations. Additionally, there was no evidence to 
support the hypothesis that inflammation is a mediator in the association between selective serotonin 





Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by 
periodic episodes of worsening symptoms (e.g., shortness of breath, irregular breathing, and worse 
coughing with increased phlegm production), also called pulmonary exacerbations [104, 105]. 
Exacerbations in COPD are important because they have a negative impact on quality of life, increase 
mortality rates, accelerate the decline in lung function, and have high societal costs. Although exacerbations 
are expected in COPD, epidemiological studies in the general population [106-108] and in primary care 
practices [109] show that exacerbation-like events (exacerbations similar to COPD) can occur among those 
who do not meet criteria for COPD [110]. Tan and colleagues looked at cross-sectional data of 5,176 people 
from a population-based study on lung health. Participants were queried on chronic respiratory symptoms 
(chronic cough or phlegm, wheezing and shortness of breath) and exacerbations. The study defined an 
exacerbation as ‘a period of worsening of breathing problems that got so bad that it interfered with usual 
daily activities or caused the individual to miss work’. The authors found that individuals without diagnosed 
COPD or asthma have exacerbation-like events although at a lower frequency compared with those with 
COPD. 
Inflammation is responsible for many of the symptoms and reduction in quality of life [13] in COPD 
and is especially pronounced during exacerbations. Inflammatory cells damage lung parenchyma, leading 
to a reduced ability of the airways to remain open. Even in individuals with mild COPD [2], inflammation 
reduces lung function, accelerates decline in lung function overtime, and increases the risk for 
exacerbations [3-7]. Furthermore, in young adults without COPD, and independent of asthma, smoking, 
and body weight, an inverse association is seen between lung volumes and inflammation [83]. Since 
inflammation is inversely associated with lung volumes and quality of life in individuals with and without 
COPD, reducing inflammation may be beneficial for those with low lung function but no diagnosed disease, 
in addition to those with clinically defined obstructive disease. 
Agents that reduce inflammation are hypothesized to result in improvements in lung function and 
exacerbation frequency. Providing support for this hypothesis, current therapies for increasing lung 





corticosteroids do not entirely inhibit inflammation [14, 15] and have significant side effects at higher doses. 
This lack of fully effective therapy and poor side effect profile lead researchers to search for better options. 
In the pursuit of alternative medications, selective serotonin reuptake inhibitors are considered. In addition 
to having anti-inflammatory properties, they act upon serotonin, which is integral in central breathing control 
[17]. The combination of their anti-inflammatory and serotonergic effects may provide users of selective 
serotonin reuptake inhibitors with a lung function and exacerbation-prevention benefit while avoiding the 
side effects of inhaled steroids.  
Mediation 
A decreased forced expiratory volume in one second (FEV1) is the measure primarily used to show 
reduced lung function in COPD [51]. The association between selective serotonin reuptake inhibitors and 
lung function was explored in Chapter 3, however one area largely untested is inflammatory markers being 
the mechanism behind the presumed association between selective serotonin reuptake inhibitors and lung 
function. Reduced lung function is associated with increased levels of the inflammatory markers interleukin-
6 (IL-6) and C-reactive protein (CRP) [111]. Selective serotonin reuptake inhibitors reduce these 
inflammatory cytokines, although results have varied and are typically measured in participants with major 
depressive disorder, not COPD [41].  
Seen in both animal [32-34], and human [16] models, selective serotonin reuptake inhibitors reduce 
the microglial production of the PI-cytokine TNF-α and the free radical nitric oxide, both key players in 
inflammation in the brain [35]. In the lungs, fluoxetine, a selective serotonin reuptake inhibitor, inhibits 
airway inflammation through affecting the capacity of monocytes and lung epithelial cells to produce 
inflammatory cytokines [36]. These effects are potentially due to selective serotonin reuptake inhibitors’ 
influence on serotonin, as serotonin has a role in anti-inflammatory processes [33, 37].  
Although tricyclic antidepressants, serotonin norepinephrine reuptake inhibitors and selective 
serotonin reuptake inhibitors are all thought to have serotoninergic effects, in two similar studies by Bianchi, 




serotonin [33, 37]. Additional trials show serotonin-norepinephrine reuptake inhibitors [16] and tricyclic 
antidepressants [38] do not have anti-inflammatory effects.  
The selective influences of serotonin may explain the discrepancy between the effects of selective 
serotonin reuptake inhibitors and other classes of antidepressants on inflammation. Both tricyclic 
antidepressants and serotonin-norepinephrine reuptake inhibitors increase norepinephrine, but selective 
serotonin reuptake inhibitors do not [39]. Consistent with the known pro-inflammatory effects of 
norepinephrine on innate immune cells [40], serotonin-norepinephrine reuptake inhibitors are associated 
with an increase in inflammatory markers [41], indicating that norepinephrine may cancel out the anti-
inflammatory effects of serotonin.  
 We therefore aim to investigate whether those who use selective serotonin reuptake inhibitors have 
a lower exacerbation rate than those who do not use selective serotonin reuptake inhibitors. This study 
tests whether selective serotonin reuptake inhibitor use is associated with a reduction in pulmonary 
exacerbations, after adjusting for potential confounders, in a large cohort of both individuals with and without 
COPD. Additionally, we assess if inflammatory markers mediate the association between selective 
serotonin reuptake inhibitor use and lung function (specifically, FEV1).  
 The data for this paper came from the Subpopulations and Intermediate Outcome Measures in 
COPD Study (SPIROMICS), funded by the National Heart, Lung and Blood Institute (ClinicalTrials.gov 
Identifier: NCT01969344). SPIROMICS is an observational study that prospectively collected phenotypic, 
biomarker, genetic, genomic, and clinical data from subjects with the purpose of identifying homogeneous 
subgroups of COPD patients as well as preliminary validation of intermediate biological or clinical outcome 
measures. Over 2700 participants were enrolled between November 12, 2010 and July 31, 2015 at six 
clinical centers (Winston-Salem, NC; Ann Arbor, MI; San Francisco, CA; Los Angeles, CA; New York City, 






follow-up visits (visits 2-4); additionally, participants receive quarterly telephone calls in between visits to 
assess for exacerbations, hospitalizations, and mortality.  
 The SPIROMICS protocol, including information about the populations from which recruitment 
occurred, detailed criteria, and other information, is available at www.cscc.unc.edu/spiromics. As shown in 
Table 4.1, four strata were enrolled, two with and two without COPD: non-smokers, smokers, mild/moderate 
COPD and severe COPD. Briefly, participants were between 40-80 years of age at baseline who either had 
a smoking history of ≤1 pack-year (considered a non-smoker) and no known current lung disease (no history 
of COPD) (n=202) or current or former smokers (>20 pack-years) with and without evidence of COPD 
(smokers without COPD (n=941), mild/moderate COPD (n=1207), and severe COPD (n=624)). Exclusion 
criteria are non-COPD obstructive lung disease or a history of diseases or treatments likely to interfere with 
interpretation of study tests, BMI > 40 kg/m2 at baseline, hypersensitivity or intolerance of bronchodilators 
used in assessments, and diagnosis of unstable cardiovascular disease [112]. Full inclusion/exclusion 
criteria for each strata are given in Appendix Table 18. 
Participants were recruited by means of physician referral, advertisement for the study in clinical 
areas or self-referral at the study website (www.spiromics.com). The institutional review boards of all 
collaborating institutions and the National Heart Lung and Blood Institute (National Institutes of Health, 
Bethesda, MD, USA) approved the protocols of SPIROMICS and all procedures described herein. All 
participants provided informed consent. SPIROMICS approved a proposal for this analysis. 
Exposure variable 
The exposure is use of selective serotonin reuptake inhibitors. At each annual visit, information was 
collected on medical history and current medication use. Information on medications and supplements used 
in the past 3 months were collected through a structured questionnaire. The questionnaire asked detailed 
information on common oral and inhaled corticosteroids, bronchodilators, statins, beta-blockers, and 





use of different antidepressants was classified according to the Anatomical Therapeutic Chemical 
classification (selective serotonin reuptake inhibitors, tricyclic antidepressants, and serotonin 
norepinephrine reuptake inhibitors) [85]. We coded this variable into an indicator variable (yes (1)/no (0)) 
for each antidepressant class to indicate whether a participant was taking the drug or not at the time of the 
visit. 
Outcome variable 
Self-reported exacerbation data was gathered prospectively by quarterly phone calls and annual 
visits with the use of a structured questionnaire. Participants were asked how many episodes of chest 
trouble flare ups have they had since the last follow-up (‘since your last (clinic visit or telephone contact) on 
(date), have you had a flare-up of your chest trouble?’; ‘If Yes, how many episodes of chest trouble flare 
ups have you had since (date)?’). If an episode was reported, further questions on antibiotics, oral steroids, 
and office visits, and hospitalizations were queried. Acute exacerbations were defined as events that 
required health care (i.e., office visit, hospital admission, or emergency department visit for a respiratory 
flare-up) involving the use of antibiotics or systemic corticosteroids, or both. The participants’ usual 
providers, who were aware of their patient’s enrollment in an observational study, managed exacerbations; 
the study did not provide guidance on management.  
Hypothesized confounders 
 To identify potential confounders and the minimal set necessary for control, we developed a 
directed acyclic graph based on previous literature (Appendix Figure 2). From the literature aided by the 
directed acyclic graph, we deemed age, gender, depressive symptoms, baseline FEV1, and number of prior 
exacerbations before enrolling in the study to be potential confounders. 
Age: Increased age is associated with increased exacerbations [113, 114] and increased likelihood of 
antidepressant use (after the age of 12) [115]. We used age as a continuous variable. 
Gender: Women are twice as likely as men to take antidepressant medication [115]. Men have an increased 




did not report it. For those who were genotyped, genotyping sex was compared with the response on the 
form and there was complete agreement. Gender is coded dichotomously (male (0)/female (1)). 
Smoking status and pack-years: Increased smoking is associated with an increased risk for exacerbations 
[117] and depression is associated with higher smoking rates, thereby increasing exacerbations. 
Depression is also associated with antidepressant use. Smoking status is categorized into current smokers 
or former smokers (1), defined as >20 pack-years, and never smokers (0), defied as ≤1 pack-year. 
Pack-years is a measure of smoking status for duration and amount of smoking. Quantification of pack-
years is important because increased tobacco exposure is closely associated with increased exacerbations 
[93, 94]. Additionally, increased pack-years are seen in depression [95]. Pack-years will be used as a 
continuous variable. 
Depressive symptoms: Current depressive symptoms are associated with increased risk for exacerbations 
[105, 118] and with antidepressant use. Although the argument can be made that depressive symptoms is 
on the causal pathway between selective serotonin reuptake inhibitors and FEV1, we were more concerned 
with potential confounding as this is not the causal pathway of interest in this study. In SPIROMICS, the 
Hospital Anxiety and Depression Scale (HADS) score is used at each annual visit to assess for depressive 
symptoms. This 7-item questionnaire assesses enjoyment, cheerfulness, lethargy, and self-confidence.  
Although baseline FEV1 and number of prior exacerbations are not part of the minimal sufficient adjustment 
sets for estimating the total effect of selective serotonin reuptake inhibitors on exacerbations, we will include 
them in the model since they are strongly indicative of risk for exacerbations.  
Baseline FEV1: A decreased forced expiratory volume in one second (FEV1) is the measure primarily used 
to show reduced lung function in COPD [51]. Predicted reference values have been calculated and 
compared with samples of healthy subjects drawn from the general population to yield percent predicted 
(%) standards. While many different percent predicted standards exist, the American Thoracic Society uses 
an equation that gives referents based on height, age, gender, and race [86]. A lower FEV1 is associated 
with an increased risk of exacerbations [114, 118, 119] and is a measure of disease severity. FEV1 was 




function testing and interpretation [50, 120, 121]. In order to include a baseline measure of severity of 
disease, continuous percent of predicted FEV1 at visit 1 (baseline) will be used. 
Number of prior exacerbations before enrolling in the study: Prior exacerbations are a strong indication of 
future risk for exacerbations [119]. This information was gathered at the baseline visit through a structured 
questionnaire. Participants were asked if they had an episode of breathing problems in the last 12 months 
and if yes to provide how many episodes. For each episode, they were then asked further questions on 
additional antibiotic use, oral steroids, health care, hospital and emergency room visits. 
Inflammation as a potential mediator 
  Part of the hypothesis for selective serotonin reuptake inhibitors’ therapeutic effect on lung function 
is through a reduction in inflammation. Inflammatory markers include serum levels of IL-6 and CRP, 
measured at visits 1 and 2 in the morning after a fast. Approximately 70 ml of blood was collected per visit, 
including plasma and serum.  
  Analyses were conducted in SAS 9.4. We excluded participants if a) they did not have exposure 
(medication) information available b) were on more than one antidepressant at the same time or c) were 
missing data on any confounder included in the model. For more details on decision about missing data, 
see Error! Reference source not found., Handling Missing Data.  
Confounder selection: After identifying a set of potential confounders, we explored which of the added 
covariates had the most influence on the parameter of interest. We then added a minimally adjusted model 
that included only the covariates that changed the crude exposure-outcome hazard ratio (HR) by more than 
10%. Since prior literature shows strong relationships between these hypothesized confounders and both 
selective serotonin reuptake inhibitors and exacerbations, we also created a fully adjusted model using all 





Main analyses: Time to first exacerbation was calculated. Observation time began on the day the subject 
enrolled into the study. If any participants were lost to follow-up or died, they were censored at the date of 
last known contact. 
Time to first exacerbation 
A Cox proportional hazards model with time-dependent covariates (sometimes called an extended 
cox model) [122] was used to obtain hazard ratios (HRs) for time to first exacerbation since enrolling in the 
study [123]. Time dependent variables included smoking status, smoking pack-years, depression score, 
and antidepressant use [124]. Fixed covariates included age at baseline, gender, baseline FEV1 and 
number of exacerbations prior to enrolling in the study. The proportional hazards assumptions was checked 
to determine if there was a constant relationship between the outcome and the covariate, see Error! R
eference source not found., Assessing proportional hazards for details on checking the modeling 
assumptions. Results are presented as HRs with 95% confidence intervals (CI).   
Mediation 
Data from visit 1 and visit 2 (when both spirometry (FEV1) and inflammatory markers were evaluated) are 
used to test the hypothesis that the effect of selective serotonin reuptake inhibitors on lung function is partly 
mediated through a reduction in inflammation. Mediation was assessed using the four Baron and Kenny 
steps: 1) the direct relationship between the dependent variable (FEV1) and the independent variable 
(selective serotonin reuptake inhibitors) was meaningful, 2) the independent variable (selective serotonin 
reuptake inhibitors) was associated with the mediator (inflammation), 3) the mediator was associated with 
the dependent variable and 4) a previously meaningful relationship between the independent and 
dependent variable was reduced in magnitude after controlling for the mediator (assumptions were 
checked: controlled for mediator outcome confounding and there was no interaction between the exposure 






As seen in Table 4.2, 81% of the SPIROMICS cohort was eligible for this study (2221 eligible 
participants). The mean age of the sample at the start of the study was 64 years; 48% were women, the 
average height was 170 cm with an average weight of 81 kg. The cohort consisted of 79% White, 16% 
Black, 1% Asian, 2% Pacific Islander and less than 1% each consisting of American Indian and mixed 
race/ethnicity. Approximately 34% were smokers, with an average of 48 pack-years. The mean percent 
predicted FEV1 was 67%. The average HADS score was four, with 18% of the cohort classified as being 
depressed. Participants had an average of 0.4 (range 0-6) exacerbations prior to enrolling in the study. 
Twelve individuals were on more than one antidepressant at any point during follow-up and therefore 
excluded from further analyses.  
Appendix Table 19 compares the baseline characteristics between the antidepressant groups. 
Notably, the no antidepressant group had a higher proportion of men and black participants and a lower 
HADS score. 
Confounders  
 Only HADS depression score changed the crude HR by 10% or more, as seen in Table 4.3. As 
mentioned previously, prior literature shows strong relationships between the hypothesized confounders 
and both selective serotonin reuptake inhibitors and exacerbations, so we have decided to keep them in an 
additional fully adjusted model.  
Time dependent Cox regression 
There were 837 (38%) participants who reported having an exacerbation during follow-up; 144 
(17%) of these were users of selective serotonin reuptake inhibitors. The average follow-up time was 
864±301 (range 75 to 1889) days; the time to first reported exacerbation since enrolling in the study was 




Table 4.4.  In the crude analysis, for any given visit, if a participant was on selective serotonin 
reuptake inhibitors they had a 36% higher rate of first exacerbations (crude HR 1.36, 95% CI: 1.13 to 1.65) 
than if they were not on selective serotonin reuptake inhibitors. This association decreased and was no 
longer significant after adjustment (adjusted HR: 1.12, 95% CI: 0.86 to 1.44). This was true when adjusting 
for HADS depression score alone (adjusted model 1) or the complete adjusted model (adjusted model 2). 
When including only participants with COPD (Table 4.5), there was a significant association in the crude 
and depression adjusted model, but the confidence intervals widened slightly in the fully adjusted model. 




Appendix Table 20 and Appendix Table 21, there were no significant associations between 
serotonin norepinephrine reuptake inhibitors or tricyclic antidepressants and exacerbations. As shown in 
Appendix Table 22, in any given exam, if a participant was on antidepressants, their rate of first 
exacerbation is 38% higher (crude HR: 1.38, 95% CI: 1.56 to 1.64) than if they were not on any 
antidepressant; but this also was no longer meaningful after adjustment.  
Post-hoc analyses 
 Similar to Chapter 3, approximately 30% of those on antidepressants still had HADS scores 
indicating they were depressed (uncontrolled depression); therefore, we stratified by HADS scores 
indicating depression to see if there was potential for confounding that was not sufficiently controlled. 
Participants with a HADS score ≥8 are identified as having depression, while those with a score <8 are not 
[126]. At baseline, there were 389 participants identified as having depression (average HADS: 10±2) and 
1820 without depression (average HADS: 3±2). There were 89 (23%) participants that were depressed and 
on selective serotonin reuptake inhibitors and 223 (12%) that were not depressed and on selective 
serotonin reuptake inhibitors. The results of the crude and adjusted cox models, stratified by depression 
status, are presented in Appendix Table 23 and Appendix Table 24. There was still no evidence to support 
our hypothesis of a protective effect from selective serotonin reuptake inhibitors.  
Mediation 
Inflammatory markers included CRP and IL-6. There were 1,346 participants who had inflammatory 
markers and pulmonary function measured at visit 1 and 390 who had them measured at visit 2. Selective 
serotonin reuptake inhibitors were not found to have a beneficial effect on FEV1 (Tables 4.6 &4. 7, Column 
A), however performing a mediational analysis will still allow us investigate why our hypothesis did not hold. 
The inflammatory markers were tested for their association between selective serotonin reuptake inhibitors 
and FEV1. Higher IL-6 measures were associated with a lower likelihood of being on selective serotonin 




Table 4.6, Column B). At neither time point was there a meaningful association between CRP and 
selective serotonin reuptake inhibitors (Table 4.7, Column B). Higher CRP measures were associated with 




Table 4.6, Column C). After controlling for inflammatory cytokines, the effect of selective serotonin 




Table 4.6 and Table 4.7, Column D). Neither IL-6 nor CRP were associated with both the 
exposure and outcome measures. 
Since there was no association between IL-6 and FEV1, but it has previously been associated in 
prior studies of COPD patients [127, 128], we performed an additional mediational analysis, excluding those 
without COPD (n=369 at visit 1 and n=108 at visit 2) to see if the association was seen in those with lower 




Appendix Table 26). 
In summary, neither IL-6 nor CRP were found to have a consistent relationship with both selective 
serotonin reuptake inhibitors and only CRP was found to be related to FEV1. 
 We hypothesized that participants on selective serotonin reuptake inhibitors would be associated 
a lower exacerbation rate than those not on selective serotonin reuptake inhibitors. We are unaware of any 
studies that have investigated this association. This study aimed to test the association between selective 
serotonin reuptake inhibitors and exacerbations in a cohort of adults with and without COPD with 
appropriate confounder control. The results did not support our hypothesis; indeed, associations were in 
the opposite direction. Using a large dataset, we found that selective serotonin reuptake inhibitors were 
associated with a 36% higher rate of first exacerbation since enrolling in the study compared with not being 
on a selective serotonin reuptake inhibitor. After controlling for age, gender, current smoking status, pack-
years, baseline FEV1, HADS depression score and number of exacerbations prior to enrolling in the study 
these associations were no longer significant but remained in the same direction. Results remained similar 
when stratifying by depression status. There was no association between selective serotonin reuptake 
inhibitors and rate of first exacerbation in depressed participants.  
 We also examined the potential mediational role of inflammatory markers between selective 
serotonin reuptake inhibitors and lung function. We were surprised to find that IL-6 was not associated with 
FEV1 in the mediation analysis, since prior research has associated IL-6 with FEV1 [127, 128]. This 
persisted even when removing participants without COPD.  
As a secondary analysis, we looked at other antidepressant groups. No association was seen in 
the serotonin norepinephrine reuptake inhibitors and tricyclic antidepressant groups.  
There are several limitations to this study, including several sample-related limitations. 
Unfortunately, we do not have data on the specific drug (other than antidepressant type) that was prescribed 





additives may change their effects on lung function. For example, in the systematic literature review 
(Chapter 2), it was noted that studies investigating citalopram and fluoxetine were consistently among the 
studies with positive associations. The dose of the medication would allow us to assess if a certain dosing 
level is needed for the anti-inflammatory effects of antidepressants to affect lung function. Additionally, we 
would ideally like our mediational analysis to have longitudinal data (with the visits are separated by a 
maximum of a few months) where our independent variable preceded the mediational variable and the 
mediational variable precedes the dependent variable in order to establish temporality. However, in these 
data the independent variable (selective serotonin reuptake inhibitors) and the mediational variable 
(inflammatory markers) were taken at the same exam. If we were to use the longitudinal data, our sample 
sizes would be severely diminished, since there was a large drop in the number of participants who had 
blood draws at visit 2. Additionally, the timing of the measurement is spaced out by a year or more, which 
is unlikely to be relevant as we hypothesize a concurrent effect.  
There are several strengths to this study as well. This investigation was among the first to assess 
the impact of antidepressants on pulmonary exacerbations using epidemiologic methods. To assess the 
impact of selective serotonin reuptake inhibitors, we conducted an analysis on an observational study of a 
large cohort of participants with and without COPD. In order to control for the limitations of this approach, 
including the confounders being measured in parallel or after the exposure was implemented, we performed 
a rigorous statistical approach where we allowed participants to change their confounder status over time 
instead of assuming they stayed constant. While still potentially suffering from bias due to residual 
confounding, this method addresses confounding by time-variant attributes. For example, some of the 
exacerbations occurred during a period in which the participant had not yet been prescribed 
antidepressants, or had discontinued pharmacotherapy. With a time-dependent approach, events are 
classified according the most recent study information available [129]. Unlike logistic regression, Cox 
proportional hazards take into account differences across individuals in the period of risk for the outcome 
For example, a person’s status with regard to antidepressant use and type may change over at any time 




In conclusion, there is no evidence to support our hypothesis of participants using selective 
serotonin reuptake inhibitors having a lower exacerbation rate or inflammation mediating the pathway 
between selective serotonin reuptake inhibitors and lung function. Further research can improve upon this 
study by including measures of confounders prior to and after antidepressant initiation to understand the 






Figure 4.1. Schedule of SPIROMICS study contacts 
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Table 4.1. SPIROMICS stratum criteria 
 Non-Smokers 






Mild/Mod COPD  
(stratum 3) 
Smokers with 
Severe COPD               
(stratum 4) 
Smoking status <1 pack-year >20 pack-years >20 pack-years >20 pack-years 
Bronchodilator Status 








FEV1/FVC ratio criteria FEV1//FVC>.7 FEV1//FVC>.7 FEV1//FVC<.7 FEV1/FVC<.7 
Other Lung Function 
Criteria 
FVC>LLN FVC>LLN FEV1>50% pred. FEV1<50% pred. 







Table 4.2. Total eligible cohort (N=2221) baseline characteristics  




Age, years, mean±SD 64±9  
Gender   
Male 1158 52 
Female 1063 48 
Race   
White 1761 79 
Black 361 16 
Asian 23 1 
Pacific Islander 51 2 
American Indian 10 .45 
Mixed 15 .68 
Height, cm, mean±SD 170±10  
Weight, kg, mean±SD 81±18  
Current or former smokers   
Yes 760 34 
No 1461 66 
Smoking history pack-years#, mean±SD 48±39  
FEV1 % predicted, mean±SD 67±27  
COPD Stage   
None 661 31 
Mild 327 16 
Moderate 647 31 
Severe 331 16 
Very Severe 138 7 
HADS Score, mean±SD 4±3  
Depressed (HADS≥8) 394 18 
Number of exacerbations prior to enrolling 0.41±0.89 
cm: centimeters, kg: kilogram; FEV1: forced expiratory volume in one second; 
HADS: Hospital Anxiety and Depression scale; #among ever-smokers. Shaded 









Table 4.3. Hazard ratios for potential confounders between selective serotonin reuptake inhibitors and 
exacerbations 
 HR for SSRIs and 
exacerbations 
95% CI 
Crude  1.35 1.13 to 1.62 
+ Age 1.36 1.13 to 1.62 
+ Gender 1.29 1.08 to 1.55 
+ HADS depression score 1.17 0.97 to 1.40 
+ Baseline FEV1 1.30 1.09 to 1.56 
+ Prior exacerbations 1.27 1.06 to 1.52 
+ Current smoking 1.35 1.13 to 1.62 
+ Smoking pack-years 1.37 1.14 to 1.64 





Table 4.4. Crude and adjusted Hazard Ratios (HRs) for time to first exacerbation using time dependent cox 
regression 
 A. Unadjusted model B. SSRIs and Depression C. Adjusted model†  
b 95% CI b 95% CI b 95% CI 
SSRI vs. No SSRIs* 1.36 1.13 to 1.65 1.17 0.96 to 1.42 1.12 0.86 to 1.44 
Depression score   1.08 1.06 to 1.10 1.04 1.01 to 1.07 
Ageǂ     0.97 0.85 to 1.10 
Gender     1.42 1.16 to 1.73 
Baseline FEV1ǂ     0.82 0.78 to 0.85 
Prior Exacerbations     1.42 1.32 to 1.52 
Current Smoker     0.94 0.76 to 1.18 
Pack-yearsǂ     1.01 0.99 to 1.03 
*indicates participants that were on other antidepressants or on no antidepressants. †Time-dependent variables 
included antidepressant status, current smoking status, smoking pack-years, and HADS depression score. ǂAge, 





Table 4.5. Crude and adjusted Hazard Ratios (HRs) for time to first exacerbation using time dependent cox 
regression, excluding those without chronic obstructive pulmonary disease 
 A. Unadjusted model B. SSRIs and Depression C. Adjusted model†  
b 95% CI b 95% CI b 95% CI 
SSRI vs. No SSRIs* 1.53 1.24 to 1.88 1.29 1.04 to 1.60 1.20 0.91 to 1.58 
Depression score   1.08 1.06 to 1.10 1.04 1.01 to 1.07 
Ageǂ     0.96 0.85 to 1.14 
Gender     1.37 1.10 to 1.70 
Baseline FEV1ǂ     0.82 0.77 to 0.86 
Prior Exacerbations     1.39 1.29 to 1.50 
Current Smoker     0.95 0.74 to 1.21 
Pack-yearsǂ     1.01 0.98 to 1.03 
*indicates participants that were on other antidepressants or on no antidepressants. †Time-dependent variables 
included antidepressant status, current smoking status, smoking pack-years, and HADS depression score. ǂAge, 






Table 4.6. Generalized linear regression coefficients for Baron and Kenny mediation steps for Interleukin-
6 receptor as a mediator of the relationship between selective serotonin reuptake inhibitors and forced 
expiratory volume in one second 
 A. SSRI to FEV1* B.  SSRI to IL6  C. IL6 to FEV1 D. SSRI to FEV1 
controlling for IL6* 
 b 95% CI b 95% CI b 95% CI b 95% CI 
Visit 1 -0.09 -4.21 to 4.04 0.01 -0.02 to 0.04 0.07 -0.10 to 0.24 -0.18 -4.31 to 3.95 
Visit 2 -3.09 -11.41 to 5.22 -0.04 -0.08 to -0.01 -0.09 -0.40 to 0.21 -2.89 -11.27 to 5.49 
SSRI: selective serotonin reuptake inhibitor; FEV1: forced expiratory volume in one second 





Table 4.7. Generalized linear regression coefficients for Baron and Kenny mediation steps for C-reactive 
protein as a mediator of the relationship between selective serotonin reuptake inhibitors and forced 
expiratory volume in one second 
 A. SSRI to FEV1* B. SSRI to CRP C. CRP to FEV1 D. SSRI to FEV1 
controlling for CRP* 
 b 95% CI b 95% CI b 95% CI b 95% CI 
Visit 1 -0.09 -4.21 to 4.04 -0.05 -0.14 to 0.10 -3.60 -4.72 to -2.47 -0.28 -4.36 to 3.80 
Visit 2 -3.09 -11.41 to 5.22 -0.06 -0.28 to 0.17 -4.36 -6.35 to -2.37 -3.03 -11.20 to 5.14 
SSRI: selective serotonin reuptake inhibitor; FEV1: forced expiratory volume in one second 





 The prevalence of COPD has been increasing; according to the World Health Organization, total 
deaths from COPD are projected to increase by more than 30% in the next 10 years [130]. While there is 
no cure for COPD, current treatments are focused on relieving symptoms, slowing the progression of 
disease and improving overall health. Bronchodilators, corticosteroids and combination bronchodilators 
plus inhaled glucocorticosteroids are medicines used to improve low lung function [131]. However, they can 
have debilitating side effects leading researchers to look for alternative treatments. Since selective 
serotonin reuptake inhibitors have anti-inflammatory effects and act upon serotonin, which is central in 
breathing control, this dissertation tested if they improve lung function and reduce the risk for pulmonary 
exacerbations. 
 Extensive literature searches across multiple electronic databases yielded 24 peer-reviewed 
studies that assessed antidepressants and lung function, only eight of these assessed selective serotonin 
reuptake inhibitors. The interpretability of these studies is hindered by methodological limitations, 
particularly a failure to control for important confounders or inadequate measure and testing of confounders. 
Results tended to vary by inclusion of participants with comorbid depression, severity of lung function 
impairment, and type of antidepressant. Additionally, the sample sizes were small with a large proportion 
(54%) having unclear or incomplete follow-up of participants or unbalanced attrition between the treatment 
and control groups. Furthermore, adherence rates were unrealistic since the data was not real-world but 
patients were being continuously followed-up and monitored.  Due the potential for outcome reporting bias, 
small sample sizes and the plausibility of a mechanism of action, more research is needed using population-
based data to provide information on the potential for certain antidepressants in improving lung function. 
The current study was designed to improve on prior studies, which typically reported only one measure, 
through its use of both objective and patient reported lung function (FEV1 and dyspnea) in two large cohorts, 
while controlling for important confounders. Using both objective and subjective measurements are 
important, as they allow us to determine not only if the lung function clinically improved, but if the participants 
feel better. 




 For the most part, this study did not support our hypothesis of an association between selective 
serotonin reuptake inhibitors and lung function and dyspnea; indeed, associations were in the direction of 
a harmful effect. In Chapter 3, we utilized the prospective information gathered in the Multi Ethnic Study of 
Atherosclerosis (MESA) to assess the concurrent relationship between selective serotonin reuptake 
inhibitors and FEV1% and dyspnea. We used two different approaches in analyzing the data, regression 
and difference-in-difference analyses. In both the unadjusted and adjusted linear and logistic regression 
analyses, selective serotonin reuptake inhibitors had an inverse association with FEV1% and increased 
odds of dyspnea. Adjustments included controlling for depression score, smoking status and pack-years, 
and other types of antidepressants. The association was moderately attenuated by the inclusion of 
confounders in the model, but remained negative in the fully adjusted model. The difference-in-difference 
results were consistent with the regression analyses in that the group who were on selective serotonin 
reuptake inhibitors had a significant decrease in FEV1% compared with the group who remained 
consistently off selective serotonin reuptake inhibitors.  
  It was surprising to find a relatively strong inverse association between selective serotonin 
reuptake inhibitors and FEV1% and dyspnea. When reviewing the literature, no studies reported an inverse 
association between selective serotonin reuptake inhibitors and lung function. There was one study that 
reported an inverse association, but the type of antidepressant was not assessed and was likely mixed, as 
it was a large population-based cohort [77].  
One possible explanation for this inverse association was depression; although depression was 
controlled for through the CES-D score, we had no measure of the severity of depression prior to being on 
an antidepressant. Since depression is linked to increased levels of inflammation [103], it is possible that 
the increased inflammation seen in depression overrides the potential anti-inflammatory effects of selective 
serotonin reuptake inhibitors on reducing inflammation. However, in the post-hoc analysis when controlling 
for CES-D score alone, it had little to no effect on the crude model, which is not consistent with the argument 
that depression was the cause of our inverse association between selective serotonin reuptake inhibitors 




  Chapter 4 built off the previous chapter and tested if selective serotonin reuptake inhibitors were 
associated with a lower exacerbation rate than those not on selective serotonin reuptake inhibitors. Using 
the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) we tested whether 
selective serotonin reuptake inhibitor use is associated with a reduction in pulmonary exacerbations, after 
adjusting for potential confounders (age, gender, smoking status and pack-years, depressive symptoms, 
baseline FEV1 and number of prior exacerbations), in a large cohort of both individuals with and without 
COPD. Similar to the results of Chapter 3, in the crude analysis, for any given visit, if a participant was 
using selective serotonin reuptake inhibitors they had a higher rate of first exacerbations since enrolling in 
the study than if they were not using selective serotonin reuptake inhibitors. When stratifying by depression 
score, there was still no evidence to support our hypothesis of a protective effect from selective serotonin 
reuptake inhibitors.  
Part of the hypothesis for selective serotonin reuptake inhibitors’ therapeutic effect on lung function 
is through a reduction in inflammation. In order to test the inflammatory hypothesis, we assessed if 
inflammatory markers mediate the association between selective serotonin reuptake inhibitor use and lung 
function. Even though selective serotonin reuptake inhibitors were not found to have a beneficial effect on 
FEV1, performing a mediational analysis allows us to investigate why our hypothesis did not hold: was it 
because selective serotonin reuptake inhibitors did not influence inflammation? Alternatively, that 
inflammation did not influence lung function? Investigating mediation allows us to further understand our 
results. The inflammatory markers were tested for their association between selective serotonin reuptake 
inhibitors and FEV1. Neither IL-6 nor CRP were associated with both the exposure and outcome measures. 
IL-6 was associated with selective serotonin reuptake inhibitors only at visit 2, but was not associated with 
FEV1 during either time period. CRP was consistently associated with FEV1 at visit 1 and visit 2, but not 
with selective serotonin reuptake inhibitors at any point. This leads us to believe that selective serotonin 
reuptake inhibitors do not influence these anti-inflammatory markers enough to cause an increase in lung 
function. Additionally, since selective serotonin reuptake inhibitors were not associated with inflammatory 
markers, they are not causing an increase in the inflammatory response, leading to the inverse association 
with lung function (lower lung function). Further studies are needed to elucidate this inverse association 




truly do lower lung function, this should be noted and the risks and benefits weighted for individual patients 
and their needs with their practitioners.   
 There were no interventional studies found in the literature that supported the hypothesis of 
selective serotonin reuptake inhibitors improving lung function. However, tianepine was found to reduce 
symptoms and increase pulmonary function in children with asthma [74]. Tianepine is a selective serotonin 
reuptake enhancer; instead of inhibiting the uptake of serotonin, like a selective serotonin reuptake inhibitor, 
it increases the uptake of serotonin, lowering serotonin’s activity. Since tianeptine has the opposite effect 
on serotonin, this suggests that the effects of serotonin on lung function may not be as clear as we hoped 
and that further study is warranted. It is possible that an increase in serotonin is harmful to lung function, 
instead of being beneficial. It is also possible that we are seeing reverse causation. Although we controlled 
for prior exacerbations, indicating severity of disease, control may be insufficient. Participants with worse 
disease may be more likely to be depressed, leading to use of a selective serotonin reuptake inhibitor, 
which is why we are seeing selective serotonin reuptake inhibitors having an inverse association with lung 
function.  
Although this study addresses weaknesses evident in the existing literature, this project had its own 
limitations. In both MESA and SPIROMICS, the specific brand of antidepressant was not assessed (other 
than antidepressant class) nor the dose. While drugs in an antidepressant class have a similar chemical 
make-up, other fillers and additives may change their effects on lung function. For example, in Chapter 2, 
open-label studies investigating citalopram and fluoxetine consistently had positive associations. The dose 
of the medication would allow us to assess if a certain dosing level is needed for the anti-inflammatory 
effects of antidepressants to affect lung function. Additionally, we would ideally like our mediational analysis 
to have longitudinal data (where the visits are separated by a maximum of a few months) where our 
independent variable preceded the mediational variable and the mediational variable precedes the 
dependent variable in order to establish temporality. However, in these data the independent variable 
(selective serotonin reuptake inhibitors) and the mediational variable (inflammatory markers) were taken at 
the same exam. If we were to use the longitudinal data, our sample sizes would be severely diminished, 




timing of the measurement is spaced out by a year or more, which is unlikely to be relevant as we 
hypothesize a concurrent effect. Lastly, controlled for depression under the theory that is a confounding 
variable in the relationship between selective serotonin reuptake inhibitors and lung function. If SSRIs work 
through directly on inflammation (depression causes SSRI use -> SSRIs directly improve inflammation and 
lung function), then depression would be seen as a confounder. However, it is also possible that depression 
is a mediator in the relationship between selective serotonin reuptake inhibitors and lung function.  
Despite these limitations, the current project has several notable strengths. It provides novel 
information on the effects of selective serotonin reuptake inhibitors on spirometry, dyspnea, and pulmonary 
exacerbations. It highlights that antidepressants may not be as safe as previously thought in patients with 
low lung function, and encourages further investigation into this relationship. Depression is a common co-
morbidity among individuals with low lung function, signifying that antidepressant use may be significant in 
this population. If these antidepressants are worsening lung function, it is pertinent for caregivers to be 
aware of the potential side effects to carefully weigh the risks and benefits of antidepressant treatment. 
In addition to the potential clinical application of the information generated from our analyses, this 
dissertation adds to the literature on selective serotonin reuptake inhibitors and their effects on lung function 
in general. We were able to investigate the association of selective serotonin reuptake inhibitors on 
spirometry, dyspnea and pulmonary exacerbations in two large cohorts that included individuals with 
diagnosed COPD. Our inclusion of multiple confounders represents an improvement over prior work, which 
were limited in their adjustment and follow-up of participants.  
Future studies should explore differences in reduced low lung function due to genetic susceptibility 
or smoking-induced disease since the inflammatory markers may vary as the cause of the disease is 
different. If future studies replicate these results and selective serotonin reuptake inhibitors are found to 
have an inverse association with lung function, then we recommend a larger meta-analysis and an oversight 
committee in order to formulate guidelines. It is likely that the benefits and side effects will need to be 




In conclusion, although small, poorly controlled studies have shown a beneficial association 
between selective serotonin reuptake inhibitors and lung function, we found an inverse association between 
selective serotonin reuptake inhibitors and spirometry, dyspnea and pulmonary exacerbations. Overall, the 
results suggest that selective serotonin reuptake inhibitors may not be beneficial for individuals with low 
lung function, and may even be harmful. Further research in the form of prospective, interventional trials is 
ideal to further elucidate this in order to make recommendations for the treatment of patients with low lung 
function, but questionable given the results that selective serotonin reuptake inhibitors may harm lung 
function. We suggest analyses in the form of observational studies to first determine if the results of these 
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Appendix Figure 2. Directed Acyclic Graph for hypothesized confounders with exacerbations in the 
SPIROMICS study 











Appendix Table 1. Criteria for risk of bias assessment 
Domains Prompting items for consideration 
Study participation a. Adequate participation in the study by eligible persons  
b. Description of the source population or population of interest  
c. Description of the baseline study sample  
d. Adequate description of the sampling frame and recruitment 
e. Adequate description of the period and place of recruitment  
f. Adequate description of inclusion and exclusion criteria 
Study Attrition a. Adequate response rate for study participants  
b. Description of attempts to collect information on participants who dropped out  
c. Reasons for loss to follow-up are provided  
d. Adequate description of participants lost to follow-up  
e. There are no important differences between participants who completed the study 
and those who did not 
Outcome Measurement 
and Reporting 
a. A clear definition of the outcome is provided  
b. Method of outcome measurement used is adequately valid and reliable  
c. The method and setting of outcome measurement is the same for all study 
participants 
d. There is no selective reporting of results 
Study Confounding a. All important confounders are measured  
b. Clear definitions of the important confounders measured are provided  
c. Measurement of all important confounders is adequately valid and reliable  
d. The method and setting of confounding measurement are the same for all study 
participants  
e. Appropriate methods are used if imputation is used for missing confounder data  
f. Important potential confounders are accounted for in the study design  






Appendix Table 2. Methods of dyspnea assessment 
Study Method 
Brown 2005 Asthma control questionnaire 
Brown 2012 Asthma control questionnaire 
Borson 1992 100-mm horizontal visual analog scale before and 
after 12-minute walk test; Pulmonary Function 
Status Instrument 
Carroll 1990 Visual Analog Scale (VAS) 
Eiser 2005 Diary card data recording nocturnal waking’s due 
to dyspnea, and breathlessness and effect of 
breathlessness on quality of life 
Grove 1995 Borg during 6-minute walk test; activity 
questionnaire in which for fifty common activities 
they were asked to specify if a daily activity was 
avoided or interrupted because of breathlessness. 
Lacasse 2004 Chronic Respiratory Questionnaire 
Momtaz 2015 Modified Borg Scale 
Perna 2004 Modified Borg Scale 
Strom 1995 Graded on a six step scale, ranging from 0=no 
dyspnea to 6=dyspnea  






Appendix Table 3. Detailed results of each study 
Adams, C., et al. 
After one, two and three years of amitriptyline treatment lung functions of cystic fibrosis participants, 
measured as FEV1 % predicted, improved significantly in the treatment group (Table and Figure below) 
Treatment Number of 
participants 











Amitriptyline 20 61.518.5 61.516.9 68.720.3 - - 0.001 
  Differences -0.54.4 7.67.0 - - 0.0008 
 12 57.318.6 59.818.5 65.921.7 64.922.2 - 0.009 
  Differences 2.22.4 6.57.9 5.610.3 - 0.075 
 5 55.323.8 56.823.5 64.326.1 64.425.0 64.525.7 0.050 
  Differences 1.52.3 7.67.4 7.67.4 7.78.0 0.07 
Controls 14 70.017.4 65.824.0 65.617.8 - - 0.010 
  Differences -2.65.1 -1.83.3 - - 0.32 
 10 65.516.0 63.717.0 61.816.5 61.616.9 - 0.051 
  Differences -1.85.9 -1.93.0 -2.13.7 - 0.45 
 5 64.320.0 63.120.4 62.119.1 61.722.5 62.121.1 0.075 
  Differences -1.27.0 -1.03.9 -1.43.0 -1.01.3 0.48 
FEV1 % predicted efficacy of amitriptyline in participants with cystic fibrosis at baseline, the year before, one year 
after, after two and three years of amitriptyline treatment compared to controls.  
 
Borson, S., et al. 
No difference between groups. Pulmonary function numbers not reported. Antidepressant treatment did not 
substantially affect dyspnea during day-to-day activities; there was however associated with small 





Nortriptyline (n=13) Differential 
Treatment Effect 
During 81 activities of daily living    
Low demand Entry 2.1±1.8 2.7±1.8 0.37±0.28 
 Exit 1.9±1.6 2.1±1.5*  
Moderate demand Entry 4.3±2.5 5.2±2.5 0.22±0.58 
 Exit 4.2±2.6 5.0±2.5  
High demand Entry 5.2±2.8 6.8±2.7 0.70±0.69 





Brown, E.S., et al. (2005) 
There were no significant differences between the citalopram and placebo group in change in ACQ (-7.1  
7.6 vs -8.5  10.1, p=0.47). 
Changes in asthma outcomes were similar between the groups. However, the citalopram group required 
less systemic corticosteroids during the trial. This finding is of clinical importance as systemic corticosteroid 
therapy is associated with numerous side effects and is a marker for severe asthma exacerbations.  
 
Brown, E.S., et al. (2012) 
The combined asthma control questionnaire (ACQ) scores did not improve significantly in the initial effect 
(t20=0.2, p=0.86) or in the slope (F1,18=0.6, p=0.4548). Similarly, no significant between-group differences 
were found in the initial effect or the slope (table below). The effect side at week 12 was small (0.24).  
Outcome Measure F Value p-value Effect size 
ACQ total score    
Initial effect: week 0-1 F (1,21)=0.3 0.6052  
Slope: week 1-12 F(1,17)=<0.01 0.9852 0.24 
 
Carroll, N., et al. 
No statistical difference in visual analog scale (VAS) (dyspnea questionnaire) completed by participants. A 
small increase was noted during the placebo limb when the same scale was completed independently by 
the spouse. The median VAS registered by the spouse was 47 (range 34-82) at entry, 54 (range 35-77) on 
placebo and 46 (range12-68) on protriptyline (p<0.01). 
No difference between groups for spirometry. No numbers reported for FEV1, although authors state that 






Eiser, N., et al. (2005) (crossover) 
Dyspnea numbers not reported for the double-blinded study. 
No difference between groups for spirometry outcome. 
 Active Paroxetine Placebo  
 Baseline Post Rx p Baseline Post Rx p p2y 
FEV1 1.13±0.64 1.12±0.69 0.430 1.15±0.68 1.13±0.62 0.298 0.417 
FVC 2.54±0.82 2.57±0.86 0.407 2.74±1.12 2.72±1.01 0.360 0.345 
RV 4.06±1.21 3.71±1.21 0.082 3.92±1.18 3.52±1.64 0.211 0.295 
p taken from paired t-tests comparing within-subject effect of treatment; p2y taken from unpaired t-tests 
compares differences produced by active treatment and placebo between groups 
 
Eiser, N., et al. (2005) (cohort) 
No difference between groups for spirometry or dyspnea. 
 Baseline Post Rx p-value 
FEV1 1.14±0.65 1.18±0.70 0.219 
FVC 2.64±0.97 2.71±0.90 0.367 
RV 4.06±1.21 3.52±1.64 0.480 
Dyspnea 3.19±0.50 3.10±0.71 0.300 
 
Gordon, G.H., et al. 
FEV1 and FVC tended to be higher after treatment compared with placebo, but no statistical significance 
was seen. 
 Baseline Desipramine Placebo 
FEV1 (ml) 775±262 770±277 657±255 







Grove, A., et al. 
No effect of mianserin, prednisolone (corticosteroid) did increase FVC however. 
 FEV1 (l) FVC (l) Borg Scale 
Baseline 0.92  2.53 12 (11-13) 
Placebo 0.90 (0.83-0.97) 2.17 (2.03-2.30) 12.5 (11-13) 
Prednisolone 0.91 (0.85-0.98) 2.42 (2.28-2.56)* 11.5 (11-13) 
Mianserin 0.82 (0.75-0.88) 2.19 (2.06-2.32) 12.5 (11-13) 
*Significantly different from both placebo and mianserin 
 
Lacasse, Y., et al. 
The unadjusted changes in the Chronic Respiratory Questionnaire at follow-up showed improvements 
favoring treatment for dyspnea. However, this did not reach statistical significance. No numbers are 
reported, just figures. 
 
Lechin, F., et al. 
Tianeptine but not placebo provoked a dramatic and sudden decrease of clinical severity ratings 
(breathlessness) and an increase of FEV1 (p<0.0001). No numbers given, only figures. 
 
Light, R.W., et al. 
No difference between groups. 
 Baseline Placebo Doxepin Hydrochloride 
FEV1 (L) 0.87±0.30 0.82±0.25 0.80±0.21 
FVC (L) 2.45±0.55 2.22±0.45 2.16±0.52 
 
Meares, R.A., et al. 
Eleven of the 12 participants showed a significant improvement in FEV1 after the intramuscular 
administration of amitriptyline (p<0.002). Mean improvement of whole group was 17% (from 2.02 to 2.37L) 
(Improvement ranged from 11-47%). In the remaining patient that did not have in increase in FEV1, her 




Momtaz, O.M., et al. 
Dyspnea and spirometric parameters were significantly improved in group I participants who had received 
antidepressant/anxiolytic therapy but not in the non-treated group II participants. Dyspnea actually 
increased in the group II participants. 
Group I-treated group 
 At the start 3 months later p-value 
FVC (L/s) 2.08±0.54 2.18±0.55 0.01 
FEV1 (L/s) 1.10±0.49 1.20±0.44 0.01 
Dyspnea 4.36±0.99 3.68±1.09 0.001 
 
Group II-non-treated group 
 At the start 3 months later p-value 
FVC (L/s) 1.86±0.44 1.83±0.41 0.50 
FEV1 (L/s) 1.06±0.38 1.04±0.29 0.80 
Dyspnea 4.50±1.01 5.17±0.99 0.001 
 
Nahrlich, L., et al. 
Fev1 improved (both absolute and relative to baseline) in both the ITT and PP population. In contrast, 












Intent to treat Amitriptyline 19 +0.6±5.7 0.034 +0.2±11.4 0.08 
 Placebo 17 -3.8±6.9  -6.1±11.5  
Per protocol Amitriptyline 16 +2.2±5.2 0.013 +3.6±7.9 0.013 







Nascimento, I., et al. 
Higher values of FEV1 in participants on antipanic drugs than when they were in the washout period; this 
persisted even after inhalation of bronchodilator. 
Panic disorder participants on antipanic drugs 
 Before salbutamol After salbutamol 
 Observed % predicted Observed % predicted 
FVC (L) 4.31±0.95 104.63±12.66 4.31±0.94 104.72±12.24 
FEV1 (L) 3.58±0.71 107.09±13.74 3.66±0.75 109.27±13.54 
Panic disorder participants without antipanic drugs 
 Before salbutamol After salbutamol 
 Observed % predicted Observed % predicted 
FVC (L) 4.15±0.85 102.90±11.64 4.16±0.92 102.90±12.42 
FEV1 (L) 3.42±0.67* 101.81±14.40* 3.54±0.70 105.18±13.25* 
*significantly different from value with antipanic drug (p<0.05) 
 
Papp, L.A., et al. 
No significant change in spirometric indices. Pulmonary function numbers not reported. 
 
Perna, G., et al. 
All participants showed improved respiratory function measures and a strong decrease in breathing 
discomfort (percentage of decrease in score on the BORG scale=54±16%). 




After one month of 
citalopram 
p-value 
FEV1 0.93±0.13 0.91±0.17 1.12±0.15 p<0.05 







Riethmuller, J., et al. 
After 14 days of treatment, FEV1 had improved significantly in the 25 mg/d amitriptyline group relative to 









Absolute Relative Slopes p-value 
Placebo 13 0     
Amitriptyline 7 25 +3.0±4 +4.0±7 +1.5±2 0.048 
Amitriptyline 8 50 +0.7±3 +0.6±9 +0.4±2 0.28 
Amitriptyline 8 75 -0.7±4 -0.06±9 +0.3±2 0.79 
Amitriptyline 23 25-75 +1.0±4 +1.5±8 +0.7±2 0.07 
 
Series, F., et al. (1989) 
No change. 
 Baseline 2 weeks 10 weeks 
FEV1% 40.8±3.9 42.4±4.6 46.0±3.9 
FVC% 56.0±2.9 59.2±2.5 59.2±2.7 
 
Series, F., et al. (1993) 
There were no significant changes in expiratory flow. 
 
 Control Treated 
 Baseline 10 weeks Follow-up Baseline 10 weeks Follow-up 






Strom, K., et al. 
Neither protriptyline nor placebo had any impact on the dyspnea score. 
No difference between groups. 




p-value Protriptyline Placebo p-value 
FEV1 (L) 0.6±0.2 0.7±0.2 NS 0.7±0.3 0.7±0.3 NS 
 
Sugihara, H., et al. 






+ Poor (±) - Good to 
Excellent 
Poor 
In adults        
Males (41) 7 6 11 6 11 24 (59%) 17 (41%) 
Females (19) 1 8 4 1 5 13 (68%) 6 (32%) 
All (60) 8 (13%) 14 15 7 16 37 (62%) 23 (38%) 
In children under 
15 (14 
participants, 11 
males and 3 
females) 
2 (14%) 4 (29%) 5 (36%) 2 (14%) 1 (7%) 11 (79%) 3 (21%) 
Excellent (+++)-Subjective and objective symptoms disappeared completely 
Good (++): Steroid therapy was withdrawn successfully and dyspnea disappeared but wheezing remained; 
or (+) Dosage of steroid hormone was reduced to one-third and the number of attacks decreased or 
dyspnea improved. 
Poor (): No response was observed or is some improvement was observed, it could not be considered to 







Van Milligen, B.A., et al. 
Women with higher depressive symptom severity and women using antidepressants had significantly 
poorer lung function. This was not true for men. Actual number of FEV1 not given, only beta associations. 
 Men (n=543)  Women (n=1086)  
 B (±S.E.) p B (±S.E.) p 
Depression Reference  Reference  





Appendix Table 4. Detailed attrition results 
Study Treatment group Control group 
Adams 2016 # who left: 8 participants (40%) left in the 
second year and an additional 7 (75%) in the 
third 
reason: not reported 
# who left: 4 (28.6%) participants left in the 
second year and an additional 5 (64% total) 
in the third 
reason: not reported 
Borson 1992 # who left: 5 (27.8%) 
reason: 3 for side effects of drug (dry mouth, 
sedation, and/or orthostatic hypotension); 2 
for non-drug related reasons 
# who left: 1 (5.6%) 
reason: died of cardiopulmonary arrest 
Brown 2005 # who left: 8  
Reason: it is unclear if these 8 were part of 
the placebo or control group. 
# who left: 8 
Reason: it is unclear if these 8 were part of 
the placebo or control group. 
Brown 2012 # who left: 1 
reason: 1 participant had no post-baseline 
data, but it is not clear if they were in the 
treatment or placebo group 
# who left: 1 
reason: 1 participant had no post-baseline 
data, but it is not clear if they were in the 
treatment or placebo group 
Carroll 1990 # who left: 0 
reason: not applicable 




# who left: none 
reason: 4 participants who had drawn active 
antidepressant treatment developed side 
effects on paroxetine- nausea and vomiting- 
and finished study in single-blind fashion 
taking Lofepramine 140 mg. 
# who left: 0 
reason: not applicable 
Eiser 2005 
(open-label) 
# who left: 0 
Reason: 1 patient who had drawn placebo 
initially developed nausea on the open 
Paroxetine and continued in the open-label 
portion on Dothiepin 150 mg daily. 2 
participants, 1 initially on active and 1 on 
placebo, did not improve when on active 
paroxetine, despite increase to 40mg. 
Therefore, their treatment was changed to 
Dothiepin 150mg daily for open label.  
not applicable-no control group 
Gordon 1985 # who left: 2 (15.4%) 
reason: 1 had intolerable side effects (not 
explicitly stated) and 1 had new onset of 
multifocal atrial tachycardia 
# who left: 5 (38.5%) 
reason: 4 of these were hospitalized (2 with 
severe exacerbations of COPD, 1 with 
myocardial infarction, and 1 with ventricular 
arrhythmias) and 1 moved 
Grove 1990 # who left: 0 
reason: not applicable 
# who left: 0 
reason: not applicable 
Lacasse 2004 # who left: 7 (58.3%) 
reason: 1 died before starting, 3 
discontinued intervention, 2 refused to 
continue, 1 had side effects (tremor) 
# who left: 7 (63.6%) 
reason: 1 died before starting, 3 
discontinued intervention, 2 refused to 
continue, 1 had severe exacerbation 




Reason: 5 left due to failure to follow 
protocol; 5 dropped out due to lack of 
motivation (3rd and 4th weeks); 3 ruled out 
before first week because of epileptiform 
abnormalities. Authors did not indicate 
whether participants dropped in the 
treatment or placebo phase. 
Reason: Authors did not indicate whether 
participants dropped in the treatment or 
placebo phase. 
Light 1986 # who left: 3 (25%) 
reason: intolerable drowsiness, blurry vision 
and nausea and vomiting  
# who left: 0 
reason: not applicable 
Meares 1971 # who left: 0 
reason: not applicable 
not applicable-no control group  
Nahrlich 2013 # who left: 2 (9.5%) from ITT, additional 3 
(23.8%) from PP 
reason: 2 excluded from ITT analysis (1 
refused medication, 1 had high C-reactive 
protein); an additional 3 were excluded from 
the PP analysis (2 had high C-reactive 
protein, 1 was not correctly medicated) 
# who left: 2 (10.5%) from ITT, an additional 
4 (31.6%) from PP 
reason:  2 excluded from ITT analysis (one 
due to missing lung function follow-up value, 
one due to high CRP); an additional 4 were 
excluded from the PP analysis due to high 
CRP 
Nascimento 2009 # Who left: 1 (8%) 
reason: did not participate 
not applicable- no control group 
Momtaz 2015 # who left: 0 
reason: not applicable 
# who left: 0 
reason: not applicable 
Papp 1995 # who left: 0 
reason: not applicable 
not applicable- no control group 
Perna 2004 # who left: 0 
reason: not applicable 
not applicable- no control group 
Riethmuller 2009 # who left: 7 (37%) 
reason: 1 patient discontinued treatment 
after 10 days due to an adverse event 
(authors do not report what treatment they 
were on); 6 participants were excluded from 
the analysis according to criteria of study 
plan (dose reduction or exacerbation) 
# who left: 7 (37%) 
reason: 1 patient discontinued treatment 
after 10 days due to an adverse event 
(authors do not report what treatment they 
were on); 6 participants were excluded from 
the analysis according to criteria of study 
plan (dose reduction or exacerbation) 
Series 1989 # who left: 2 (14.3%) 
Reason: 2 participants were excluded before 
the second visit because the treatment for 
the COPD had changed; the week 2 study 
was not carried out in two participants 
because of technical problems, and 1 
participants who developed 
bronchopneumonia. Therefore, data is 
presented on 12 participants, 10 at 2 weeks 
and 11 at 10 weeks. 
not applicable- no control group 
Series 1993 # who left: 0 
Reason: The authors note a range of follow-
up times, but say that they were the same on 
average between the treated and control 
groups. 
# who left: 0 




Strom 1995 # who left: 3 (21.4%) 
reason: 2 for medication side effects (dry 
mouth, visual disturbance, dizziness and 
fatigue) and 1 for exacerbation of COPD 
# who left: 0 
reason: not applicable 
Sugihara 1965 # who left: unknown 
reason: Reports that drug had to be 
withdrawn in some participants but does not 
give specific number 
not applicable-no control group 
Van Milligen 2011 # who left: 0 
reason: not applicable 
# who left: 0 






Appendix Table 5. Risk of bias assessment for each study 








Study Participation Follow-up based off previously randomized study. 20 out of the 
59 participants from the original study asked for continuing 
amitriptyline treatment, since they volunteered it is likely that 
they had a favorable effect during the first trial, which is why they 
wanted to continue therapy. 
High risk 
Study Attrition Over three years 75% left treatment group and 64% left control 
group 
High risk 
Outcome Measurement and 
Reporting 
All pre-defined outcomes are reported Low risk 
Study Confounding  Both groups were similar with regard to gender, age, weight, 












Study Participation moderate to severe COPD and coexisting depression Low risk 
Study Attrition 3 participants left the trial because of side-effects and 2 
discontinued for non-drug related reasons (27.8% of treatment 
group); 1 died of cardiopulmonary arrest while receiving placebo 
(5.6% of placebo group) 
High risk 
Outcome Measurement and 
Reporting 
No reporting of exact spirometry measures, even though they 
were an outcome of the study. However, many measures were 
collected and the authors likely did not have room to show non-
significant improvements. 
High risk 
Study Confounding  Randomized; Assignment to treatment condition was performed 
by pharmacist blind to study questions using a table of random 
numbers; Pharmacy-controlled. All personnel blind to 
medication assignment 
Low risk 
Other Although not significant, baseline FEV1 was different between 
treatment and control groups; Pill counts, weekly patient reports 















Study Participation out patients with asthma and current major depressive disorder Low risk 
Study Attrition Unclear Unclear 
Outcome Measurement and 
Reporting 
All pre-defined outcomes are reported Low risk 
Study Confounding  Randomized; Double blind -Medication or placebo in identical 
appearance 
Low risk 
Other Increased dosage for those who showed no response High risk 
 








Study Participation out patients with asthma, major depressive disorder and at least 1 
course of oral corticosteroids in the prior 12 months 
Low risk 
Study Attrition Unclear Unclear 
Outcome Measurement 
and Reporting 
All pre-defined outcomes are reported Low risk 
Study Confounding  Randomized using a randomization program (random number 
sequence); Double blind-Medication or placebo in identical 
appearance 
Low risk 
Other Increased dosage for those who showed no response High risk 
 








Study Participation severe disease (FEV1<40%) and previously documented 
hypercapnia while stable 
Low risk 
Study Attrition One male patient died during second phase (placebo) and was 
excluded from analysis. No discontinuations from side-effects 
Low risk 
Outcome Measurement and 
Reporting 
No numbers reported for spirometry measures, even though 
they are an outcome of the study. 
High risk 
Study Confounding  Randomized study, randomization method not described; 
Double-blinded trial. The exact method is not described. 
Low risk 
















Study Participation clinical depression; well-documented, stable COPD; no 
psychotropic drugs within 3 months 
Low risk 
Study Attrition Four participants who had initially drawn active anti-depressant 
treatment developed significant side effects on Paroxetine and 
finished study taking Lofepramine 140 mg in a single-blind 
fashion. 
High risk 
Outcome Measurement and 
Reporting 
Dyspnea measure not reported High risk 
Study Confounding  Randomized study, randomization method not described; 
double-blinded; researchers did not have access to the previous 
measurements of lung function 
Low risk 








Study Participation  All participants from randomized crossover study Low risk 
Study Attrition 1 patient who had drawn placebo initially developed nausea on 
the open Paroxetine and continued in the open-label portion on 
Dothiepin 150 mg daily. 2 participants, 1 initially on active and 
1 on placebo, did not improve when on active paroxetine, 
despite increase to 40mg. Therefore, their treatment was 
changed to Dothiepin 150mg daily for open label. 
High risk 
Outcome Measurement and 
Reporting 
All outcomes reported Low risk 
Study Confounding  It was decided it was unethical to withhold treatment for 
depression longer than 6 weeks, after the RCT portion (above), 
all participants continued taking paroxetine 20mg daily in an 
open fashion until all participants had received 3 months of 
treatment 
Low risk 















Study Participation stable state and FEV1 < 1 liter Low risk 
Study Attrition Of the original 13 participants, 7 left the study before its 
completion; 5 of them were in placebo group; only report on 6 
that completed 
High risk 
Outcome Measurement and 
Reporting 
All pre-specified outcomes are reported. Low risk 
Study Confounding  Order of drugs assigned randomly by hospital pharmacy; 
Double-blinded. Pharmacy controlled blinding. 
Low risk 
Other Maximum tolerated dose given or 100 mg, not standardized;  Pill 
counts and medication diaries 
High risk 








Study Participation out patients with stable COPD (FEV1<60% with less than 15% 
reversibility after salbutamol) 
Low risk 
Study Attrition No dropouts Low risk 
Outcome Measurement and 
Reporting 
Results not reported on functional assessment questionnaire High risk 
Study Confounding  Randomized trial; double blind Low risk 








Study Participation home care COPD participants (FEV1≤50%) who are depressed Low risk 
Study Attrition 14 participants left trial, 7 in treatment group and 7 in placebo 
group 
High risk 
Outcome Measurement and 
Reporting 
All outcomes reported Low risk 
Study Confounding  Randomized trial; double blind Low risk 
Other Maximum of 20mg or highest dose not associated with any side 
















Study Participation children with asthma, FEV1<70% Low risk 
Study Attrition Unclear at which stage (treatment or placebo) the participants 
dropped out 
Unclear 
Outcome Measurement and 
Reporting 
All pre-defined outcomes are reported, but no numbers are 
presented, only figures 
High risk 
Study Confounding  Randomized, method not given; Double-blinded. Interviewers 
were unaware of the participants treatment group; identical 
dark capsules; crossover design 
Low risk 








Study Participation FEV1 <1.25 L and FEV1/FVC <50%; no major antipsychotic 
drugs and tricyclic antidepressant within 2 months; had 
depression and anxiety 
Low risk 
Study Attrition 3 participants left study due to side-effects of drug High risk 
Outcome Measurement and 
Reporting 
All outcomes reported Low risk 
Study Confounding  Double-blind; crossover design Low risk 
Other Various dosing of doxepin given (150mg max, if side effects 
occurred- dose was decreased) 
High risk 








Study Participation 12 asthmatics from medical outpatient clinic, not selected in any 
way 
Low risk 
Study Attrition None Low risk 
Outcome Measurement and 
Reporting 
All-pre-defined outcomes are reported Low risk 
Study Confounding  No control High risk 
Other It is unclear if the participants knew when they were getting the 
















Study Participation No mention of how participants were chosen for which group;  
severe COPD with depression and/or anxiety 
High risk 
Study Attrition no dropouts Low risk 
Outcome Measurement and 
Reporting 
All pre-specified outcomes are reported. Low risk 
Study Confounding  Matched study, no randomization mentioned by authors High risk 
Other Matched on sex, all were stage II or IV COPD Low risk 








Study Participation cystic fibrosis participants >14 years of age, FEV1 >30% and 
<90% 
Low risk 
Study Attrition There was an error in the randomization so one patient in treated 
group received placebo and one patient in placebo group 
received treatment. 
High risk 
Outcome Measurement and 
Reporting 
All pre-defined outcomes are reported, both ITT and PP 
analyses are reported 
Low risk 
Study Confounding  Randomized using statistical software; Double-blinded; 
placebo was corn-starch capsules 
Low risk 
Other Authors report 21 assigned to treated, 19 assigned to control, 19 
treated and 17 controls for ITT, and 16 treated and 13 controls 
for PP, however the baseline characteristics table reports 19 

















Study Participation panic disorder participants with or without agoraphobia; in good 
physical condition, no past or current diagnosis of respiratory 
disorders, no history of smoking 
Low risk 
Study Attrition 1 participant refused to participate in follow-up Low risk 
Outcome Measurement and 
Reporting 
All pre-defined outcomes were reported Low risk 
Study Confounding  No control; single-blind High risk 
Other Participants were on multiple medications, making it hard to 
determine which drug had the effect 
High risk 








Study Participation COPD participants with and without comorbid anxiety recruited 
from an outpatient pulmonary clinic 
Low risk 
Study Attrition No dropouts Low risk 
Outcome Measurement and 
Reporting 
No specific numbers reported, just descriptive results High risk 
Study Confounding  No control High risk 








Study Participation severe COPD participants that were on stable medications for 1 
year; no current mood or anxiety disorders 
Low risk 
Study Attrition No dropouts Low risk 
Outcome Measurement and 
Reporting 
All pre-specified outcomes are reported. Low risk 















Study Participation Cystic fibrosis participants attending the CF center of the 
Children’s University Hospital of Tuebingen; detailed inclusion 
and exclusion criteria 
Low risk 
Study Attrition Even number of dropouts of treatment and placebo Low risk 
Outcome Measurement and 
Reporting 
All pre-defined outcomes are reported Low risk 
Study Confounding  Randomized;  Double-blinded Low risk 
Other 18 participants were analyzed with intent to treat (ITT), 13 were 
analyzed per protocol (PP). Authors report both ITT and PP 
results 
Low risk 








Study Participation COPD with and FEV1 <65% and an FEV1/FVC <65%; clinical 
state and treatment unchanged for at least 4 weeks 
Low risk 
Study Attrition Two participants were excluded before the second visit because 
the treatment for their COPD had been changed. Week 2 study 
not carried out in two participants because of technical 
problems, and one patient who developed bronchopneumonia 
was not evaluated at 10 weeks. 
High risk 
Outcome Measurement and 
Reporting 
All pre-specified outcomes are reported.  Low risk 
Study Confounding  No control High risk 
Other The dose of protriptyline was reduced to 10 mg once a day after 
2 weeks’ treatment in two participants because of severe 
















Study Participation Participants who were enrolled in previous trials High risk 
Study Attrition The authors report a range of follow-up times, but say that on 
average it was equal for both the treatment and control groups 
Low risk 
Outcome Measurement and 
Reporting 
All pre-specified outcome were reported Low risk 
Study Confounding  The treatment and control groups did not differ on their follow-
up duration, age, weight, or pulmonary function. 
Low risk 
Other Dose of protriptyline was reported as a range (10-20mg) High risk 








Study Participation COPD with mild or moderate stable hypoxemia; detailed 
inclusion and exclusion criteria 
Low risk 
Study Attrition Three participants receiving protriptyline were withdrawn from 
the trial, two because of side effects and one due to an 
exacerbation. 
High risk 
Outcome Measurement and 
Reporting 
All pre-specified outcomes are reported.  Low risk 
Study Confounding  Randomized study, method not described; Double-blind, 
placebo-controlled 
Low risk 
Other No mention of patient compliance; baseline FEV1 was different 














Study Participation Persons with current depressive and/or anxiety disorders 
(n=1629) and healthy controls without lifetime diagnosis (n=629) 
Low risk 
Study Attrition None Low risk 
Outcome Measurement and 
Reporting 
All pre-specified outcomes are reported Low risk 
Study Confounding  Socio-demographic (age and years of education), health status 
(BMI, lung medication and chronic diseases) and lifestyle 
(smoking status and physical activity) 
Low risk 
Other No control for severity of disease (depression) High risk 
 
  








Study Participation Hospitalized in and out patients with bronchial asthma; no 
details given on inclusion and exclusion criteria 
High risk 
Study Attrition No dropouts Low risk 
Outcome Measurement and 
Reporting 
All pre-defined outcomes are reported Low risk 
Study Confounding  No control High risk 
Other Participants who had wheezing, slight dyspnea only at night or 
severe drowsiness after use of Amitriptyline were given only 
single dose of 20-40mg at bedtime. If symptoms aggravated by 
drug, drug discontinued; if no response, the drug was increased 
until the patient showed a response one-way or the other. If no 
response seen after an appreciable length of time, therapy was 
discontinued. 





Appendix Table 6. Demographic age, gender, and race/ethnicity breakdown from MESA Exam 1-5 
Category Exam 1 Exam 2 Exam 3 Exam 4 Exam 5 
Age at Baseline 45-54 29% 29% 30% 30% 33% 
 55-64 28% 28% 28% 28% 31% 
 65-74 30% 29% 29% 30% 28% 
 75-84 14% 14% 13% 12% 8% 
Gender Female 53% 52% 53% 53% 53% 
 Male 47% 48% 47% 47% 47% 
Race/Ethnicity African-American 28% 27% 27% 27% 26% 
 Chinese-American 12% 12% 12% 11% 12% 
 Hispanic 22% 22% 21% 21% 21% 
 White 39% 40% 40% 40% 39% 







Appendix Table 7. MESA assay census for exams 1-5 
 Exam 1 Exam 2 Exam3 Exam4 Exam5 
 N=6814 N=6232 N=5939 N=5704 N=4651 
Questionnaires 
Personal History X X X X X 
Medical History X X X X X 
Medications X X X X X 
Psycho-Social X X X X X 
Procedures/Assessments 
Anthropometry X X X X X 
Spirometry    A A 






























Appendix Table 9. Associations of confounders at exam 5 with selective serotonin reuptake inhibitors and 
outcome variables 
Sample characteristics 
  Crude relationship to  
A. SSRI B. FEV1%  C. Dyspnea 
OR 95% CI b 95% CI OR 95% CI 
Health Insurance       
None Ref Ref Ref Ref Ref Ref 
Medicaid 1.05 0.35 to 3.21 -1.86 -6.07 to 2.34 1.75 0.97 to 3.14 
Medicare 1.38 0.50 to 3.84 -0.08 -4.07 to 3.91 1.27 0.71 to 2.27 
HMO 1.54 0.62 to 3.84 -1.92 -5.38 to 1.53 1.00 0.60 to 1.68 
VA/Other 2.14 0.80 to 5.73 2.04 -6.30 to 1.69 1.59 0.90 to 2.80 
Cigarette smoking status       
Never-smokers Ref Ref Ref Ref Ref Ref 
Former smokers 1.29 0.94 to 1.78 -3.09 -4.58 to -1.59 1.31 1.06 to 1.62 
Current smokers 2.02 1.42 to 3.41 -10.77 -13.73 to -7.82 1.42 0.95 to 2.12 
Smoking pack-years 1.07 1.00 to 1.13 -1.65 -2.00 to -1.30 1.11 1.06 to 1.16 
CES-D Score 1.06 1.04 to 1.07 -0.12 -0.21 to -0.02 1.06 1.05 to 1.07 





Appendix Table 10. Unadjusted and adjusted difference-in-difference analysis of percent of predicted 
forced expiratory volume in one second: serotonin norepinephrine reuptake inhibitors 
Unadjusted     
Comparison group 1 
n=28 
SNRI use at 
Exam 4 
SNRI use at 
Exam 5 
Absolute difference 
between exam 4 and 5 
p-value 
Control Group (on/on) 86% 85% 1  
Treatment Group (on/off) 96% 96% 0  
Difference 10 9 1 0.58 
Comparison group 2 
n=2382 
    
Control Group (off/off) 94% 96% 2  
Treatment Group (off/on) 92% 94% 2  
Difference 2 2 0 0.74 
Adjusted†     
Comparison group 1 
n=28 
SNRI use at 
Exam 4 
SNRI use at 
Exam 5 
Absolute difference 
between exam 4 and 5 
p-value 
Control Group (on/on) 105% 112% 7  
Treatment Group (on/off) 111% 116% 5  
Difference 6 4 2 0.74 
Comparison group 2 
n=2382 
    
Control Group (off/off) 93% 94% 1  
Treatment Group (off/on) 90% 92% 2  
Difference 3 2 1 0.59 
The first comparison group had 19 patients that remained on serotonin norepinephrine reuptake inhibitors (control 
group) compared to 9 who went from being on serotonin norepinephrine reuptake inhibitors at exam 4 to being off 
them at exam 5 (treatment group). The second comparison group had 2356 patients that remained off serotonin 
norepinephrine reuptake inhibitors (control group) compared to 26 who went on them at exam 5 (treatment group).  






Appendix Table 11. Unadjusted and adjusted difference-in-difference analysis of percent of predicted 
forced expiratory volume in one second: tricyclic antidepressants 
Unadjusted     
Comparison group 1 
n=29 
TCA use at Exam 4 TCA use at Exam 5 Absolute difference 
between exam 4 and 5 
p-value 
Control Group (on/on) 90% 93% 3  
Treatment Group (on/off) 99% 103% 4  
Difference 9 10 1 0.77 
Comparison group 2 
n=2381 
    
Control Group (off/off) 94% 96% 2  
Treatment Group (off/on) 87% 83% 4  
Difference 7 13 6 0.08 
Adjusted†     
Comparison group 1 
n=29 
TCA use at Exam 4 TCA use at Exam 5 Absolute difference 
between exam 4 and 5 
p-value 
Control Group (on/on) 80% 72% 8  
Treatment Group (on/off) 86% 76% 10  
Difference 6 4 2 0.57 
Comparison group 2 
n=2381 
    
Control Group (off/off) 93% 94% 1  
Treatment Group (off/on) 87% 83% 4  
Difference 6 11 5 0.11 
The first comparison group had 13 patients that remained on tricyclic antidepressants (control group) compared to 
16 who went from being on tricyclic antidepressants at exam 4 to being off them at exam 5 (treatment group). The 
second comparison group had 2366 patients that remained off tricyclic antidepressants (control group) compared 
to 15 who went on them at exam 5 (treatment group). 








Appendix Table 12. Unadjusted and adjusted difference-in-difference analysis of proportion of participants 
reporting dyspnea: serotonin norepinephrine reuptake inhibitors 
Unadjusted     
Comparison group 1 
n=45 
SNRI use at Exam 4 SNRI use at Exam 5 Absolute difference 
between exam 4 and 5 
p-value 
Control Group (on/on) 25% 21% 4%  
Treatment Group (on/off) 25% 22% 3%  
Difference 0 1 1 0.96 
Comparison group 2 
n=2365 
    
Control Group (off/off) 13% 14% 1%  
Treatment Group (off/on) 16% 19% 3%  
Difference 3% 5% 2% 0.61 
Adjusted†     
Comparison group 1 
n=45 
SNRI use at Exam 4 SNRI use at Exam 5 Absolute difference 
between exam 4 and 5 
p-value 
Control Group (on/on) 25% 9% 16%  
Treatment Group (on/off) 19% 21% 2%  
Difference 6 12 18 0.17 
Comparison group 2 
n=2365 
    
Control Group (off/off) 13% 14% 1%  
Treatment Group (off/on) 5% 4% 1%  
Difference 8 10 2 0.84 
The first comparison group had 19 patients that remained on serotonin norepinephrine reuptake inhibitors (control 
group) compared to 9 who went from being on serotonin norepinephrine reuptake inhibitors at exam 4 to being off 
them at exam 5 (treatment group). The second comparison group had 2356 patients that remained off serotonin 
norepinephrine reuptake inhibitors (control group) compared to 26 who went on them at exam 5 (treatment group).  







Appendix Table 13. Unadjusted and adjusted difference-in-difference analysis of proportion of participants 
reporting dyspnea: tricyclic antidepressants 
Unadjusted     
Comparison group 1 
n=28 
TCA use at Exam 4 TCA use at Exam 5 Absolute difference 
between exam 4 and 5 
p-value 
Control Group (on/on) 39% 15% 24%  
Treatment Group (on/off) 20% 20% 0%  
Difference 19 5 24 0.23 
Comparison group 2 
n=2382 
    
Control Group (off/off) 13% 15% 2%  
Treatment Group (off/on) 38% 50% 12%  
Difference 25 35 10 0.23 
Adjusted†     
Comparison group 1 
n=28 
TCA use at Exam 4 TCA use at Exam 5 Absolute difference 
between exam 4 and 5 
p-value 
Control Group (on/on) 31% 7% 24%  
Treatment Group (on/off) 12% 14% 2%  
Difference 19 7 26  
Comparison group 2 
n=2382 
   0.18 
Control Group (off/off) 13% 14% 1%  
Treatment Group (off/on) 33% 43% 10%  
Difference 20 29 9 0.38 
The first comparison group had 13 patients that remained on tricyclic antidepressants (control group) compared to 
16 who went from being on tricyclic antidepressants at exam 4 to being off them at exam 5 (treatment group). The 
second comparison group had 2366 patients that remained off tricyclic antidepressants (control group) compared 
to 15 who went on them at exam 5 (treatment group). 










Appendix Table 14. Percent of predicted forced expiratory volume in one second at exam 4: controlling for 
depression only 
 A. Unadjusted model B. Adjusted model 1 C. Adjusted model 2 
b 95% CI b 95% CI b 95% CI 
SSRI -4.66 -7.31 to -2.02 -4.27 -6.95 to -1.60 -4.41 -7.07 to -1.75 
CES-D Score (continuous)   -0.07 -0.15 to 0.003   
Depressed vs. not depressed     -1.47 -3.20 to 0.26 






Appendix Table 15. Percent of predicted forced expiratory volume in one second at exam 5: controlling for 
depression only 
 A. Unadjusted model B. Adjusted model  C. Adjusted model 2 
b 95% CI b 95% CI b 95% CI 
SSRI -3.22 -6.37 to -0.08 -2.78 -5.96 to 0.39 -2.93 -6.10 to 0.23 
CES-D Score (continuous)   -0.10 -0.20 to -0.010   
Depressed vs. not depressed     -1.73 -3.79 to 0.34 






Appendix Table 16. Dyspnea at exam 4: controlling for depression only 
 A. Unadjusted model B. Adjusted model  C. Adjusted model 2 
OR 95% CI OR 95% CI OR 95% CI 
SSRI 1.99 1.41 to 2.80 1.38 0.96 to 1.99 1.63 1.15 to 2.32 
CES-D Score (continuous)   1.07 1.06 to 1.08   
Depressed vs. not depressed     2.98 2.39 to 3.72 






Appendix Table 17. Dyspnea at exam 5: controlling for depression only 
 A. Unadjusted model B. Adjusted model  C. Adjusted model 2 
OR 95% CI OR 95% CI OR 95% CI 
SSRI 1.76 1.20 to 2.57 1.39 0.93 to 2.06 1.50 1.01 to 2.21 
CES-D Score (continuous)   1.06 1.05 to 1.07   
Depressed vs. not depressed     2.40 1.88 to 3.08 






Appendix Table 18. SPIROMICS inclusion/exclusion criteria [112] 







Inclusion Criteria     
Between age 40 and 80 (inclusive) at Baseline Visit  X X X X 
Able to tolerate and willing to undergo study procedures X X X X 
<1 pack-year history of smoking X    
>20 pack-year history of smoking  X X X 
Pre-bronchodilator: FEV1/FVC >=.7 and FVC>LLN X    
Post-bronchodilator: FEV1/FVC >=.7 and FVC>LLN  X   
Post bronchodilator: FEV1/FVC < .7 and FEV1  > 50% pred   X  
Post bronchodilator: FEV1/FVC < .7 and FEV1 < 50% pred    X 
Able to understand English and/or Spanish X X X X 
     
Exclusion Criteria     
Women only: Cannot be pregnant at baseline or plan to become pregnant 
during the course of the study 
X X X X 
Dementia or other cognitive dysfunction which in the opinion of the 
investigator would prevent the participant from consenting to the study or 
completing study procedures 
X X X X 
Has plans to leave the area in the next 3 years X X X X 
Smoking history of > 1 pack-year but <21 pack-years X X X X 
Has a BMI > 40 kg/m2 at baseline exam X X X X 
Prior significant difficulties with pulmonary function testing X X X X 
Hypersensitivity to or intolerance of albuterol sulfate or ipratropium 
bromide or propellants or excipients of the inhalers 
X X X X 
Non-COPD obstructive lung disease (various bronchiolitides, sarcoid, 
LAM, histiocytosis X) or parenchymal lung disease, pulmonary vascular 
disease, pleural disease, severe kyphoscoliosis, neuromuscular 
weakness, or other conditions, including clinically significant 
cardiovascular and pulmonary disease, that, in the opinion of the 
investigator, limit the interpretability of the pulmonary function measures. 
X X X X 
History of interstitial lung disease X X X X 
Current diagnosis of asthma X    
History of lung volume reduction surgery or lung resection X X X X 
History of lung or other organ transplant X X X X 
History of endobronchial valve therapy X X X X 
History of large thoracic metal implants (e.g., AICD and/or pacemaker) 
that in the opinion of the investigator limit the interpretability of CT scans 
X X X X 
Currently taking >=10mg a day/20mg every other day of prednisone or 
equivalent systemic corticosteroid 
X X X X 
Currently taking any immunosuppressive agent X X X X 
Current illicit substance abuse, excluding marijuana X X X X 
History of or current use of IV Ritalin X X X X 
History of or current use of heroin X X X X 
History of illegal IV drug use within the last 10 years or more than 5 
instances of illegal IV drug use ever  
X X X X 
Known HIV/AIDS infection X X X X 
History of lung cancer or any cancer that spread to multiple locations in 
the body 
X X X X 
History of or current exposure to chemotherapy or radiation treatments 
that, in the opinion of the investigator, limits the interpretability of the 
pulmonary function measures. 
X X X X 
Diagnosis of unstable cardiovascular disease including myocardial 
infarction in the past 6 weeks, uncontrolled congestive heart failure, or 
uncontrolled arrhythmia  

















N and (%) or 
MeanSD 
N and (%) or 
MeanSD 
N and (%) or 
MeanSD 
N and (%) or 
MeanSD 
Age, years, mean±SD 64±9 64±9 59±8 65±8 
Gender         
Male 1017 (56) 113 (35) 12 (35) 18 (38) 
Female 810 (44) 208 (65) 22 (65) 30 (63) 
Race         
White 1422 (78) 280 (87) 28 (82) 40 (83) 
Black 326 (18) 27 (8) 4 (12) 4 (8) 
Asian 21 (1) 1 (.31) 1 (3) 0 (0) 
Pacific Islander 41 (2) 7 (2) 0 (0) 2 (4) 
American Indian 7 (.38) 2 (.62) 0 (0) 1 (2) 
Mixed 10 (.55) 4 (1) 1 (3) 1 (2) 
Height, cm, mean±SD 170±10 168±9 165±10 167±8 
Weight, kg, mean±SD 82±18 81±18 78±19 82±18 
Current or former smokers         
Yes 618 (34) 113 (35) 15 (44) 16 (33) 
No 1209 (66) 208 (65) 19 (56) 32 (67) 
Smoking history pack-years# 48±41 49±29 41±21 53±30 
FEV1 % predicted, mean±SD 67±27 66±28 71±29 74±24 
COPD Stage         
None 526 (31) 107 (34) 13 (39) 18 (38) 
Mild 284 (17) 33 (11) 3 (9) 8 (17) 
Moderate 530 (31) 94 (30) 10 (30) 16 (33) 
Severe 262 (15) 58 (19) 7 (21) 6 (13) 
Very Severe 117 (7) 21 (7) 0 (0) 0 (0) 
HADS Score, mean±SD 4±3 6±4 8±4 5±4 
Depressed (HADS≥8) 276 (15) 92 (29) 16 (47) 12 (25) 
Number of exacerbations 









cm: centimeters, kg: kilogram; FEV1: forced expiratory volume in one second; HADS: Hospital Anxiety 
and Depression scale; SSRI: selective serotonin reuptake inhibitors, TCA: tricyclic antidepressants, 






Appendix Table 20. Crude and adjusted Hazard Ratios (HRs) for time to first exacerbation using time 
dependent cox regression: serotonin norepinephrine reuptake inhibitors 
 A. Unadjusted model B. SNRIs and Depression C. Adjusted model†  
b 95% CI b 95% CI b 95% CI 
SNRI vs. Other* 1.27 0.75 to 2.15 0.96 0.56 to 1.63 1.18 0.60 to 2.31 
Depression score   1.09 1.07 to 1.11 1.04 1.01 to 1.07 
Ageǂ     0.97 0.85 to 1.10 
Gender     1.43 1.18 to 1.74 
Baseline FEV1ǂ     0.82 0.78 to 0.85 
Prior Exacerbations     1.41 1.31 to 1.52 
Current Smoker     0.94 0.75 to 1.17 
Pack-yearsǂ     1.01 0.99 to 1.03 
*Other indicates participants that were on other antidepressants or on no antidepressants. †Time-dependent variables included  
antidepressant status, current smoking status, smoking pack-years, and HADS depression score. ǂAge, baseline FEV1, and  






Appendix Table 21. Crude and adjusted Hazard Ratios (HRs) for time to first exacerbation using time 
dependent cox regression: tricyclic antidepressants 
 A. Unadjusted model B. TCAs and Depression C. Adjusted model†  
b 95% CI b 95% CI b 95% CI 
TCA vs. Other* 1.28 0.79 to 2.07 1.15 0.71 to 1.86 1.50 0.77 to 2.91 
Depression score   1.09 1.07 to 1.11 1.04 1.01 to 1.07 
Ageǂ     0.97 0.85 to 1.10 
Gender     1.43 1.17 to 1.74 
Baseline FEV1ǂ     0.82 0.78 to 0.85 
Prior Exacerbations     1.41 1.32 to 1.52 
Current Smoker     0.95 0.76 to 1.18 
Pack-yearsǂ     1.01 0.99 to 1.03 
*Other indicates participants that were on other antidepressants or on no antidepressants. †Time-dependent variables 
included antidepressant status, current smoking status, smoking pack-years, and HADS depression score. ǂAge, 





Appendix Table 22. Crude and adjusted Hazard Ratios (HRs) for time to first exacerbation using time 
dependent cox regression: any antidepressants 
 A. Unadjusted model B. TCAs and Depression C. Adjusted model†  
b 95% CI b 95% CI b 95% CI 
Any vs. Other* 1.38 1.56 to 1.64 1.17 0.98 to 1.40 1.18 0.93 to 1.50 
Depression score   1.08 1.06 to 1.10 1.04 1.01 to 1.07 
Ageǂ     0.97 0.85 to 1.10 
Gender     1.41 1.15 to 1.72 
Baseline FEV1ǂ     0.82 0.78 to 0.85 
Prior Exacerbations     1.41 1.32 to 1.52 
Current Smoker     0.94 0.76 to 1.18 
Pack-yearsǂ     1.01 0.99 to 1.03 
*Other indicates participants that were on other antidepressants or on no antidepressants. †Time-dependent variables 
included antidepressant status, current smoking status, smoking pack-years, and HADS depression score. ǂAge, 




Appendix Table 23. Crude and adjusted Hazard Ratios (HRs) for time to first exacerbation using time 
dependent cox  
regression: Depressed  
 A. Unadjusted model B. SSRIs and 
Depression 
C. Adjusted model†  
b 95% CI b 95% CI b 95% CI 
SSRI vs. Other* 0.96 0.67 to 1.37 0.93 0.65 to 1.34 0.89 0.56 to 1.39 
Depression score   1.03 0.98 to 1.08 1.03 0.94 to 1.12 
Ageǂ     0.93 0.71 to 1.21 
Gender     1.51 1.00 to 2.30 
Baseline FEV1ǂ     0.86 0.79 to 0.93 
Prior Exacerbations     1.35 1.19 to 1.53 
Current Smoker     0.96 0.64 to 1.46 
Pack-yearsǂ     0.94 0.86 to 1.03 
*Other indicates participants that were on other antidepressants or on no antidepressants. †Adjusted for age, gender, 
smoking status, pack-years, HADS depression score, baseline FEV1 and prior number of exacerbations before 
enrolling into the study. Time-dependent variables included antidepressant status, current smoking status, smoking 





Appendix Table 24. Crude and adjusted Hazard Ratios (HRs) for time to first exacerbation using time 
dependent cox regression: Not depressed  
 A. Unadjusted model B. SSRIs and 
Depression 
C. Adjusted model†  
b 95% CI b 95% CI b 95% CI 
SSRI vs. Other* 1.43 1.14 to 1.79 1.32 1.05 to 1.65 1.27 0.93 to 1.73 
Depression score   1.11 1.07 to 1.14 1.09 1.03 to 1.15 
Ageǂ     0.99 0.86 to 1.14 
Gender     1.42  1.13 to 1.78 
Baseline FEV1ǂ     0.81 0.77 to 0.84 
Prior Exacerbations     1.47 1.35 to 1.61 
Current Smoker     0.92 0.71 to 1.20 
Pack-yearsǂ     1.02 1.00 to 1.03 
*Other indicates participants that were on other antidepressants or on no antidepressants. †Adjusted for age, gender, 
smoking status, pack-years, HADS depression score, baseline FEV1 and prior number of exacerbations before 
enrolling into the study. Time-dependent variables included antidepressant status, current smoking status, smoking 






Appendix Table 25. Generalized linear regression coefficients for Baron and Kenny mediation steps for 
Interleukin-6 receptor as a mediator of the relationship between selective serotonin reuptake inhibitors and 
forced expiratory volume in one second excluding participants without COPD 
 A. SSRI to FEV1* B. SSRI to IL6 C. IL6 to FEV1 D. SSRI to FEV1 
controlling for IL6* 
 b 95% CI b 95% CI b 95% CI b 95% CI 
Visit 1 -2.88 -7.53 to 1.77 0.006 -0.02 to 0.03 0.12 -0.06 to 0.30 -3.01 -7.66 to 1.64 
Visit 2 -0.76 -10.14 to 8.61 -0.03 -0.07 to 0.006 -0.02 -0.04 to 0.32 -0.79 -10.20 to 8.63 
SSRI: selective serotonin reuptake inhibitor; FEV1: forced expiratory volume in one second 






Appendix Table 26. Generalized linear regression coefficients for Baron and Kenny mediation steps for C-
reactive protein as a mediator of the relationship between selective serotonin reuptake inhibitors and forced 
expiratory volume in one second excluding participants without COPD 
 A. SSRI to 
FEV1* 
B. SSRI to CRP C. CRP to FEV1 D. SSRI to FEV1 
controlling for CRP* 
 b 95% CI b 95% CI b 95% CI b 95% CI 
Visit 1 -2.88 -7.53 to 1.77 -0.003 -0.15 to 0.15 -3.85 -5.11 to -2.58 -3.16 -7.75 to 1.44 
Visit 2 -0.76 -10.14 to 8.61 0.03 -0.23 to 0.30 -5.00 -7.29 to -2.71 -1.42 -10.57 to 7.74 
SSRI: selective serotonin reuptake inhibitor; FEV1: forced expiratory volume in one second 





For Chapter 3 and Chapter 4, we employed the complete case method for missing data, which 
involves the analysis of the set of observations with no missing values. When missing data is Missing 
Completely at Random (MCAR), this estimator is unbiased.  
In Chapter 3, we only had 664 observations that were dropped due to missing values; therefore, 
this method was logical to employ in a large dataset, minimizing the efficiency losses. To assess any 
potential biases from removing incomplete cases, we compare the missing and non-missing observations 
on available data [132]. We compared the demographics of the participants with missing variables 
(Appendix Table 27Error! Reference source not found. and Appendix Table 28). At exam 4, 295 participants 
were missing information on medications, 112 on spirometry, 216 on dyspnea, 231 on CES-D score, 187 
on health insurance and smoking status, and 184 on smoking pack-years; this lead to a total of 664 
participants being excluded. In those with missing information, there was a higher proportion of males, 
Asians, Hispanics, and mild COPD. Although statistically significant, this is likely due to the large sample 
size. At exam 5, 98 participants were missing information on medications, 23 on spirometry, 202 on 
dyspnea, 200 on CES-D score, 131 on health insurance, 146 on smoking status, and 184 on smoking pack-
years; this lead to a total of 406 participants being excluded. Similar to exam 4, in those with missing 
information, there was a higher proportion of males and Asians. Additionally, there was also a larger 
proportion of those with no COPD and a smaller proportion of people reporting dyspnea.  
In Chapter 4, there were 97 participants missing information on demographics (age, gender), 146 
missing HADS depression score, 102 missing FEV1, 723 missing antidepressant medication use, 139 
missing smoking status, and 198 with no exacerbation follow-up information, leading to 853 participants 
being excluded ( 
STATISTICAL APPENDIX 




Appendix Table 29).  In those with missing information, there was a higher proportion of Black 
participants, current smokers, and participants with no COPD. Although statistically significant, this is likely 
due to the large sample size; there were no clinically meaningful differences between the missing and non-
missing cohorts that would suggest that our results would be different with the inclusion of these 





Appendix Table 27. MESA: Basic demographic comparison of missing and non-missing observations: 
Exam 4 
 







N or  
mean±SD 
% N or  
mean±SD 
%  
Age, years 67±10 na 66±10 na <0.001 
Gender      
Male 266 48 1748 49 0.51 
Female 290 52 1794 51  
Race/ethnicity      
White 253 46 1254 35 <0.001 
Asian 39 7 567 16  
African-American 195 35 907 26  
Hispanic 69 12 814 23  
Height, cm 167±10 na 166±10 na 0.05 
BMI, kg/m2 29±6 na 28±6 na 0.03 
Health Insurance      
None 18 4 189 5 0.04 
Medicaid 28 6 297 8  
Medicare 58 12 341 10  
HMO 310 65 2331 66  
VA/Other 63 13 384 11  
Cigarette smoking status      
Never-smokers 209 44 1835 52 0.03 
Former smokers 210 44 1371 39  
Current smokers 57 12 325 9  
Smoking history pack-years# 24±23 na 22±26 na 0.32 
FEV1 % predicted, mean (SD) 91±19 na 94±18 na 0.02 
COPD Stage      
None 277 79 2757 78 0.003 
Mild 30 9 449 13  
Moderate 33 10 295 8  
Severe 8 2 35 1  
Very Severe 3 1 6 <1  
Dyspnea, No. (%) 84 19 541 15 0.06 
CES-D Score  8±8 na 8±8 na 0.02 
Depressed (CES-D≥16) 70 11 489 14 0.02 

















N or  
mean±SD 
% N or  
mean±SD 
%  
Age, years 73±10 na 69±9 na <0.001 
Gender      
Male 178 53 1449 49 0.42 
Female 156 47 1505 51  
Race/ethnicity      
White 131 39 1134 38 0.003 
Asian 25 8 424 14  
African-American 104 31 763 26  
Hispanic 74 22 633 21  
Height, cm 165±10 na 166±10 na 0.03 
BMI, kg/m2 29±6 na 28±6 na 0.003 
Health Insurance      
None 12 5 136 5 0.03 
Medicaid 27 10 233 8  
Medicare 42 16 320 11  
HMO 150 57 1944 66  
VA/Other 33 13 318 11  
Cigarette smoking status      
Never-smokers 130 50 1595 54 0.42 
Former smokers 108 42 1146 39  
Current smokers 20 8 191 7  
Smoking history pack-years# 24±25 na 22±25 na 0.12 
FEV1 % predicted, mean (SD) 96±42 na 95±20 na 0.66 
COPD Stage      
None 172 63 2169 74 <0.001 
Mild 36 13 457 16  
Moderate 13 12 275 9  
Severe 12 4 47 2  
Very Severe 19 7 2 <1  
Dyspnea, No. (%) 36 18 440 15 0.29 
CES-D Score  8±7 na 8±8 na 0.38 
Depressed (CES-D≥16) 32 8 421 14 <0.001 






Appendix Table 29. SPIROMICS: Basic demographic comparison of missing and non-missing observations 
 






N or  
mean±SD 
% N or  
mean±SD 
%  
Age, years 59±10 64±9 <0.001 
Gender      
Male 420 56 1158 52  
Female 336 44 1063 48 0.10 
Race/ethnicity      
White 505 67 1761 79  
Black 215 28 361 16  
Asian 10 1 23 1  
American Indian 4 .53 10 .45  
Pacific Islander 1 .13 0 0  
Mixed 18 2 51 2 <0.001 
Height, cm 170±9 170±10 0.18 
Weight, kg 79±18 81±18 0.001 
Current smokers      
Yes 334 47 760 34  
No 380 53 1461 66 <0.001 
Smoking history pack-years# 41±30 48±39 <0.001 
FEV1 % predicted 71±28 67±27 0.002 
COPD Stage      
None 263 39 661 31  
Mild 77 12 327 16  
Moderate 176 26 647 31  
Severe 103 15 331 16  
Very Severe 48 7 138 7 <0.001 
HADS Score 4±4 4±3 0.26 
Depressed (HADS≥8) 127 15 294 18 0.06 














A graph of the Kaplan-Meier estimate of the survival function was created to check for proportional hazards. 
As seen below, the survival function is approximately parallel, does not cross until the data are sparse near 










ASSESSING PROPORTIONAL HAZARDS 
Users of SSRIs 





The log-log plot plots the logarithm of the negative logarithm of the estimated survivor function against the 













Users of SSRIs 





In order to check the linearity of the covariate vector, the Schoenfeld Residuals against time were examined. 
There is no increasing pattern, until the end where observations become sparse. 
 
Plot of Schoenfeld Residuals 
